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General Introduction
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soliD tumor treatment
Cancer is a malignancy that will become more prevalent due to the demographic change 
towards an aging society [1-3]. When diagnosed early at a local stage, some cancers have 
a good prognosis for cure, while a diagnosis at a late stage makes treatment challenging 
and remains often palliative. As a tumor originates form the patient’s own tissue, it can 
evade immune response and do not offer distinct targets for a more cancer specific treat-
ment [4]. 
The classical cancer therapies used in the clinic are surgery, radiotherapy and che-
motherapy. Surgery, although invasive, is a successful option if a tumor is diagnosed 
at an early stage in its development. However, resection of a tumor frequently includes 
removal of a margin of healthy tissue to reduce the chance of recurrence. In some cases, 
tumors are not resectable or only partly resectable, when vital organs or tissues are 
involved [5, 6]. Often chemotherapy or radiotherapy is given before or after surgery to 
reduce the local recurrence from residual cancer cells. Radiotherapy makes use of high 
energy photon radiation to treat cancers. The principle is based on cancer cells being less 
capable of recovering from damage induced by radiation than healthy cells. Therefore, 
radiotherapy is often given in multiple treatment rounds with sufficient recovery time 
in between for irradiated healthy tissues to recover [7, 8]. As radiation is intrinsically 
carcinogenic, it is dose limited and may even induce secondary cancers at a later stage. 
Chemotherapy is a method that makes use of drugs that interfere with cell division by 
interactions with DNA and can consequently cause cancer cell death [9, 10]. Because 
cancers have a more rapid growth rate than healthy tissues and are less capable of repair-
ing DNA, chemotherapy causes a higher cytotoxic effect on cancer cells than healthy 
cells [11]. However, other healthy cell types with high growth rates are also affected by 
chemotherapy. This can cause side effects like hair loss, toxic effects in the intestine and 
bone marrow, which results in anemia. Next to these disadvantages, the DNA damaging 
effect of chemotherapy can also result in carcinogenic effects in healthy tissues.
Although cancer therapy has substantially improved over the last decades, a lot of 
cancers still are unsuccessfully treated by the conventional therapies. The conventional 
therapies do not act tumor specific and pose a risk to the patient as they cause side 
effects in healthy tissue. Because of these reasons, novel and more targeted therapies 
need to be investigated [12, 13].
liposomal chemotherapy for soliD tumors
Traditional chemotherapy implies the intravenous (i.v.) administration of a chemo-
therapeutic drug which ideally has a more cytotoxic effect on cancers than on healthy 
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tissues. This is caused by the effect of chemotherapy on the cellular level as described 
above, but also due to specific microenvironmental factors within a tumor. Solid tumors 
have various typical characteristics like a necrotic core, high interstitial fluid pressure 
because of the absence of lymphatic drainage and a chaotically and tortuously developed 
vascular network. Fast developing tumors have the tendency to develop immature blood 
vessels which are chaotically organized [14], are variable in blood flow rate and direc-
tion [15] and contain gaps in the endothelial cell lining [16]. These gaps allow materials 
in the blood stream to diffuse into the tumor interstitium, a process which was first 
shown for macromolecules by Matsumura and Maeda in 1986 [17] and was termed as 
the “enhanced permeability and retention” (EPR) effect. In traditional chemotherapy, 
small chemotherapeutic molecules can penetrate the endothelium of blood vessels 
in the majority of tissues. However, because of their small size, the retention of these 
molecules in the tumor interstitium is low since blood flow mediated convection also 
removes the drug relatively quickly before it can get taken up by tumor cells [18-20]. 
Furthermore, chemotherapeutic drugs have a short circulation half-life and this pre-
vents sufficient amount of drug from reaching the tumor and be therapeutically effec-
tive [21]. To increase the circulation time and reduce side effects of chemotherapeutic 
drugs, liposomes were proposed as drug carriers in the 70s [22]. The average diameter 
of commonly used liposomes is ~100 nm and was considered sufficiently small to ac-
cumulate in solid tumors by the EPR effect [23-25]. One of the best described liposomal 
chemotherapeutics which has reached the clinic is Doxil®, a liposome encapsulating 
doxorubicin (Dox) (Figure 1) [26]. This liposomal formulation is composed of the hy-
drogenated soy phosphatidylcholine (HSPC), cholesterol and 1,2-distearoyl-sn-glycero-
3-phosphoethanolamine-N-(amino(polyethylene glycol)-2000) (DSPE-PEG2000). The 
natural product HSPC is a 9:1 mixture of 1,2-distearoyl-sn-glycero-3-phosphocholine 
(DSPC) and 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), respectively and is 
the main lipid building block of the liposome. Cholesterol is added to increase mem-
brane stability [27]. The PEG2000 polymer conjugated to the DSPE lipid provides a steric 
coating on the surface of the liposome, which reduces interaction with serum opsonins, 
blood cells and cells of the reticuloendothelial system, which improves circulation time 
over not “pegylated” liposomes [28-30]. Liposomes can be loaded with Dox by a pH [31] 
or ion gradient [32], which is also known as active loading. Here the liposome aqueous 
core has an excess of protons relative to the external media that causes Dox that enters 
the liposome to become protonated and is therefore unable to migrate back out. Exceed-
ing a certain interior concentration, Dox will precipitate and crystallize inside the core 
of the liposome (Figure 1).
When tested in patients, the half-life of Doxil® in the bloodstream was approximately 
45h whereas free Dox was totally cleared within minutes after i.v. administration [33]. 
Furthermore, pegylated liposomes containing Dox also reduced side effects and showed 
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higher intratumoral Dox concentrations [34-36]. However, despite the indicated accu-
mulation of liposomes in tumors in various pre-clinical [37, 38] and clinical occasions 
[25, 39], a significant therapeutic response of Doxil® over conventional chemotherapy in 
a clinical setting is lacking [40-43]. These findings can be explained by the EPR effect 
being highly variable between tumor types [25] and within patient populations [44]. 
Furthermore, discussion remained if the encapsulated Dox becomes bioavailable to the 
tumor cell nucleus to have its therapeutic effect or whether Dox is retained in the lipo-
some and be therapeutically ineffective [45]. This resulted in a demand for liposomal 
formulations that could release their contents more effectively in a solid tumor, and 
thereby possibly being more effective in a broader set of cancer malignancies.
thermosensitive liposomes
The research on developing liposomal formulations which release contents under influ-
ence of an environmental trigger focused on several options. Some examples of stimuli 
which have been investigated for drug release from liposomes are pH, ultrasound and 
Hydrophobic bilayer
Hydrophilic core
Cholesterol
Crystallized Doxorubicin
HSPC
DSPE-PEG2000
Figure 1. Schematic representation of the Doxil® liposome. The liposome is composed of a hydrophobic lipid bilayer 
with an entrapped aqueous compartment. Hydrogenated soy phosphatidylcholine (HSPC) is the main lipid used in the 
formulation and cholesterol provides higher stability of the lipid bilayer. The polyethylene glycol (PEG) 2000 group 
on the 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) lipid reduces interaction of the liposomes with pro-
teins and cells of the reticuloendothelial system, thereby prolonging circulation time of the liposome. Doxorubicin is 
actively loaded into the hydrophilic core of the liposome where it resides in a crystallized form.
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temperature [46]. The last-mentioned has the advantage that it can also influence the 
tumor in multiple ways, which will be further described in the next section. When design-
ing a thermosensitive liposome (TSL), one has to select the appropriate lipids for drug re-
lease at a preferred temperature [47]. Each phospholipid has a melting temperature (Tm) 
that when approached, causes a lipid bilayer to undergo a phase transition from a solid 
gel phase to a liquid crystalline phase and thereby increases membrane permeability. In 
the solid gel phase, the lipid molecules are well organized with carbon chains largely in 
a stretched orientation and polar lipid head groups being immobile. Just below the Tm, 
at the pre-melting temperature, the enthalpy of the lipid molecules decrease and this 
increases mobility of the lipid head groups thereby slightly increasing the permeability 
of the membrane. A further increase in temperature will induce the carbon chains to 
become more flexible and thereby greatly increases fluidity and thus permeability of the 
membrane [48]. Furthermore, heating the lipid bilayer around the Tm will induce grain 
boundaries between lipid rafts that underwent phase transition and others that have 
not [49, 50]. This creates structural packing defects which further increase permeability 
of the membrane, thereby facilitating more pronounced transmembrane movement of 
any compound [51]. Greatly exceeding the Tm will cause the entire membrane to reach 
the liquid crystalline phase and grain boundaries will not be present anymore, this will 
cause the membrane permeability to decrease again [52, 53]. The chemical structure 
of the carbon chain of a lipid is the most important factor that determines the Tm of a 
lipid bilayer and by mixing different lipids in specific ratios; one can design a liposome 
with an optimal Tm based on the selected lipids and the quantities of each. Experiments 
on the feasibility of using mild hyperthermia (40-43°C; HT) for release of compounds 
from liposomes were first described by Yatvin and Weinstein in 1978, where they showed 
that the release of neomycin or carboxyfluorescein from a 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC; Tm = 41 °C) liposome can be shifted to the mild hyperthermia 
range by adding 33 % (mol) of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC; Tm = 
55 °C) to the lipid composition of the particle [54].
In the late 80s and early 90s, the encapsulation of chemotherapeutics was investigated 
for cancer therapy and showed the first promising results in terms of stability at body 
temperature, release of the drug at mild HT, induction of cytotoxic effects on cancer 
cells in vitro and increased drug levels in heated tumors in vivo (Figure 2A) [55-57]. 
After pegylation proved to give higher circulation half-lives for stable liposomes (e.g. 
Doxil®), PEG made its introduction into thermosensitive liposomes (TSL) as well [58, 
59]. This pegylated TSL is in literature often termed as the traditional thermosensitive 
liposome (TTSL), which next to the basic lipids, also contained cholesterol for increased 
membrane stability (Figure 2B). However, Needham and Dewhirst hypothesized that 
the TTSL had to be altered in order to ensure total drug release which is fast enough 
considering the short transition time of a liposome migrating through the vasculature of 
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a heated tumor [60, 61]. In order to do so, cholesterol and DSPC were removed in order 
to reduce membrane rigidity and lower the overall Tm of the liposome, respectively. More 
importantly, lysolipid was added to the formulation. This “low temperature sensitive 
liposome” (LTSL) relies on the micelle forming capacity of the lysolipid to generate pores 
at the grain boundaries which induces a higher drug release rate than a lysolipid-lacking 
TSL (Figure 2C) [48, 62]. Therefore, the LTSL showed higher Dox delivery to tumors than 
the TTSL [63] and resulted in a significant therapeutic response in multiple tumor types 
[64]. The LTSL formulation is undergoing commercialization by Celsion Corporation 
under the name ThermoDox® and is currently tested in clinical trials for liver cancers 
[65-67], breast [68], and pediatric cancers [69]. The clinical trials on liver cancer where 
LTSL was tested in combination with radiofrequency thermal ablation (RFA; see next 
section) showed no increase in progression free survival versus RFA treatment alone. 
The clinical trial on breast cancers has not provided survival data so far, but did show 
a 48% local overall (partial and complete) response rate for tumors treated with LTSL 
Dox TSL
1989-1991
Dox TTSL
1994-1995
Dox LTSL
1999-2000
HT
HT
HT
A
B
C
Figure 2. Schematic representation of Dox release from different TSL formulations described through time. The first 
Dox loaded TSL (A) was composed of dipalmitoyl-phosphatidylcholine (DPPC; red), distearoylphosphatidylcholine 
(DSPC; blue) and cholesterol (orange). At HT, the melting temperature (Tm) of the DPPC lipid is exceeded and the 
hydrocarbon chains (black tails) become disordered, creating grain boundaries with adjacent lipids through which the 
drug can cross the bilayer of the TSL. The “traditional TSL” (TTSL; B) closely resembles Doxil® in lipid makeup (Figure 
1), where hydrogenated soy phosphatidylcholine (HSPC) is replaced by a mix of DPPC and DSPC with the appropri-
ate net Tm to ensure drug release in a similar fashion as the first described Dox loaded TSL. The low TSL (LTSL; C) is 
by removing DSPC, HSPC and cholesterol more optimized for rapid drug release. The LTSL is composed of DPPC, 
DSPE-PEG2000 and the lysolipid monostearoylphosphatidylcholine (MSPC; purple). Initially, the same grain boundar-
ies are formed at HT as for the previously mentioned TSLs. However, the additional lysolipids can migrate across the 
liposomal bilayer, forming a pore at the grain boundary, which can be further stabilized by PEG, through which Dox 
is released.
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and mild HT. These findings implicate that clinical cancer treatment with LTSL and 
HT is not conclusive and that optimization of the therapy is required. The first factor 
to investigate for optimization of the therapy is the liposome formulation. Banno et al 
[70] and Paoli et al [71] described that LTSLs have a significantly shorter circulation 
half-life than TSL that did not contain lysolipid. Their findings, combined with in vitro 
and in vivo experiments from others [72, 73], also suggested that lysolipids may not stay 
associated with the liposome in circulation. 
Additionally, Li and colleagues showed that by removing lysolipids from the formu-
lation, the stability of the formulation can be increased without losing much of the 
thermosensitivity for rapid drug release. This increase in TSL stability also caused the 
formulation to be therapeutically more effective than LTSL [74]. These findings suggest 
that more investigation on alternatives for LTSL can be beneficial for optimizing the 
therapy. 
Other examples of promising LTSL alternatives are TSL formulations with a detergent 
as a lysolipid replacement [75] or usage of pegylation alternatives for longer circulation 
time, without losing thermosensitivity [76]. The above-mentioned findings on TSLs 
illustrate that TSL-mediated drug delivery is a treatment with high potential for many 
types of solid tumors. However, there is still a demand for an optimal formulation that 
shows 1) high drug retention inside the liposomal carrier in circulation at body tempera-
ture, 2) high circulation half-life of the particle and 3) instant release at HT. A second 
factor that might be responsible for the above-mentioned results of the first clinical 
trials of LTSL is the infusion and HT workflow. Here, the LTSLs are infused before the 
RFA is applied and because of the relatively poor stability and circulation half-life of 
these particles, much of the administered dose can already be cleared before the tumor 
is brought to the desired temperature.
hyperthermia in Drug Delivery
Next to using HT as a trigger for drug release from thermosensitive liposomes, HT can 
also directly influence the tumor and its microenvironment. The first descriptions of us-
ing HT for cancer treatment date back to the writings of Hippocrates [77]. Additionally, 
findings where tumors appeared to shrink due to high fevers have also been described 
over a century ago [78, 79]. In cancer therapy, HT can be used solely to treat cancers [80, 
81]. The effectiveness of this form of therapy depends on the specific heating protocol, 
duration of heating and the tissue type that is exposed [82, 83]. RFA is an example of 
a treatment that relies on only the heating of tissues for therapy. Here, a RFA probe 
is placed inside the tumor to induce heating up to 100 °C, thereby inducing local cell 
death [84]. However, HT is usually applied in the clinic in the mild range (40-43 °C) 
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as an additive to radiotherapy or chemotherapy where it has been shown to enhance 
therapeutic effect of these classical treatments [85, 86]. The increased sensitivity of 
cancers to chemotherapeutic drugs when exposed to HT is suggested to be caused by 
an increase in permeability of the cancer cell membrane and consequently higher drug 
uptake [87, 88]. In the field of drug delivery to solid tumors by nanomedicine, it is 
the influence on the tumor microenvironment that proved to be an interesting feature. 
HT influences the tumor microenvironment in multiple ways e.g. increasing blood flow 
and oxygenation [89-92]. But more importantly, HT appeared to improve tumor vessel 
permeability to small molecules [93], proteins [94], antibodies [95, 96] and liposomes 
[97-99]. The improved accumulation of these compounds in heated tumors is caused 
by increased perfusion [93] and a broadening of gaps in the endothelial lining of the 
affected blood vessels [97, 100, 101]. Although increased liposome accumulation by HT 
solely is interesting to exploit for cancer therapy [102, 103], the combination with direct 
cytotoxicity, enhanced chemosensitivity and the local triggered drug release from TSL 
by HT, is likely a more promising multi-edged therapy (Figure 3) [63, 104]. Currently, 
novel methods are developed to heat tumors more specifically and reduce heating of 
surrounding tissues. HT by high-intensity focused ultrasound (HIFU) is one example 
that is non-invasive and can be specifically directed to the tumor, a method that has 
gained attention as an effective tool for drug delivery in combination with TSL [105]. 
There are also examples of nanoparticles that can generate heat by an external trigger 
e.g. gold nanorods that generate heat by a near-infrared laser for Dox release by TSL 
[106] or liposomes that next to the encapsulated drug, contain magnetic nanoparticles 
(MNPs) that can generate heat by exposure to an alternating magnetic field (AMF), 
thereby releasing the drug [107, 108].
image-guiDeD Drug Delivery
The previously mentioned results show that TSLs in combination with HT have high 
potential for clinical translation. However, there is a need for a better understanding on 
how injected particles behave when entering blood circulation, their pharmacokinetics, 
biodistribution, the interaction and behavior within the heated tumor and how this 
affects the drug that it carries. A suitable approach is the use of non-invasive imag-
ing using e.g. positron emission tomography (PET), single-photon emission computed 
tomography (SPECT), magnetic resonance imaging (MRI) or fluorescence to follow 
and possibly quantify nanomedicines that carry a contrast and/ or imaging tracer in 
vivo. This field of image-guided drug delivery has become very broad and consists of 
a large amount of different types of particles, imaging techniques and drug delivery 
methodologies [109, 110]. For local drug release therapies, an ideal nanoparticle and its 
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encapsulated cargo should be able to be imaged by one or more of the above-mentioned 
techniques (Figure 4). Using nuclear or optical imaging has shown that HT can increase 
the intratumoral uptake of the particle when a tumor was heated during [99] or before 
i.v. administration [100], respectively. However, imaging the drug remains the most 
important parameter to consider and this has been intensively investigated in various 
cases by encapsulating MRI contrast agents into TSLs [111, 112]. Here, the paramagnetic 
contrast agent is encapsulated inside the TSL limiting its interaction with the outside 
water pool. Upon release, the contrast agent generates an increase in T1 relaxation 
time when it regains exposure to the surrounding water, which is visualized by MRI 
in vivo, thereby providing a representative indicator for the release and localization of 
Dox in an actual tumor. This concept was introduced by Viglianti et al [113, 114] where 
MnSO4 was coencapsulated with Dox in TSLs. They showed by MRI that the contrast 
agent was highly released in the well-perfused periphery of the heated tumor and this 
was in good correlation with Dox measurements in the same tissues by fluorescence or 
high-performance liquid chromatography (HPLC). Other studies where Gd(HPDO3A)
(H2O) was used as MRI contrast agent showed comparable results and thereby indicates 
the robustness of the methodology [99, 101, 115-117]. MnSO4 and Gd(HPDO3A)(H2O) 
Tumor interstitium
Tumor cell
Endothelial cell
Dox TSL
Tumor blood vessel
37°C
40-43°C
1
2
4
3
Figure 3. Schematic representation of factors influencing therapeutic response of a tumor to drug delivery by ther-
mosensitive liposomes (TSL) and hyperthermia (HT). At 37°C (A), TSLs migrate through the tumor blood stream with 
particles accumulating in the tumor interstitium by gaps in the endothelial cell lining. When the tumor is heated to 
mild hyperthermic temperatures (40-43°C; B), direct apoptosis can be induced when given with the right timing, dura-
tion and intensity (1). Furthermore, chemosensitivity of the tumor can be increased (2). The gaps in the endothelial 
lining are broadened (3) and more particles can extravasate deeper into the tumor interstitium. Finally, HT causes a 
rapid drug release from TSLs (4), which is taken up by the cells in the area.
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were recently compared as imaging agents for Dox release from TSL [118]. Although both 
agents can represent Dox remarkably well, Mn2+ showed impairment in Dox release at 
41°C and higher drug leakage at body temperature, leaving Gd(HPDO3A)(H2O) as the 
most suitable choice for imaging Dox release in a potentially future clinical setting. MRI 
for visualizing drug release and HIFU as the HT source (MR-HIFU) is currently getting 
more attention as a very promising theranostic methodology for treatment with Dox 
loaded TSL that could be translated to clinical use. Several studies in a rabbit model have 
shown high drug delivery to solid tumors that resulted in significant therapeutic efficacy 
[119-121] and recently, phase I clinical trials were initiated for pediatric refractory solid 
tumors that will further investigate the therapeutic potential of MR-HIFU with LTSL 
[69].
aim of the thesis
This thesis is focused on improving drug delivery by TSL and HT, and gaining a better 
understanding of the therapy and robustness of its efficacy. Throughout this thesis, Dox 
was used as a drug compound.
In Chapter 2, different TSL formulations and Dox loading methods is compared in 
order to obtain a TSL with optimal Dox retention at 37°C and instant total release at 
42°C. Furthermore, the correlation between in vitro stability tests and the actual in vivo 
outcome is investigated extensively.
A B C
PET
SPECT
MRI
Fluorescence
RF HT
HIFU
Ultrasound
Laser
AMF
Figure 4. Representation of an ideal image guided drug delivery scenario. A nanomaterial can be tagged with a com-
pound e.g. MRI contrast agent, radioactive compound or fluorescent dye (yellow flag) prior to intravenous admin-
istration (A). The tag can represent the nanoparticle or the incorporated drug and accumulates in the tumor which 
can be imaged by e.g. PET, SPECT, MRI or fluorescence imaging (B). Thirdly, the carrier needs to be susceptible to a 
non-invasive trigger for drug release at the target site e.g. HT induced directly by radiofrequency (RF HT) or HIFU, or 
indirectly by exposing accumulated MNPs or gold nanorods to an AMF or laser light, respectively. Other triggers like 
ultrasound or light can also be used for drug release (C). 
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In Chapter 3, the intravascular Dox release from TSLs is compared to a delivery scheme 
that comprises interstitial drug release after liposomoal accumulation that is achieved 
in preheated tumors. Further investigation is performed on factors influenced by HT 
that improved local drug delivery and the role of the tumor microenvironment herein.
In Chapter 4, the therapeutic response of two different orthotopic breast cancer mod-
els to temperature induced Dox delivery by TSLs is investigated. The motivation is to 
understand how differences in tumor microenvironment and growth rate between these 
tumors affect Dox delivery and therapeutic response. 
In Chapter 5, an isolated limb infusion model is introduced to investigate release 
kinetics from TSL and the delivery of the drug after a single passage through a heated 
tumor. The preliminary data shows that a considerable amount of TSL passages through 
a heated tumor are required for the delivery of a therapeutically relevant Dox dose. With 
future optimization of the model and experimental design, more quantitative data can 
be obtained which will improve the understanding of the delivery dynamics of Dox to 
solid tumors by TSLs.
In Chapter 6, approaches for development of a magnetic nanoparticle containing 
liposome for image-guided drug delivery is described. Though no liposomes with a high 
payload of magnetic nanoparticles could be obtained, this chapter contains an in depth 
analysis on liposomal preparations which could serve as a starting point for future suc-
cessful production of magnetoliposomes.
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abstract
In numerous studies, thermosensitive liposomes (TSLs) for local heat-triggered delivery 
of Doxorubicin (Dox) to tumors have been investigated, with TSLs having different lipid 
formulations, drug loading methodology and testing procedures. To gain more insight in 
these parameters, we investigated TSLs with four variable DSPC-DPPC lipid ratios (50, 
60, 70 or 80% DPPC and 5 mol% of DSPE-PEG2000) using either ammonium sulfate or 
a citrate buffer for Dox loading. Ammonium sulfate loading of Dox yielded more stable 
TSLs than citrate loading. At 37°C, leakage was unnoticeable for all ammonium sulfate 
TSLs. At 42°C, complete release occurred within seconds, except for 50% DPPC TSLs, 
where slow and incomplete release was observed in vitro but also in vivo using a dorsal 
skinfold window chamber. In contrast to in vitro assays, blood kinetics studies indicated 
a burst release of Dox upon injection and higher leakage for all TSLs. In therapeutic 
studies, hyperthermia in combination with TSLs repressed BFS-1 sarcoma growth. Our 
study shows that prediction of therapeutic efficacy purely based on differences found in 
vitro is difficult, instead, parameters obtained from pharmacokinetic studies in vivo, and 
the exact timing of the delivery protocol need to be taken into account. 
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introDuction
Chemotherapy of solid tumors is complicated by the narrow therapeutic window typical 
for low molecular weight cytostatics like doxorubicin (Dox). Site-directed chemotherapy 
allows improving the therapeutic window by sparing the healthy organs from exposure 
to the drug while increasing drug concentrations in the targeted tissue. One approach for 
local drug delivery is the heat-triggered release of drugs that are encapsulated in aqueous 
lumen of temperature sensitive liposomes (TSLs). Upon heating, the lipid bilayer passes 
through a melting phase transition temperature (Tm) from a gel to a liquid-crystalline 
phase. The exact temperature and broadness of the phase transition depends on the 
exact lipid formulation and can be adjusted to be in the range of hyperthermic (HT) 
temperatures (41<T/˚C<43). As the phase transition is associated with a rapid increase 
in membrane permeability, TSLs can be exploited for rapid temperature-induced drug 
release. Stability at body temperature, release kinetics and Tm are strongly determined 
by the exact composition of the lipid bilayer, the chemical properties of the drug and 
other formulation aspects. Above concept was introduced by Yatvin and Weinstein 
et al. using a TSL based on 1,2-dipalmitoyl-sn-glycerophosphocholine (DPPC) and 
1,2-distearoyl-sn-glycerophosphocholine (DSPC) for temperature-induced neomycin 
and methotrexate delivery, respectively [1,2]. Although they achieved a 3.6 times in-
crease in tumor methotrexate levels when compared to free methotrexate or liposomal 
methotrexate without heating, the formulation showed poor blood circulation times 
and relatively slow release kinetics. 
The most important goal in optimizing TSL formulations is to minimize drug leakage 
at body temperature while maximizing drug release at HT. The problem is that perfor-
mance of TSL in vitro may not reflect their behaviour under in vivo conditions due to the 
more complex environment. Upon injection of the formulation in vivo, the liposomal 
release and stability might change and additionally, new parameters will come into play: 
e.g. time between injection and HT, the HT duration, the blood kinetics of the liposomal 
carrier and tumor characteristics e.g. perfusion [3–6]. A simplified equation describing 
the intricate balance between all these factors is depicted in Eq.1. [7].
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The liposome plasma concentration ([liposome]plasma) will decrease upon time after injection 
due to clearance by the reticulo-endothelial system (RES), while the rate of clearance depends 
on liposomal composition. The [Dox/liposome] represents the fraction of Dox still present 
within the liposome and decreases when the Dox leaks out of the liposome (at 37°C) or gets 
released from the liposome (at 42°C). It is therefore related to the liposome stability and release 
kinetics. The plasma flow in the tumor plasma space (plasma flow tumor/ plasma volume 
tumor) is dependent on the tumor type and its microenvironment. The released fraction of Dox 
per tumor residence time (tres) depends on the combination of tumor perfusion, which will 
influence the tres, and the release kinetics of the liposomal formulation. Furthermore, the Dox 
that is released from the liposomes within the tumor enters the interstitial space at a rate that is 
influenced by the Dox concentration already present in the tumor and when it enters, it can 
partially be washed out by blood flow mediated convection [7]. The Dox influx and outflux can 
be subsumed under the Dox retention parameter. Finally, the total Dox available to the tumor 
will depend on the total HT time (tstop – tstart).   
Over the years, different attempts have been made on improving the original TSL formulation 
used by Yatvin and Weinstein. Gaber et al. added pegylated lipids to the TSL formulation in 
order to increase its circulation time and therefore the [liposome]plasma  parameter [8]. Later, 
Needham et al. and Li et al. showed that the incorporation of pegylated lipids not only increases 
the liposome circulation time but also influences their release kinetics [9,10]. Needham et al. 
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the liposome stability and release kinetics. The plasma flow in the tumor plasma space 
(plasma flow tumor/ plasma volume tumor) is dependent on the tumor type and its 
microenvironment. The released fraction of Dox per tumor residence time (tres) depends 
on the combination of tumor perfusion, which will influence the tres, and the release 
kinetics of the liposomal formulation. Furthermore, the Dox that is released from the 
liposomes within the tumor enters the interstitial space at a rate that is influenced by 
the Dox concentration already present in the tumor and when it enters, it can partially 
be washed out by blood flow mediated convection [7]. The Dox influx and outflux can 
be subsumed under the Dox retention parameter. Finally, the total Dox available to the 
tumor will depend on the total HT time (tstop – tstart).
Over the years, different attempts have been made on improving the original TSL 
formulation used by Yatvin and Weinstein. Gaber et al. added pegylated lipids to the TSL 
formulation in order to increase its circulation time and therefore the [liposome]plasma 
parameter [8]. Later, Needham et al. and Li et al. showed that the incorporation of 
pegylated lipids not only increases the liposome circulation time but also influences 
their release kinetics [9,10]. Needham et al. greatly improved the rate of Dox release by 
the incorporation of lysolipids into low temperature sensitive liposomes (LTSLs, cur-
rently in clinical trials in a slightly different formulation as Thermodox® by Celsion) [11]. 
Unfortunately, the [Dox/liposome] parameter of this formulation is still suboptimal due 
to premature leakage under physiological conditions [7]. In work previously published 
by our group, we have described a TSL consisting of DPPC, DSPC and 1,2-distearoyl-
sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-
PEG2000) in a molar ratio of 80:15:5. The release of carboxyfluorescein and Dox from these 
liposomes was rapid and quantitative within seconds when exposed to a temperature of 
42°C [10,12]. However, also this formulation displayed considerable leakage (up to 30% 
after one hour) under physiological conditions. 
Aim of this study is to further improve above TSL formulation by systematic variation 
of its lipid composition and to investigate above explained parameters that contribute 
to the overall performance in drug delivery and relate them to the therapeutic efficacy 
of the formulations. Four TSL formulations were prepared by varying DPPC/DSPC ratio 
while maintaining a constant 5% mol:mol of DSPE-PEG2000. For all TSLs, the stability 
at 37°C and the release kinetics at 42°C were measured in vitro by fluorometry. The 
intraliposomal buffers ammonium sulphate ((NH4)2SO4) or citrate were compared in 
their effect on Dox loading efficiency, stability and release kinetics [13,14]. The blood ki-
netics of the liposomal carrier and the leakage of these formulations were investigated in 
vivo. Further in vivo studies have been carried out in the form of murine dorsal skinfold 
intravital microscopy which showed the release patterns of these different liposomal 
formulations and the drug distribution in the tumor micro-environment. Finally, a 
therapeutic efficacy study was performed in a murine BFS-1 sarcoma (Figure 1). With 
33
Optimization and analysis of TSL
2
the presented data we aim to provide more insight in which parameters matter most in 
conducting an optimal therapy and to what extent in vitro data can be translated to in 
vivo therapeutic effect.
Figure 1. Schematic depiction of the presented workflow. In vitro characteristics like Dox release kinetics and leakage 
at physiological temperatures (A, B) were compared to release and leakage in vivo by studying Dox and carrier blood 
kinetics (C) and dorsal skinfold intravital microscopy (D). While these studies gave insight in the Dox supply to the 
tumor, a therapeutic study (E) was needed to study the result of the interplay of these factors with other therapeutically 
relevant factors like Dox tumor uptake, Dox tumor distribution and sensitivity of tumor cells to the drug.
materials anD methoDs
materials
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol)-2000] (DSPE-PEG2000) were purchased from Lipoid 
(Germany). DSPE-diethylenetriaminepentaacetic acid (DTPA) was obtained from 
Avanti polar lipids Inc. Doxorubicin-hydrochloride solution (2 mg/ml) was ordered from 
Accord Healthcare. All remaining chemicals were from Sigma Aldrich. PD-10 desalting 
columns were bought from GE-Healthcare Life Sciences.
preparation of liposomes
Four liposomal formulations, were prepared with a different molar ratio of DPPC:DSPC 
but keeping a constant molar fraction of 5% DSPE-PEG2000. In detail, these formulations 
have molar ratios of DPPC:DSPC:DSPE-PEG2000 of 80:15:5 (TSL80), 70:25:5 (TSL70), 
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60:35:5 (TSL60) and 50:45:5 (TSL50). Liposomes were prepared by the film hydration 
and extrusion method at 60°C. The lipid film was hydrated in a 300 mM citrate buffer 
pH 4.5 or a 250 mM (NH4)2SO4 buffer pH 5.5. Extrusion was done using a thermobarrel 
extruder (Northern Lipids, Vancouver, Canada). Samples were extruded 5 times through 
polycarbonate filters of 200, 100, 80 and 50 nm pore size. Liposomes were brought onto 
a PD-10 column and eluted with HEPES buffer pH 7.4. Subsequently, the phosphate 
concentration was determined with an ammonium molybdate spectrophotometric assay 
[15]. Dox loading was achieved by establishing as sample with a molar Dox:lipid ratio of 
0.15:1 in HEPES buffer pH 7.4 that was incubated in a thermoshaker for 1 hour at 39°C 
and 300 rpm. Size and zeta potential measurements were carried out using dynamic 
light scattering (DLS) with a Zetasizer Nano ZS (Malvern Instruments, Worcestershire, 
UK). Transition temperatures (Tm) of liposomes were determined by differential scan-
ning calorimetry (DSC). 
liposome radiolabeling
Measurement of the blood kinetics was performed using radiolabeled liposomes. TSLs 
incorporating 0.1 mol% DSPE-DTPA in the phospholipid bilayer were prepared and 
loaded with Dox in a similar fashion as described above. Subsequently, these TSLs were 
radiolabeled by 40 minutes incubation at 26˚C with 111InCl3 in 2.5M sodium acetate pH 
5.0. The radiochemical purity was tested with iTLC (running buffer: 10 mM EDTA in sa-
line). After 10 minutes incubation with 10 mM EDTA at 26˚C, the sample was washed 10 
times with saline in a Amicon Ultra-0.5 mL centrifugal filter (50 kDa MWCO,Millipore) 
in order to dilute the sodium acetate and remove unbound 111In to yield a radiochemical 
purity of ≥ 97%. No free Dox was observed in the supernatant.
release kinetics of liposomes
For temperature dependent release testing, liposomes were added to preheated fetal 
bovine serum (FBS) (Sigma) and incubated for 5 min at designated temperatures in a 
thermoblock at 800 rpm. After measurement of the Dox fluorescence (excitation 482 
nm; emission 594 nm), 50 µL 10% Triton-X100 (Sigma) was added to the sample and the 
sample was measured again to determine its 100% release signal. The resulting points 
per formulation were fitted with non-linear regression. Based on the fits, the tempera-
ture at which 50 % of the encapsulated Dox would be released after 5 min incubation in 
FBS was determined (R50). The time dependent release analysis has been investigated in 
a largely similar fashion. A FBS containing cuvette was pre-heated to the temperature of 
choice and after 1 min of measurement, liposomes were spiked into the serum via surgi-
cal tubing and the sample was measured for 1 hour. Percentage release was calculated 
by: % release= (Sn-Sbase)/(Smax-Sbase)*100%, where Sn is the signal measured by a sample, 
Sbase is the signal of a similar sample not exposed to elevated temperatures and Smax is the 
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maximum signal of a sample (either by exposure to HT, or adding Triton X-100). In an 
additional experiment, fl uorescence measurements were performed with free Dox and 
empty liposomes at a Dox:lipid ratio of 0.15:1 in FBS in order to test for any quenching or 
scattering eff ects the presence of liposomes may have (Figure 2). All formulations were 
prepared in triplo and release assays were conducted in triplo for all formulations.
cryo-transmission electron microscopy
(NH4)2SO4 TSL (50µL) samples in FBS (450µL) which were exposed to 42°C for 1 h were 
1:1 diluted with distilled water before freezing. Sample preparation was performed by 
applying a 2 µl droplet of suspension to a lacy carbon fi lm and subsequently plunge-
freezing this sample into liquid ethane using a Vitrobot. The resulting amorphous ice 
fi lm was prepared using the following blot conditions: blot time (2 sec), blot off set (2 
mm) and blot total (1). Subsequently, cryo-TEM studies were performed using a FEI 
TECNAI F30ST (300kV, using a cryo-holder, keeping the sample at –173°C during the 
studies). Imaging was done in low-dose mode on a CCD camera (1k x 1k). For several 
locations on the sample, images were acquired at under-focus conditions.
In vivo experiments
bfs-1 tumors
BFS-1 sarcoma cells were grown in vitro in DMEM medium supplemented with 10% 
inactivated FBS and 5% penicillin/streptomycin. 1∙106 cells were injected subcutane-
ously into the fl ank of ten weeks old C57BL/6 mice (Harlan). When tumors reached 
the desirable size, 1 mm3 fragments were dissected and transplanted to the mice in the 
experimental groups. All BFS-1 animal study protocols were approved by the committee 
of Animal Research of Erasmus MC, Rotterdam, the Netherlands.
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Figure 2. Dox fl uorescence as a function of Dox concentration in the presence of empty liposomes, measured in FBS. 
The open circle represents the concentration of Dox at which all in vitro experiments were performed. N=3 for each 
concentration.
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blood kinetics and biodistribution
111In-labeled TSLs (10 ± 2 MBq/mL TSL solution, ~1.0 ± 0.1 MBq/mouse, 5 mg Dox/
kg bodyweight in 96 ± 11 µL) were injected via the tail vein of C57BL/6 mice under 
isoflurane anesthesia. Blood samples were taken according to two timelines. For the first 
timeline blood samples were drawn at 2, 10, 45, 150 and 210 minutes after injection (n = 
3). During this period, the mice were kept under anesthesia and their temperature was 
maintained by a heated plate and heating pads, ensuring contact temperatures always 
≤ 37˚C. Body temperatures were always between 35 and 37˚C as measured by a rectal 
probe. For the second timeline, animals were kept under anesthesia for 90 minutes 
while blood samples were drawn at 10, 30 and 60 minutes, followed by blood samples 
from the awake animals at 2, 3.5, 6 and 24 hours (n = 3). The blood samples and stan-
dards of the 111In-labeled TSLs were weighed and their radioactivity was counted with 
a 1480 Automatic Gamma Counter (WizardTM 3’’, Perkin Elmer). Dox concentrations 
of the blood samples were determined according to the procedure outlined below. The 
percentage of the injected dose was calculated for the total organ or for the total blood 
assuming a total blood volume of 7.8% of the body weight. This relationship was derived 
by calculating the total blood volume of each mouse from the first group (first timeline) 
based on the blood level of liposomal carrier at the 2 min time point, by assuming the 
liposomal carrier was still fully present at this time point. The animal study protocols 
were approved by the committee of Animal Research of Maastricht University, Maas-
tricht, the Netherlands.
Doxorubicin quantification
Blood samples (~10-20 μL/sample) and pieces of organs (~100 - 200 mg/organ) obtained 
during the blood kinetics and biodistribution experiments were analyzed for their Dox 
concentrations according to the protocol previously described [16]. An aqueous solution 
of daunorubicin (0.5 µg/mL in 1 mL H2O for the blood samples, 2 µg/mL in 1.5 mL 
H2O for the organ samples) was added to all samples as an internal standard for Dox 
quantification, followed by homogenization for 30 min at 30 Hz in a Qiagen Tissuelyser. 
Subsequently, 125 µL of the homogenized blood and tissue solutions were incubated 
with 50 μL AgNO3 in water (33% w/v) for 10 minutes at room temperature. The Dox was 
extracted by mixing with 1.25 mL chloroform/isopropanol (2:1 v/v). The organic phase 
was obtained by centrifugation (10 min at 3600 rpm) and transferred to a clean tube 
and evaporated to dryness at 40 ˚C under N2 flow. The resulting residue was dissolved 
in 200 µL H2O. HPLC analysis was performed on an Agilent Technologies system (1100 
series) equipped with an autosampler and fluorescence detector (λex = 485 nm and λem = 
590 nm). 50 µL of each sample was injected on an Eclipse XDB-C18 column (5 µm, 4.6 × 
150 mm2 Agilent). The Dox and daunorubicin were eluted in 6 and 12 min respectively, 
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using an isocratic fl ow of 1 mL/min with 30% (v/v) acetonitrile in H2O containing 0.1% 
TFA (v/v).
pharmacokinetic parameter estimation
The blood kinetic data of the four diff erent liposomal carriers (from both timelines) 
were fi tted using a mono-exponential function to derive the blood half-lives as well as 
the clearance of the liposomal carrier by the reticuloendothelial system (RES) (kRES). 
44 
 
𝑐𝑐𝑙𝑙𝑙𝑙𝑙𝑙(𝑡𝑡) = 𝑐𝑐𝑙𝑙𝑙𝑙𝑙𝑙(0) ∙  exp (−𝑘𝑘𝑅𝑅𝑅𝑅𝑅𝑅  ∙  𝑡𝑡)                    Eq.2 
 
in which clip(t) represents the liposomal concentration in the blood. 
The leakage of the liposomes was estimated based on the Dox blood kinetics data from the first 
3.5 h after injection of both timelines using on a simple pharmacokinetic model (Eq. 3 to 5, 
Figure 3). 
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concentration of free Dox in the blood stream, and t1/2,leak the leakage half-life of Dox from the 
liposomes, respectively. The parameter t1/2,dox is the half-life of free Dox in the bloodstream of 
mice, which is set to 1.2 min [17,18].This model takes into account the measured kclear,RES as 
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in which clip(t) represents the liposomal concentration in the blood.
The leakage of the liposomes was estimated based on the Dox blood kinetics data from 
the fi rst 3.5 h after injection of both timelines using on a simple pharmacokinetic model 
(Eq. 3 to 5, Figure 3).
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Figure 3. Schematic representation of the model used to estimate the burst and leakage half-lives (ln(2)/kleak) based 
on the total amount of Dox measured (Liposomal Dox + Free Dox), the Dox elimination constant kel as derived from 
literature [16] and the liposomal clearance time (ln(2)/kleak) as derived from the liposomal carrier blood kinetic data.
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intravital imaging by murine dorsal skinfold window chamber model
Twelve weeks old C57BL/6 mice received a dorsal skinfold window chamber with a BFS-
1 sarcoma implant and were imaged using intravital confocal microscopy within two 
weeks after placement of the window [19]. During imaging, the mice are under isofl urane 
anesthesia and body temperature was kept stable at 37°C using a thermal stage and was 
monitored by a rectal probe. 5 mg/kg liposomal Dox in 100 µL phosphate buff ered saline 
(PBS) was injected intravenously and liposomes were allowed to circulate for 15 min. The 
window was kept at 37°C using an external circular electric heating coil that was attached 
to the window glass on the back side of the window chamber. The temperature in the 
window was continuously monitored using a thermocouple that was inserted into the 
window chamber. The temperature was increased to 42°C and the imaging continued for 
another hour. Three animals were used per formulation.
therapeutic effi  cacy in a murine bfs-1 sarcoma model
Ten weeks old C57BL/6 mice were given a ± 3 mm3 murine BFS-1 tumor fragment, trans-
planted subcutaneously in the right hind limb. When the tumor reached 200 mm3 within 
three weeks, the tumors were heated to hyperthermia (HT; 42°C) or normothermia (NT; 
37°C) conditions for one hour under anesthesia. Each treatment group consisted of eight 
animals. In case of a HT experiment, the right hind limb was submerged into a 42.5°C 
water bath for 10 min to bring the intratumoral temperature to 42°C (Figure 4, compa-
rable to previously published tumor heating by water bath [20]). Body temperature was 
checked by rectal insertion of a temperature probe and was averagely 35-37°C. 5 mg/
kg Dox in 100 µL PBS were intravenously injected and the tumor was kept at 42°C for 
an additional hour. In case of a NT experiment, the same procedure was applied while 
the mouse was kept at 34-36°C (temperature probe in rectum) by putting the mouse 
on a heating plate and an aluminum foil cover was used to prevent body temperature 
loss. 10 min after subjecting the mice to NT or HT conditions, an intravenous injection 
0 10 20 30 40 50 60
38
40
42
44
46
Time (min)
In
tra
tu
m
or
al
te
m
pe
ra
tu
re
 (
C
)
Figure 4. Intratumoral temperature measurement over time during heating of the tumor-bearing limb in a water bath 
at a temperature of 42.5 ˚C. Temperature was measured by introducing a thermocouple probe inside the center of the 
tumor. N=12 for each time point.
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was performed with one of the four investigated liposome formulations or saline. Mice 
were sacrificed 30 days after treatment, or when the tumor exceeded the maximum al-
lowed size (3375 mm3 or 18 mm in one dimension), when the tumor became necrotic 
and caused an open wound. The efficacy of the treatment was judged based on tumor 
doubling time.
statistics
All in vitro data are represented as mean ± standard deviation of experiments performed 
in triplicates. The R50 and Tm values were analyzed by two-way ANOVA after equal vari-
ances were verified by Levene’s test. Other in vitro data were analyzed by independent 
two-samples T-tests. The area under de curve (AUC) for Dox in different liposomal 
formulations was analyzed by one-way ANOVA after equal variances were verified by 
Levene’s test. Tumor doubling times were analyzed by Mantel-Cox. All tests were per-
formed using IBM SPSS Statistics for Windows v. 23. All statistical tests were two-sided 
and p-values below 0.05 were considered statistically significant.
results
In vitro release and stability assays on tsl formulations with varying 
Dppc:Dspc ratios and Doxorubicin loading techniques
The TSL formulations were prepared by film hydration and extrusion and Dox was 
loaded into every formulation by (NH4)2SO4 (A) or citrate (C) loading. Four different 
TSL formulations were prepared by alternating DPPC:DSPC molar ratio while keeping a 
constant 5% molar fraction of DSPE-PEG2000. All batches were analyzed by DLS on size, 
zeta potential and polydispersity index (pdi). The results in Table 1 show that by chang-
ing the lipid ratio between DPPC:DSPC:DSPE-PEG2000, no differences in size, pdi or 
zeta-potential were observed. The Dox loading efficacy was 100%, regardless of whether 
Table 1. Size, surface charge and melting transition temperature of TSL formulations.
Formulation Size         
(nm)
Pdi Zeta potential     
(mV)
Tm            
(°C)
TSL50A 82±5 0.07±0.03 -7.8±0.9 46.7±0.1
TSL60A 80±2 0.04±0.01 -8.0±0.7 45.3±0.6
TSL70A 78±1 0.04±0.01 -7.2±1.0 44.4±0.3
TSL80A 77±4 0.03±0.02 -6.8±0.7 43.0±0.2
TSL50C 83±2 0.03±0.01 -7.8±1.4 46.4±0.1
TSL60C 83±1 0.04±0.01 -8.4±1.6 45.2±0.7
TSL70C 83±2 0.04±0.01 -7.2±0.7 44.0±0.4
TSL80C 82±3 0.04±0.01 -7.8±0.4 42.8±0.4
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citrate or (NH4)2SO4 was used. DSC analysis indicated that Tm signifi cantly decreased 
(p < 0.001, two-way ANOVA) with increasing DPPC fractions. There was no diff erence 
in Tm between (NH4)2SO4 or citrate loading (Table 1; Figure 5) as tested by a two-way 
ANOVA procedure. To test their stability and release, the liposomal formulations (0.5 
mM phosphate) were exposed to temperatures ranging from 37 to 45°C in FBS for 5 
minutes. When the R50 values of these curves were determined by non-linear regression 
(Table 2), it became apparent that in all formulations, the (NH4)2SO4 loaded liposomes 
were releasing Dox at slightly lower temperatures than when citrate was used (Fig. 6A, 
B, tested by two-way ANOVA). Fig. 6C indicates that the R50 values were consistently 
lower than Tm, yet a strong linear correlation existed between them regardless of the Dox 
loading method used (R2=0.990 for (NH4)2SO4 and 0.993 for citrate loaded liposomes). 
Next, the leakage at 37˚C and the release kinetic at 42 ˚C in FBS was studied for all 
formulations (Figure 7). The fastest release at 42°C is observed for TSL70 and TSL80 
formulations with half of the Dox already released (R50HT) after approximately 5 seconds 
(Figure 7A, B). The TSL60 required approximately 20 s (TSL60A) to 30 s (TSL60C) 
to reach 50% release, while TSL50 formulations required 6 min heating (Figure 7C, 
D). The formulations TSL60-80 reached total release (>95%) after one hour at 42°C, 
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Figure 5. Linear regression of Tm versus % DPPC. Citrate loaded liposomes did not give signifi cantly lower Tm values 
than (NH4)2SO4.
Table 2. Diff erent liposomal formulations and their corresponding R50 values calculated from the temperature depen-
dent release assays shown in Fig. 6 A and B.
Formulation R50 (°C)
TSL50A 42.48 ± 0.24
TSL60A 41.41 ± 0.16
TSL70A 40.34 ± 0.16
TSL80A 39.37 ± 0.13
TSL50C 42.89 ± 0.06
TSL60C 41.64 ± 0.09
TSL70C 40.56 ± 0.12
TSL80C 39.68 ± 0.08
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while TSL50 formulations showed with 66% incomplete release after one hour at 42°C 
(Table 3). At a physiological temperature of 37°C, citrate loaded TSLs displayed more 
leakage after one hour compared to the corresponding liposomes having an (NH4)2SO4 
internal buffer, i.e. 6 ±1% versus 1 ±1% for TSL70; independent samples T-test, p = 
2.2∙10-4, and 15 ±1% versus 8 ±1 % for TSL80 independent samples T-test, p = 0.002, 
A B
C
Figure 6. Temperature dependent release profiles after 5 min exposure to 37-45°C of the different liposomal formula-
tions when (NH4)2SO4 (A) or citrate (B) was used for Dox loading. For each formulation, three batches (n=3) were 
tested. Release (R50) as a function of Tm for both Dox loading methods is shown (C).
A B
DC
Figure 7. Time dependent release profiles of the different liposomal formulations when (NH4)2SO4 (A) or citrate (B) 
was used for Dox loading. The time when R50HT was reached for each formulation is shown in (C) for (NH4)2SO4 and in 
(D) for citrate. For each formulation, three batches (n=3) were tested.
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respectively. Consequently, all the following studies described were carried out with TSL 
formulations with ((NH4)2SO4) based Dox loading. Leakage at 37˚C as well as release 
at 42˚C from these liposomes was dependent on the presence of serum proteins since 
in HEPES buffer under HT conditions, leakage and release decreased (Figure 8A). This 
result was different compared to lysolipid containing formulations, where presence of 
serum was required to a lesser extent (Figure 8B).
Table 3. Different liposomal formulations and their corresponding Dox release percentage after 1h incubation in FBS 
at 37°C or 42°C.
cryo-tem analysis on Dox release from tsl formulations
The release characteristics for TSL50-80A formulations were further investigated using 
cryo-TEM images (Figure 9). The Dox crystals inside liposomes were quantified before 
and after heating to 42˚C for 1 hour in FBS. At least five cryo-TEM recordings were made 
for each formulation and scored for the presence of Dox crystals after HT exposure. 
All liposomal formulations showed the presence of Dox crystals (Figure 10A-D) before 
heating. After heating, 70% of the TSL50A liposomes still showed presence of crystals 
inside though with an altered morphology (Figure 10E), while 30% of liposomes were 
A B
Figure 8. Comparison of Dox release between FBS and HEPES buffer pH 7.4. TSL70A shows instant total release at 
42°C in FBS while the release in HEPES is not higher than 5% (A). LTSL prepared according to Needham et al [9] shows 
in FBS and HEPES a rapid release at 42°C which reached completion faster in FBS than in HEPES (B). All tests done 
at n=3.
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empty. For the TSL60A a higher fraction of empty liposomes was observed compared 
to liposomes with Dox crystals still present (Figure 10F). After heating, TSL70A and 
TSL80A (Figure 10G, H) displayed only empty liposomes, indicating complete release 
of Dox. The fraction of empty liposomes and liposomes with Dox crystals present in the 
inner lumen after heating is shown in Figure 10I for all formulations.
TSL50 TSL60
TSL70 TSL80
Figure 9. Cryo-TEM analysis of TSL50A, TSL60A, TSL70A and TSL80A at 20mM in HEPES buffer pH 7.4. Bars indi-
cate 200nm.
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Figure 10. Cryo-TEM analysis of all TSLA formulations in FBS before (Normothermia; NT) and after 1h exposure 
to 42°C (HT). For the TSL50A formulation, the partial release profile after HT becomes apparent as the majority of 
liposomes contain an alteration in shape of the Dox-SO4 crystal, whereas the other formulations show only empty li-
posomes after HT. Bars indicate 200nm. In I the condition of the Dox crystal in each liposome visualized was counted 
(at least 25 liposomes were counted per formulation).
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Doxorubicin release visualized by intravital imaging
The in vivo release properties of the (NH4)2SO4 TSL formulations were characterized 
with confocal microscopy in a BFS-1 tumor using a dorsal skinfold window model. In all 
cases a rapid increase in Dox fluorescent signal in the intravascular as well as the extra-
vascular space was observed indicating the release of Dox from the liposomes. However, 
TSL50A had a slower release rate than the other formulations (Fig. 11). 
blood kinetics study on tsl and Doxorubicin circulation time
The blood kinetics of all four 111In-labeled TSL formulations were studied in C57BL/6 mice. 
Incorporation of 0.1% DSPE-DTPA to the lipid composition resulted in 4% more leakage 
of the TSL80A after one hour incubation at 37°C in FBS, while TSL70A did not show any 
difference in leakage (Figure 12). The injected dose (%ID) per total blood volume for the 
liposomal carrier and Dox as a function of time for both time lines combined are depicted 
in Figure 13. TSL clearance from the blood could be described by single exponential kinet-
ics. Liposomal blood half-lives reduced from 8.2 hours to ca. 4.4 h with DPPC fractions 
increasing from 50 to 80%. The liposome clearance was mainly caused by liver and splenic 
uptake (Figure 14). The overall Dox concentration found in plasma was always lower than 
that of the TSL, indicating release from its carrier. Upon injection, the Dox showed first a 
fast burst release followed by a more gradual, exponential leakage from its carrier at body 
temperature. A simple pharmacokinetic model was used to determine burst percentage 
(Eq. 5) and leakage half-lives, which are summarized in Table 4. A trend of increased leak-
age with increasing DPPC contents was observed, while burst release upon first blood 
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Figure 11. Window images on the TSL50, 60, 70 and 80 formulations. All formulations showed a relatively quick 
increase in Dox fluorescence, within seconds after the temperature in the window reached 42°C. Bars indicate 100 µm. 
Temperature reached 42°C after 5 min using a heating ring.
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Figure 12. Stability comparison between TSL formulations with and without 0.1% DSPE-DTPA lipid incorporation 
needed for radiolabeling. Addition of 0,1% DSPE-DTPA to the TSL70A or TSL80A did not result in a major defect in 
stability for both cases.
Figure 13. Blood kinetics for the liposomal carriers and Dox for all formulations expressed in % injected dose (ID) in 
the total blood volume. The data were fitted by a pharmacokinetic model and the resulting fits are indicated in the 
graph.
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contact reduced with increasing DPPC contents. From above blood kinetics data, the area 
under the curve (AUC) for Dox was calculated for all formulations, taking burst release 
and leakage into account (Table 4). The AUC for all formulations in the time range of 
1 – 60 minutes was found to be in the range between 34 ± 4 to 42 ± 6 %ID∙h/g with neither 
a statistical difference between the formulations (one-way ANOVA, equal variances, p = 
0.089) nor a correlation with the fraction of DPPC. Calculated for a timeframe from 30–90 
min, TSL70 shows a slightly higher AUC than TSL80 (one-way ANOVA, equal variances, p 
= 0.045, post-hoc Bonferroni p = 0.042). 
Figure 14. Biodistribution of Dox and the liposomal carrier for the TSL formulations. All liposomal carriers show 
predominantly liver and spleen clearance. The Dox ends up in liver and spleen as well, but additionally, a considerable 
amount of Dox can be observed in the kidney at the 3.5h time point.
Table 4. Pharmacokinetic parameters of the liposomal formulations. Values are depicted ± the standard error of the 
fitted parameters. Liposome blood half-life is derived from mono-exponential fits of the blood kinetics data. Leakage 
half-lives are obtained from a pharmacokinetic model fitted to the total Dox blood kinetics, taking the liposomal and 
Dox clearance into account. Dox t1/2 indicates the time point at which the total Dox concentration in the blood (both 
liposomal and free Dox) has reached 50%, as derived from the curves fitted by the model.
Formulation AUC 1-60 min
(%ID x h/g)
AUC 30-90 min
(%ID x h/g)
Liposome t1/2   
(h)
Dox  t1/2                   
(h)
Dox leakage t1/2      
(h)
Dox burst      
(%)
TSL50A 36 ± 7 32 ± 5 8.2 ± 0.9 2.61 6.6 ± 1.6 16 ± 3
TSL60A 35 ± 4 32 ± 4 8.3 ± 0.9 2.41 5.0 ± 1.3 23 ± 3
TSL70A 42 ± 6 35 ± 6 5.6 ± 0.4 1.59 2.7 ± 0.3 8 ± 3
TSL80A 34 ± 4 27 ± 3 4.4 ± 0.5 1.28 2.1 ± 0.3 8 ± 4
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therapeutic efficacy study in a bfs-1 sarcoma model
The therapeutic efficacy of these formulations was tested in a subcutaneous murine BFS-1 
sarcoma model. When no HT was applied, no significant reduction tumor size doubling 
time is observed for any of the formulations (Mantel-Cox test, p > 0.32; Figure 15 A, 
C, E, G, I, K & Table 5). When the BFS-1 tumors were subjected to HT, a reduction of 
NT HT
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DC
B
J
K
L
Figure 15. BFS-1 Tumor response to different kinds of TSL treatments. In A-J, the tumor growth of the individual mice 
for treatments with different liposomal formulations, at NT or HT are shown with a maximum follow up time up to 30 
days. Kaplan-Meier plots were made for tumor doubling time for the NT (K) and HT groups (L). N=8 for all groups.
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tumor doubling time was observed (Figure 15 B, L) (Mantel-Cox test, p = 3 ∙ 10-2), which 
was further enhanced by the use of any of the TSL formulations (Figure 15 D, F, H, J, L 
& Table 5) (Mantel-Cox test, TSL50A, p = 3 ∙ 10-3; TSL60A, p = 3 ∙ 10-4; TSL70A, p = 1 
∙10-3; TSL80A p = 2 ∙ 10-3), however, no difference could be detected between the TSL 
formulations when they were combined with HT (Mantel-Cox test, p > 0.18).
Discussion
In this study, a set of eight different TSL formulations with respect to lipid composition 
and Dox loading method were prepared and tested in vitro and in vivo. For the tested 
formulations the presence of serum proteins was indispensable for adequate in vitro 
drug release, suggesting an interaction of the serum proteins with the TSLs, as shown 
in Figure 8. Increasing the DSPC fraction led to an increase in Tm values, which conse-
quently influenced drug release and retention. The TSL60, 70 and TSL80 formulations 
displayed a rapid and total drug release at 42°C in FBS, except for the TSL50, which 
showed a much slower and only partial release (66% after 1 hour of HT). The internal 
buffer used for Dox loading turned out to be an important parameter, as (NH4)2SO4 
loaded formulations appeared more stable than their citrate loaded counterparts. Using 
citrate as a loading buffer seemed to slightly decrease Tm, which led to higher leakage 
at 37˚C as well as higher R50 values. Based on these in vitro experiments, (NH4)2SO4 
loaded formulations were chosen over citrate loaded liposomes for all further experi-
ments. TSL70A and TSL80A show nearly instant quantitative release at 42˚C in FBS, 
comparable to LTSL [11,21,22]. However, the advantage of TSL70A when compared to 
LTSL is that the leakage of the TSL70A formulation is limited to 1 ± 1% after 60 min in 
FBS at 37˚C making it slightly more stable than the LTSL formulation when tested under 
the same circumstances (Figure 8). For the TSL50A, Cryo-TEM images displayed a high 
fraction of liposomes still containing Dox crystals after heating. This fraction was less 
for the TSL60A formulation, and completely absent for TSL70A and TSL80A, where only 
empty liposomes were observed. As a result, above mentioned cryo-TEM findings were 
consistent with the fluorimetric assays.
Next, intravital microscopy studies were performed with TSL50A-TSL80A formula-
tions in a BFS-1 sarcoma tumor using a dorsal skinfold window chamber model. In 
line with the in vitro data, the measurements revealed a comparable slow release for 
TSL50A in vivo, while release kinetics appeared comparable for all other formulations. 
For all formulations, intravascular release was obtained followed by rapid extravasation 
into the tumor tissue. Comparable results have been reported by our group in BFS-1 
and other tumors for TSL80 and in FaDu tumors with LTSLs by Manzoor et al.[3,23]. 
Although the intravital microscopy can provide information about both in vivo release 
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kinetics and local tumor penetration depth, it has been shown by de Smet et al. [24] that 
it is paramount to study drug distribution also across the entire tumor. Although Dox 
penetration and distribution improves in the vicinity of blood vessels on cellular length 
scales upon heat treatment, it is important to realize that significant drug concentrations 
will only be reached in sufficiently perfused tumor areas, where the liposomes can enter.
Blood kinetics were assessed for all formulations using radiolabeled TSLs allowing to 
differentiate between the blood half-life of the liposomal carrier and that of Dox. All 
liposomal carriers showed a mono-exponential clearance, with blood circulation half-
lives ranging from 4 to 8 hours with increasing DSPC content. This effect might be at-
tributed to an increasing membrane rigidity with increasing DSPC content, which could 
lead to a decreasing affinity for serum opsonins and thus reduced clearance [25,26]. 
Similar behavior has been reported by Zisman et al. for cisplatin containing liposomes, 
where liposomes containing DPPC as the main constituent showed shorter blood half-
lives compared to DSPC-rich formulations [27]. Upon injection, all TSLs showed a rapid 
“burst” release of Dox, followed by a further slow leakage of Dox from its liposomal car-
rier. While the burst release decreased with increasing DPPC content, the subsequent 
leakage rate (kleak) increased. Taking the blood half-lives of the liposomal carriers into 
account, our pharmacokinetic model allowed calculating the AUC of Dox for all differ-
ent formulations. Interestingly, over the time span of 1 hour p.i., the AUC is similar for 
all formulations. The ‘burst effect’ was unexpected based on the in vitro stability studies 
and also the in vivo leakage rates were higher compared to the data obtained in vitro. 
Needham and coworkers also observed a Dox burst release from DPPC-DSPE-PEG2000 
TSLs, which they explained with an instantaneous release of membrane-bound Dox at 
Tm [9]. The lack of burst release in the in vitro data could be explained by both the ab-
sence of full blood and the difference in serum between species (bovine for in vitro and 
murine for in vivo) [8,28,29]. Although the TSL70A and TSL80A showed more leakage 
over time than the TSL50A and TSL60A, the leakage half-lives were still relatively long 
compared to LTSLs, leading to a better [Dox/liposome] parameter (Eq. 1). As Al Jamal et 
al. [30] showed, for LTSL the Dox:lipid ratio decreases to ~0.3 after 1 hour, compared to 
0.7 for TSL80A. 
A therapeutic study was performed in BFS-1 tumor bearing mice testing the efficacy 
of the TSL50-80A formulations with and without HT. Notably, exposing the tumor to 
one hour HT already induces a therapeutic effect leading to a reduced tumor growth 
compared to untreated tumors. A possible explanation can be HT induced cytotoxicity 
and blood vessel shutdown [31–33]. HT in combination with all liposomes significantly 
increased the therapeutic effect further (TSL50A, p = 3∙10-3; TSL60A, p = 3∙10-4; TSL70A, 
p = 1∙10-3; TSL80A p = 2∙10-3). For all formulations, the AUC at 37˚C was comparable, 
which can partly explain the lack of distinction between the formulations. Moreover, 
TSL60A, TSL70A and TSL80A all had similar in vitro release kinetics, whereas the 
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TSL50A formulation did show incomplete and slow release both in vitro as well as in 
vivo using the dorsal skinfold window model. The fact that this observed difference in 
release kinetics did not result in a significant therapeutic benefit might be caused by a 
saturation of the tumor tissue with Dox due to the long treatment duration and dosage.
In a current phase III clinical trial using LTSL in combination with radiofrequency 
ablation (RFA) of primary liver tumors, the treatment did not result in a significant 
increase in overall survival when compared to treatment by an RFA control (HEAT trial 
[34,35]). However, post-hoc subgroup analysis revealed a greater than two-year survival 
benefit for a subgroup of patients that received an optimized RFA treatment of 45 min-
utes or more [36,37]. This is indicative of the effect the treatment duration and other 
aspects of the clinical workflow could have on the performance of a TSL formulation. 
Above analysis and pharmacokinetic model allows evaluation of formulations for 
possible clinical application, as well as the implications of the clinical workflow, such as 
infusion time and timing of HT. For example, in above mentioned HEAT trial [34] as well 
as the OPTIMA trial [38]), both using Thermodox® in combination with radiofrequency 
ablation of primary liver tumors, Thermodox® is administered by infusion over 15-30 
minutes. According to the trial protocol, the tumor is heated by radiofrequency ablation 
which is initiated minimally 15 minutes and should be completed maximally 3 hours 
after the start of the infusion. With the Dox circulation time in mind, it is obvious that 
the Dox AUC will drop when the time between HT and TSL administration increases. 
Therefore, it is important to also assess the capabilities of a formulation at clinically 
relevant, later time points. While the Dox blood kinetics in our current study was com-
parable for the different TSL formulations in AUC from 1 – 60 minutes after injection, 
the AUC at a later time span, e.g. during a heating period from 30 to 90 minutes after in-
jection, is actually larger for the TSL70A compared to all other formulations. Therefore, 
if heating is applied at a later time period after infusion, TSL70A might give a higher Dox 
accumulation in the tumor tissue than TSL60A or TSL80A. Another aspect to consider 
is that Dox accumulation in the tumor can be limited by saturation of drug uptake using 
a treatment dose of 5 mg / kg. This effect could allow slower releasing TSL formulations 
to yield similar intratumoral Dox concentrations as faster releasing TSL explaining the 
similar therapeutic efficacy observed for TSL60,70,80A [39,40]. From a clinical workflow 
perspective, a TSL formulation is preferred that ensures a reasonably high AUC of Dox 
also at later times after injection, which eases time constraints in a clinical application. 
In this respect, TSL70A seems to be the best candidate having a relatively low burst, low 
leakage, a high AUC at later time points and rapid release (Figure 16). 
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conclusion
In search for an optimized Dox-TSL formulation, it is crucial to acknowledge that stabil-
ity and release kinetics of the formulation might not fully reflect its in vitro behavior. 
In the current study, different Dox-TSL formulations were subjected to rigorous in vitro 
and in vivo testing. A burst in Dox release was observed in vivo which was not predicted 
based on the in vitro stability and release assays. Moreover, the differences in Dox release 
between TSL formulations that were observed in vitro, were less apparent in vivo. This 
indicates that an optimal treatment with Dox-TSL is not solely dependent on an optimal 
TSL formulation alone and is likely to be influenced by the interplay between release 
kinetics, Dox saturation in the tumor area and effective tumor Dox uptake, topics which 
require further investigation. The formulations presented here display a relatively slow 
Figure 16. Schematic representation of the results found of TSL50, 60, 70 & 80. With increasing fraction of DPPC, the 
release kinetics at HT increases with similar release rates at 42°C. However, the leakage in circulation also increases 
with increasing amounts of DPPC. Furthermore, DPPC rich liposomes are more prone to interact with proteins in cir-
culation, giving them a shorter circulation time which has been indicated in various studies [26–28]. When liposomes 
contain more DSPC (TSL50 & TSL60), there is a larger likelihood for a burst release that takes place as soon as the 
particles enter circulation.
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Dox leakage and a long liposome half-life which could be beneficial in a clinical setting 
where formulations with high AUC values are demanded because of variable time spans 
between TSL infusion and HT treatment. The optimal Dox-TSL formulation needs to 
be designed keeping the clinical workflow in mind and should be selected based on 
extensive in vivo tests combined with blood kinetics modelling.
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abstract
Doxorubicin (Dox) loaded thermosensitive liposomes (TSLs) have shown promising re-
sults for hyperthermia-induced local drug delivery to solid tumors. Typically, the tumor 
is heated to hyperthermic temperatures (41-42 °C), which induced intravascular drug 
release from TSLs within the tumor tissue leading to high local drug concentrations 
(1-step delivery protocol). Next to providing a trigger for drug release, hyperthermia (HT) 
has been shown to be cytotoxic to tumor tissue, to enhance chemosensitivity and to 
increase particle extravasation from the vasculature into the tumor interstitial space. 
The latter can be exploited for a 2-step delivery protocol, where HT is applied prior to i.v. 
TSL injection to enhance tumor uptake, and after 4 hours waiting time for a second time 
to induce drug release. In this study, we compare the 1- and 2-step delivery protocols 
and investigate which factors are of importance for a therapeutic response. In murine 
B16 melanoma and BFS-1 sarcoma cell lines, HT induced an enhanced Dox uptake in 
2D and 3D models, resulting in enhanced chemosensitivity. In vivo, therapeutic effi-
cacy studies were performed for both tumor models, showing a therapeutic response 
for only the 1-step delivery protocol. SPECT/CT imaging allowed quantification of the 
liposomal accumulation in both tumor models at physiological temperatures and after 
a HT treatment. A simple two compartment model was used to derive respective rates 
for liposomal uptake, washout and retention, showing that the B16 model has a two-
fold higher liposomal uptake compared to the BFS-1 tumor. HT increases uptake and 
retention of liposomes in both tumors models by the same factor of 1.66 maintaining 
the absolute differences between the two models. Histology showed that HT induced 
apoptosis, blood vessel integrity and interstitial structures are important factors for TSL 
accumulation in the investigated tumor types. However, modeling data indicated that 
the intraliposomal Dox fraction did not reach therapeutic relevant concentrations in 
the tumor tissue in a 2-step delivery protocol due to the leaking of the drug from its 
liposomal carrier providing an explanation for the observed lack of efficacy.
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introDuction
Classical chemotherapy for treatment of solid tumors typically employs cytotoxic drugs 
with low molecular weight that have sizes below 1 nm. The latter allows the drugs to 
efficiently extravasate upon injection from the vascular compartment into the tumor 
tissue in order to reach their targets. However, as extravasation is not restricted to the 
tumor tissue, toxicity imposed on healthy tissues is limiting the therapeutic window. 
One approach to limit off-target toxicity is the encapsulation of cytotoxic drugs into 
nanoparticles, such as liposomes with sizes in the range of 50-200 nm, which reduces 
side effects observed for free drugs. In contrast to healthy tissues, tumors exhibit a poorly 
organized vascular system [1, 2] with endothelial gaps [3, 4] that allow extravasation and 
accumulation of nanoparticles up to several hundred nanometers [1, 5]. In addition, 
as tumors often lack a functional lymphatic system, which impedes efficient clearance 
of nanoparticles, substantial retention of long circulating nanoparticles is observed 
[6, 7]. This enhanced permeability and retention (EPR) effect was first described for 
macromolecules by Matsumura and Maeda [8] and is a prerequisite for liposomal drug 
targeting. Today, several lipomosal drug formulations are clinically approved, mostly 
due to their improved toxicity profile [7]. One example is Doxil®, a long circulation lipo-
somal formulation of Doxorubicin (Dox) [9, 10]. While liposomal encapsulation reduces 
off-site toxicity, it unfortunately reduces bioavailabity of the parent drug. Drug release 
from the liposomal carrier is slow as it is based on passive diffusion of the drug across 
the liposomal lipid bilayer, which strongly reduces peak concentrations [11]. An alterna-
tive approach is heat-triggered drug delivery using a drug that is encapsulated in the 
aqueous core of a temperature sensitive liposome (TSL), as first proposed by Yatvin and 
Weinstein [12]. A TSL retains the drug at body temperature, but rapidly release their pay-
load at mild hyperthermic temperatures (40-43 °C). Heating the targeted tissue to these 
temperatures, for example using radiofrequency or high intensity focused ultrasound, 
leads to rapid intravascular release with subsequent substantial drug deposition in the 
tumor, which is investigated in numerous preclinical [13-17], yet also clinical studies [18, 
19]. 
Next to providing a trigger for drug release, hyperthermia (HT) exposure can induce 
multiple other changes on cellular as well as tissue level [20, 21]. HT can cause direct 
cytotoxicity in vitro [22] and in vivo, which depends on the absolute temperature and 
exposure time, but also on the type of cell or tissue [23, 24]. Secondly, HT can increase 
chemosensitivity [25, 26] due to a synergistic effect between HT- and drug-induced cyto-
toxicity or due to an increased drug uptake as HT enhances cell membrane permeability 
[27, 28]. On tissue level, preclinical studies have shown that HT increased liposomal 
uptake in tumors [29-33]. However, clinical trials using Doxil® in combination with HT 
showed variable therapeutic outcomes, highlighting the clinical need for a liposomal 
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formulations that could more effectively release the drug [34, 35]. The latter inspired the 
design a 2-step drug delivery scheme, where first HT is applied to enhance the EPR effect 
followed by injection of TSLs. After accumulation of TSLs in the tumor, drug release is 
triggered with a second application of HT to ensure bioavailability of the drug.
In a previous study, Li et al. performed a comparative study with Dox loaded TSL 
using the aforementioned 2-step drug delivery scheme versus a 1-step intravascular 
HT-drug delivery scheme in a murine BLM melanoma model [36]. The conclusion of 
that study was that a 1-step treatment was more efficacious in treating a solid tumor 
than the 2-step approach. Here we provide a follow-up study, investigating 1-step and 
2-step HT TSL based treatments in terms of in vitro cytotoxicity, drug uptake by cells, 
therapeutic efficacy and quantitative TSL uptake by B16 melanoma and BFS-1 sarcoma 
tumors. Furthermore, extensive ex vivo investigation provide data giving more insights 
into microenvironmental factors that could play a role in TSL accumulation for B16 and 
BFS-1 tumors and the influence of HT on these factors.
materials & methoDs
materials
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
(amino(poly ethylene glycol)-2000) (DSPE-PEG2000) were purchased from Lipoid 
(Ludwigshafen, Germany). DSPE-diethylenetriaminepentaacetic acid (DTPA) was 
obtained from Avanti Polar Lipids Inc. (Alabaster, AL). Doxorubicin-hydrochloride 
solution (2 mg/ml) was ordered from Accord Healthcare. 4-(2-hydroxyethyl)-1-piper-
azineethanesulfonic acid (HEPES), (NH4)2SO4, DMEM culture medium, fetal bovine 
serum (FBS), sulforhodamine B (SRB), poly(2-hydroxyethylmethacrylate; HEMA), 
2-Amino-2-hydroxymethyl-propane-1,3-diol (Tris), NaCl, glycerol, Mayer’s hematoxy-
lin, eosin Y, Martius yellow, crystal scarlet and methyl blue were from Sigma Aldrich 
(St. Louis, MO). Nonyl phenoxypolyethoxylethanol (NP40) was purchased from ICN 
Biomedicals (Irvine, CA). Penicillin-streptomycin (Pen-Strep) solution was from Lonza 
(Breda, Netherlands). PD-10 desalting columns were bought from GE Healthcare Life 
Sciences (Buckinghamshire, UK). Entallan and rabbit-anti mouse Collagen IV antibody 
were from EMD Millipore (Billerica, MA). CD31 antibody (rat anti-mouse) was bought 
from Abcam (Cambridge, UK) and AlexaFluor 594 (goat anti-rat) and AlexaFluor 488 
(goat anti-rabbit) from Invitrogen (Carlsbad, CA). Matrigel was acquired from BD (San 
Jose, CA). Cryo compound was from Klinipath (Duiven, Netherlands). Fluoromount-
G was provided by Southern Biotech (Birmingham, AL). Cell death detection kit was 
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obtained from Roche (Woerden, Netherlands). Weigert’s hematoxylin was purchased 
from Boom Chemicals (Meppel, Netherlands).
liposome preparation
DPPC:DSPC:DSPE-PEG2000 at a molar ratio of 70:25:5 were dissolved in 9:1 (vol:vol) chlo-
roform/methanol. Solvent was evaporated using a rotary evaporator and the resulting 
lipid film was flushed under a stream of nitrogen. The lipid film was hydrated with a 250 
mM solution of (NH4)2SO4 buffer pH 5.5 and extruded five times through 200 nm, 100 
nm, 80 nm and 50 nm polycarbonate membrane filters. A pH gradient was established 
using a PD-10 column and eluting the liposomes with a pH 7.4 HEPES buffered saline 
(10 mM HEPES, 135 mM NaCl). Phosphate concentration was determined by ammonium 
molybdate assay [37]. Dox was loaded into the liposomes by mixing Dox and lipid at a 
ratio of 0.15:1 (mol:mol) and incubating it for 1 h at 39 °C in a thermoshaker. Liposomes 
were concentrated by ultracentrifugation (193000 g, 2 h, 4 °C) and resuspended in 10 
mM HEPES buffered saline pH 7.4 yielding the final formulation of Dox-loaded TSLs 
(TSLDox).
radiolabeled liposome preparation
For radiolabeled TSLs (111In-TSL), 0.1 mol% DSPE-DTPA was added to the formulation 
described above and produced in a similar fashion as the regular TSLs, with the excep-
tion that the liposomes were not loaded with Dox. 1 µmol TSLs was incubated with 30 
MBq 111In for 15 min at room temperature after the pH was set at 5.0 with 2.5 M sodium 
acetate. After incubation labeling efficiency was determined by ITLC-SG (Varian Inc.) 
and the final volume was adjusted to 200 µL with HEPES buffered saline (10 mM HEPES, 
135 mM NaCl, pH 7.4).
cellular toxicity assay
B16 or BFS-1 cells were seeded in 96-well plates and allowed to grow till 50% confluency 
in DMEM medium enriched with 10% FBS and 1% Pen-Strep. The medium was removed 
and fresh medium with a desired amount of free Dox or TSLDox was brought onto the 
cells and incubated according to Scheme 1. NT: incubation with Dox for 1 h at 37°C; 
HT42: incubation with Dox for 1 h at 42°C; HT41-NT: Preheating cells 1 h at 41°C, 4 h 
recovery at 37°C and a 1 h incubation with Dox at 37°C; HT41-HT42: Preheating cells for 1 
h at 41°C, 4 h recovery at 37°C and a 1 h incubation Dox at 42°C. For a TSLDox treatments 
on cells, 10 µM Dox was used. To apply HT, plates were put into a water bath set at the 
required temperature. After incubation, the Dox containing medium was removed and 
cells were given fresh medium for 24 h or 48 h incubation at 37°C. Cells were fixed using 
10% (w:v) trichloroacetic acid (TCA). After fixation, the plates were washed with water 
and 0.5% SRB solution was added to stain the fixed cells for 20 min. When staining was 
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completed, cells were washed with 1% acetic acid and left to dry. 10 mM Tris was added 
to resuspend the SRB and absorbance was measured at 590 nm by spectrophotometry 
(Wallac Victor 2 Counter).
cellular Doxorubicin uptake in 2D and 3D models
B16 or BFS-1 cells were seeded into 75 cm2 flasks and grown under similar conditions 
as mentioned above until 80% confluency was reached. The cells were subjected to 40 
µM Dox under four different treatment conditions as stated in Scheme 1. Exposing cells 
to elevated temperatures was done by submerging the 75 cm2 culture flask into a water 
bath. After incubation, the cells were washed with ice cold PBS, scraped from the flask 
and centrifuged at 200 g at 4°C. The pellets were resuspended in 150 µL lysis buffer (20 
mM Tris, 150 mM NaCl, 0.2% NP40, 10% glycerol, pH 7.4), followed by 30 min incuba-
tion on ice and centrifugation at 14,000 g. The pellets were resuspended and homog-
enized in 500 µL PBS by brief probe sonication and Dox concentration was measured 
by fluorometry at 485 nm excitation and 580 nm emission (Wallac Victor 2 Counter). 
Tumor spheroids were made according to a previously described method [38]. In short, 
conical shaped 96-well plates were coated with poly-HEMA and 1 x 105 cells which were 
centrifuged at 1,000 x g for 10 min in the presence of 2.5% Matrigel and incubated 
overnight at 37°C. After incubation, spheroids were handpicked and exposed to identical 
treatments as in the 2D model in a thermoshaker (no shaking). After incubation, the 
spheroids were washed in PBS, embedded into Fluoromount-G and imaged by confocal 
microscopy (Zeiss LSM 510 Meta; Oberkochen, Germany). A 5 µm Z-stack was made over 
the surface of the spheroid to determine total Dox fluorescence. For each optical slice, 
the amount of saturated Dox fluorescence pixels were counted. The sum of saturated 
pixels of all tumor slices was used as an indicator for Dox uptake. For cryo-sectioning, 
1 h 42 ºC
NT HT42
1 h 41 ºC 4 h 37 ºC 1 h 37 ºC
HT41-NT
Dox added
1 h 41 ºC 4 h 37 ºC 1 h 42 ºC
HT41-HT42
1 h 37 ºC
Scheme 1. Overview of different in vitro Dox uptake treatments. Dox exposure took place at 37°C (NT) or 42°C (HT42). 
In two additional groups, cells were preheated for 1 h at 41 °C (HT41) with a 4 h recovery at 37°C before Dox uptake under 
NT or HT42 conditions (HT41-NT and HT41-HT42, respectively).
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spheroids were embedded into Cryo Compound and snap frozen in liquid nitrogen. 
10 µm slices were made using a Cryostat (Leica CM1850 UV; Wetzlar, Germany), and 
afterwards embedded into Fluoromount-G and imaged using fluorescence microscopy 
(Zeiss Axiovert 100M; Hamamatsu Photonics C4742-98 camera controller).
b16 and bfs-1 tumor generation
Murine B16 melanoma or BFS-1 sarcoma cells (1 x 106) were subcutaneously injected 
into the flank of C57BL6 mice (Harlan) to grow bulk tumors. After reaching volumes 
of approx. 700 mm3, animals were sacrificed and tumor pieces were transplanted to 
the animals of the therapeutic studies. All animal experiments were approved by the 
Erasmus MC animal research committee, Rotterdam, The Netherlands. 
therapeutic efficacy studies in a b16 and bfs-1 model
1 mm3 B16 or BFS-1 tumor pieces were transplanted subcutaneously onto the hind limb 
of C57BL6 mice and allowed to grow to 200 mm3 after which treatments were initiated 
as shown in Scheme 2. NT: 1-step with 100 µL i.v. PBS injection and 1 h anesthesia at 
body temperature; HT42: 1-step with 100 µL i.v. PBS injection and 1 h anesthesia with 
heated tumor at 42 °C; TSLDox NT: 1-step with 100 µL 5 mg/kg TSLDox i.v. injection and 
1 h anesthesia at body temperature; TSLDox HT42: 1-step with 100 µL 5 mg/kg TSLDox 
i.v. injection and 1 h anesthesia with heated tumor at 42 °C; HT41-HT42: 2-step with 1 
h preheating tumor at 41 °C under anesthesia, 100 µL i.v. PBS injection, 4 h waiting 
period and 1 h anesthesia with heated tumor at 42 °C; TSLDox NT-HT42: 2-step with 1 
h anesthesia at body temperature, 100 µL 5 mg/kg TSLDox i.v. injection, 4 h waiting 
period and 1 h anesthesia with heated tumor at 42 °C; TSLDox HT41-HT42: 2-step with 1 
1 h 42 ºC
NT HT42
1 h 35 ºC 4 h 1 h 42 ºC
NT-HT42
1 h 35 ºC
1 h 41 ºC 4 h 1 h 42 ºC
HT41-HT42
TSLDox or PBS injection
Anesthesia
Scheme 2. Overview of 1-step and 2-step treatments in vivo. For 1-step, i.v. TSLDox administration was conducted at 
body temperature (NT) or when the tumor was brought to 42 °C (HT42). 2-step treatments were composed of keeping 
the mouse under anesthesia at body temperature for 1 h (NT-HT42) or preheating the tumor at 41 °C for 1 h (HT41-HT42), 
prior to TSLDox injection, 4h rest and a second tumor heating at 42 °C.
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h preheating tumor at 41°C under anesthesia, 100 µL 5 mg/kg TSLDox i.v. injection, 4 h 
waiting period and 1 h anesthesia with heated tumor at 42 °C. In the 1-step treatment 
protocol, the tumor was submerged into a 42.5 °C water bath for heating to 42 °C for 10 
min, followed by an i.v. injection of TSL (5 mg/kg Dox) and further heating for another 
hour. The 2-step treatment procedure included heating of the tumor to 41 °C for one 
hour and an i.v. injection of TSL (5 mg/kg Dox) 10 min after heating. Afterwards, the 
animal was allowed to rest for 4 h, followed by a second HT treatment for 1 h at 42 °C. In 
control groups normothermic (NT; 35 °C) conditions were used, where the animal was 
put under anesthesia for 1 h and kept at 35 °C on a 37 °C heating plate while covering the 
animal with tin foil. During both HT and NT experiments, the tumor bearing limb, with 
exception of the tumor itself, was coated in vaseline to prevent possible skin burns. Body 
temperatures of the mice were measured using a rectal probe.
spect/ct imaging of tsl accumulation in a b16 and bfs-1 model
1 x 106 cells were subcutaneously injected on the hind limb of C57BL6 mice and tumors 
were allowed to grow to volumes of 200 mm3. Tumors were either heated for one hour at 
41 °C prior to injection or kept at 35 °C in a similar fashion as for the therapeutic study. 
111In-TSL were i.v. injected (200 µL per mouse with an average activity of 33 ± 2 MBq 111In) 
and scans were made 4 h, 8 h, 24 h and 48 h after injection. Scans were acquired using 
the nanoSPECT/CT (Mediso Medical Imaging Systems) with the following settings for 
the SPECT scans: 20 projections, 60 seconds/projection, and a quality factor of 0.8. 
APT1 apertures were used with 1.4 mm diameter pinholes (FOV 24 + 16 mm). CT scans 
were acquired with 240 projections, 45 kVp tube voltage and 500 ms exposure. Data 
analysis was performed using InVivoScope/VivoQuant software (inviCRO, Boston, MA), 
where three-dimensional regions of interest were drawn over the tumor to calculate 
uptake of 111In-TSL at the selected time points. After the last scan, the animals were sacri-
ficed and tumors and organs were harvested, weighed and radioactivity was determined 
using a γ-counter to calculate percentage injected dose per gram (%ID/g). All data were 
corrected for radioactive decay.
pharmacokinetic modelling
The blood kinetics and pharmacokinetic parameters of the TSLDox formulation were 
determined in an earlier study (Figure 1) [39]. Results from that study showed that the 
blood half-life of liposomal carrier Clip(t) can be described with a mono-exponential 
function:
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Figure 1. Blood kinetics of TSL and Dox from injected TSLDox in C57BL6 mice. Figure is based on 
previously shown results by our group [39]. 
Results from that study showed that the blood half-life of liposomal carrier Clip(t) can be 
described with a mono-exponential function: 
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with Clip(0)=100%ID at time point of injection and t1/2,TSL = 5.6 ± 0.4 h being the circulation 
half-life of the liposomes. Upon injection, a fraction of Dox is instantaneous released (Burst = 
8 ± 3 %) followed by a slow leakage of Dox from the liposomal carrier with a half-life of t1/2,leak 
= 2.7 ± 0.3 h.  The concentration of intraliposomal dox CDox,TSL(t) can be described with the 
following equation:  
 Eq.1
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with Clip (0)=100%ID at time point of injection and t1/2,TSL = 5.6 ± 0.4 h being the cir-
culation half-life of the liposomes. Upon injection, a fraction of Dox is instantaneous 
released (Burst = 8 ± 3 %) followed by a slow leakage of Dox from the liposomal carrier 
with a half-life of t1/2,leak = 2.7 ± 0.3 h. The concentration of intraliposomal dox CDox,TSL(t) 
can be described with the following equation: 
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 Eq. 2
The concentration of (radiolabeled) liposomes in the tumor, CTSL,tumor(t), can be described 
with a simple two compartment model: 
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 Eq.3
where kin, kout and kret describe the rates of uptake, washout and retention of TSL in the 
tumor compartment. 
Concentration of intraliposomal Dox within the tumor is subsequently numerically 
calculated assuming the same burst and leakage of Dox from the liposomal carrier as 
found for TSLDox in the blood compartment. Numerical integration of Eq. 3 and fitting of 
the SPECT data was performed using Mathematica® (version 10.2, Wolfram Research).
histology
After the SPECT/CT experiments, the excised tumors were snap frozen in liquid nitro-
gen. 5 µm slices were cut and tumors were stained for vessels with an anti-CD31 antibody 
and AlexaFluor 594 or collagen with anti-collagen IV antibody and AlexaFluor 488. The 
TUNEL staining was performed with a cell death detection kit. The CD31 and TUNEL 
Figure 1. Blood kinetics of TSL and Dox from injected TSLDox in C57BL6 mice. Figure is based on previously shown 
results by our group [39].
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stains were quantified using ImageJ (version 1.48) software and by setting a manual 
threshold. A second set of frozen slices was stained with Maier’s hematoxylin and Eosin 
(H&E) or by Weigert’s hematoxylin, Martius yellow, crystal scarlet and methyl blue 
(MSB), followed by mounting in Entallan. The slices were imaged for fluorescence by 
confocal microscopy (CD31, collagen IV & TUNEL) or bright field microscopy (Leica DM 
4000B) for H&E and MSB stained sections.
statistics
All statistical tests were carried out using Graphpad Prism 5 software. All figures were 
subjected to unpaired two tailed t-test or one-way ANOVA Bonferroni test with signifi-
cant difference at p < 0.05.
results
preparation of tslDox
Loading of TSL with the formulation DPPC:DSPC:DSPE-PEG2000 at a molar ratio of 
70:25:5 with Dox was achieved with 100% efficacy. Dynamic light scattering of the 
resulting TSLDox indicated an average hydrodynamic diameter of 83 ± 3 nm and a zeta-
potential of -7.9 ± 0.9 mV. Stability at 37 °C and release kinetics at 42 °C were tested 
in culture medium (10% FBS and 1% Pen-Strep) and were found to be similar to results 
obtained with 100% FBS as described in our previous work (Figure 2) [39].
cytotoxic assays on b16 melanoma and bfs-1 sarcoma cells
In an in vitro study, murine B16 melanoma and BFS-1 sarcoma cells were exposed to 
various Dox concentrations for 1 h under the conditions depicted in Scheme 1. Both cell 
lines showed an increased sensitivity to Dox when the drug exposure was performed at 
Figure 2. Dox release from TSL at 37 °C and 42 °C in DMEM culture medium with 10% FBS and 1% Pen-Strep using 
fluorescence readout. Each curve represents an average of three measurements.
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hyperthermic temperatures (Figure 3). For B16 (Figure 3A, B) and BFS-1 (Figure 3C, D), 
the Dox sensitivity increased 8-fold. Additional pre-heating (HT41-HT42) did not result 
in a further increase in Dox sensitivity for B16. However, the 18-fold increase for BFS-1 
was significantly higher than the single HT treatment. In this case direct HT-induced 
cytotoxicity could have played a predominant role (Figure 4). B16 and BFS-1 cells were 
furthermore tested for survival after incubation with TSL (empty), 10 µM TSLDox or 10 µM 
BA
NT HT42 HT41-NT HT41-HT42
C D
10 - 9 10 - 7 10 - 5 10 - 3 10 - 1 10 1
0
20
40
60
80
100 NT
HT41-NT
HT41-HT42
HT42
[Dox] mM
%
 S
ur
vi
va
l
NT HT42 HT41-NT HT41-HT42
0
210 - 3
410 - 3
610 - 3
810 - 3
110 - 2
*** ***
IC
50
D
ox
 (m
M
)
10 - 9 10 - 7 10 - 5 10 - 3 10 - 1 10 1
0
20
40
60
80
100 NT
HT42
HT41-NT
HT41-HT42
[Dox] mM
%
 S
ur
vi
va
l
0
210 - 3
410 - 3
610 - 3
810 - 3
110 - 2
***
***
IC
50
D
ox
 (m
M
)
Figure 3. Dox cytotoxicity assay and IC50 values for B16 (A, B) and BFS-1 cells (C, D) 48h after treatment by different 
hyperthermia protocols. n = 3 for each data set. Curves were fit by non-linear regression and statistical analysis by one-
way ANOVA Bonferroni test. The significance scores of all treatments versus NT groups are indicated with asterisks. * 
= p < 0.05, ** = p < 0.01, *** = p < 0.005.
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Figure 4. Analysis on HT induced cytotoxicity on B16 (A) and BFS-1 cells (B) in the experimental groups of Figure 1. 
Survival of experimental groups is normalized versus the NT group. n = 3 per group and one-way ANOVA Bonferroni 
test was used for statistical analysis of the data. * = p < 0.05, ** = p < 0.01, *** = p < 0.005.
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free Dox under normothermic (NT; 37 °C) and HT42 conditions for 1 h. After the treat-
ment, the cells were kept in culture medium for 24 h or 48 h. At 37 °C, TSLDox induced 
little toxicity to the cells, while at 42 °C the release of Dox was sufficient to cause high cell 
death (Figure 5). The TSL by itself had no inhibitory effect on cell growth, while HT did 
show some direct cytotoxicity, which was only significant for B16 24 h after incubation 
with 72 ± 11% viable cells compared to the NT group (Figure 5A). The addition of 10 µM 
TSLDox to a 1 h incubation with HT42 resulted in an immediate cytotoxic effect 24 h after 
the incubation (Figure 5A) with 25 ± 6% for B16 and 57 ± 7% for BFS-1. This cytotoxic 
effect became even more apparent 48 h after incubation, showing an almost complete 
cell death for both cell types (Figure 5B). The TSLDox HT42 group showed similar results 
as where 10 µM free Dox was used (Dox HT42), suggesting a total Dox release from TSLDox 
in these experimental conditions. A cytotoxicity assay using a 2-step heating protocol 
was not performed, as the main cytotoxic effect was caused by the increased uptake of 
free or released Dox during HT42.
In vitro Doxorubicin uptake in 2D and 3D models
Next, the effect of HT on Dox uptake was studied in B16 and BFS-1 cells. Both cell lines 
exhibited a linear uptake of Dox over time at body temperature (Figure 6A,B). Incuba-
tion of both cell lines with Dox at HT42 significantly increased Dox uptake 9-fold for 
B16 (Figure 6A) and 6-fold for BFS-1 cells (Figure 6B). Groups were added where the 
cells were preheated at 41 °C for 1 h followed by 4 h at 37 °C to mimic a 2-step approach 
therapy. Preheating of the cells before incubation with Dox at NT (HT41-NT) or HT42 
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Figure 5. Cytotoxicity assay on B16 and BFS-1 cells 24 h (A) and 48 h (B) after a 1 h incubation with 10 µM TSLDox or free 
Dox under NT (37 °C) or HT42 (42 °C) conditions. n = 3 for each data set. Statistical analysis was carried out using one 
way ANOVA Bonferroni test comparing the treatment groups with the NT group separately at 24h and 48h. The signifi-
cance scores of all treatments versus NT groups are indicated with asterisks. * = p < 0.05, ** = p < 0.01, *** = p < 0.005.
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(HT41-HT42) conditions did not result in a significant difference compared to Dox uptake 
without preheating. Next, we used multicellular spheroids of BFS-1 cells to determine 
the Dox uptake as well as spatial distribution under the different temperature protocols 
in a 3D model. After performing similar incubation protocols as described before, the 
BFS-1 spheroids showed a similar pattern in Dox uptake than BFS-1 cells in the 2D stan-
dard culture conditions (Figure 6C). When the Dox fluorescence intensity was quanti-
fied (Figure 6D), HT42 and HT41-HT42 presented significantly more Dox positive areas 
than NT spheroids with a 6-fold and 10-fold increase in the summation of saturated 
Dox fluorescence pixels, respectively. HT41-NT treatment did not result in a significantly 
enhanced uptake. Dox did not penetrate farther than the first few cell layers into the 
spheroid, despite the heating protocol used (Figure 6E). B16 cells did not form spheroids 
and could therefore not be studied in the 3D Dox uptake model.
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Figure 6. Two-dimensional Dox uptake in B16 (A) and BFS-1 (B) cell cultures and BFS-1 spheroids (C-E). Cells or spher-
oids were exposed to 40 µM Dox for 1 h at 37 °C (NT), 42 °C (HT42), or preheated at 41 °C followed by 4 h at 37 °C before 
a 1 h exposure to 40 µM Dox at NT (HT41-NT) or HT42 (HT41-HT42). Optical slices of 5 µm made by confocal microscopy 
of the spheroid (C) were summed up to determine the Σ saturated pixels (red) per spheroid (D). Cryosections of 10 µm 
(E) of the BFS-1 spheroids show spatial distribution of Dox fluorescence (red). All data sets are composed of an n = 3 
experiment and compared by one way ANOVA Bonferroni test, * = p < 0.05, ** = p < 0.01, *** = p < 0.005. Asterisks 
show significance compared to NT groups. Scale bars represent 100 µm.
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1-step & 2-step therapeutic study
A therapeutic study with B16 (Figure 7A, B) and BFS-1 (Figure 7C, D) tumors were 
subjected to 1-step or 2-step therapies (Scheme 2). We chose 41 °C as preheating tem-
perature since it has been shown that an intratumoral increase of TSLDox accumulation 
can be established [31] without risking significant vascular damage [40]. In both B16 and 
BFS-1 tumors, TSLDox with HT42 significantly outperformed all other treatments with an 
average improvement of survival of 7.1 ± 1.4 days for B16 and 14.6 ± 2.8 days for BFS-1 
when compared to the NT group. The body temperature differed significantly between 
NT and HT42 treated mice (Figure 8). Nevertheless, it remained at a physiological level 
with 35.0 ± 0.4 °C and 36.9 ± 1.1 °C, respectively.
Quantitative spect/ct imaging of tsl accumulation in solid tumors
A SPECT/CT study with 111In-TSL (labeling efficiency > 99%) was carried out to visual-
ize the particle uptake in B16 and BFS-1 tumor bearing mice, comparing NT conditions 
versus tumor preheating for 1 h at 41°C prior to injection (HT41). SPECT imaging over 
time showed that the majority of the injected 111In-TSL were cleared by liver and spleen 
(Figure 9A, B) with tumor uptake over time. For all tumors, a maximum uptake was 
observed approx. 4 h post injection followed by a slight reduction over time leveling 
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Figure 7. Therapeutic efficacy study in C57BL6 mice with s.c. B16 or BFS-1 tumors. After treatment, results for B16 tu-
mors were plotted for growth (A) and survival (B). Survival (B) was based on a size cutoff at 300% tumor size increase. 
Error bars in growth curve (A) represent SEM and one way ANOVA Bonferroni test was used to determine differences 
of survival in B (* = p < 0.05, ** = p < 0.01, *** = p < 0.005). Asterisks above bars show significance versus NT. BFS-1 is 
presented similarly in C and D. n = 4 for NT, TSLDox NT and HT42 groups; n = 5 for all other groups.
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off at 48 h post injection. Under NT conditions, plateau values of 3.2 ± 0.5 and 1 ± 0.3 
%ID/cc were reached for B16 and BFS1 tumors respectively. Applying HT41 before injec-
tion increased uptake in both tumors, leading to higher maximum as well as plateau 
concentrations (B16: 6.2 ± 1.5 %ID/cc, BFS1: 3.3 ± 2.8 %ID/cc at 48 h p.i.) (Figure 9A-D). 
Biodistribution studies at t = 48 h p.i. were consistent with data derived from SPECT 
showing an uptake of 111In-TSL in B16 tumors 2.8 ± 0.5 %ID/g compared to a consider-
able lower uptake of 0.9 ± 0.2 %ID/g in BFS-1 tumors for NT experiments (Figure 9E,F). 
Applying HT41 before injection resulted in a significantly increased 
111In-TSL accumu-
lation measured after 48 h in B16 tumors (5.0 ± 1.0 %ID/g; Figure 9C, E) and BFS-1 
tumors (2.6 ± 1.0 %ID/g; Figure 9D, F). SPECT data were used to fit the liposomal tumor 
uptake according to a simple two compartment model, deriving the rates for uptake, 
washout and retention, kin, kout, kret, in the two different tumors under NT and HT41 
conditions (Table 1). Taking the earlier determined pharmacokinetic properties of the 
here used TSLDox formulation into account (Figure 1), the model also allowed to calculate 
the concentration of intraliposomal Dox present in the tumors as a function of time 
(Figure 9C,D). Maximum concentrations of intraliposomal Dox were reached approx. 2 
hours p.i.. In contrast to the liposomal concentrations, intraliposomal Dox concentra-
tions decreased to zero 15-20 hours p.i. due to the leakage from the liposomal carrier. 
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Figure 8. Body temperature readings of mice under anesthesia, on a 37 °C heating plate, covered with tin foil (NT), or 
mice under anesthesia with the tumor bearing limb submerged in a 42.5 °C water bath (HT42). n = 6 per group. Tem-
perature readings were performed rectally with a probe thermometer every ten minutes. For every time point, statisti-
cal analysis was performed by unpaired two-tailed t-test. * = p < 0.05, ** = p < 0.01, *** = p < 0.005.
Table 1. Pharmacokinetic parameters describing the tumor uptake and retention in B16 and BFS-1 tumors.
Tumor Condition kin / (1/h) kout / (1/h) kret / (1/h)
B16
NT 0.0157 ± 0.004 0.39 ± 0.16 1.4 ± 0.63
HT41 0.0233 ± 0.007 0.36 ± 0.22 2.5 ± 1.64
BFS-1
NT 0.0074 ± 0.003 0.69 ± 0.34 0.7 ± 0.38
HT41 0.0127 ± 0.001 0.36 ± 0.07 1.2 ± 0.24
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The uptake as well as the retention rate of liposomes in B16 tumors was ca. 2 times 
higher compared to BFS-1 tumors, while washout was comparable for both tumors. 
Notably, HT41 induced in both tumors a comparable effect with increasing the kin, and 
kret by a factor of ca. 1.66 ± 0.13 leading to a more rapid and higher uptake of liposomes 
and consequently a high Dox peak concentration.
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Figure 9. SPECT-CT study on 111In-TSL distribution in B16 (A, C, E) and BFS-1 (B, D, F) tumor bearing mice. After i.v. 
administration, scans were made at 4 h, 8 h, 24 h and 48 h for all groups. B16 (A, C) and BFS-1 (B,D) tumors showed 
111In-TSL accumulation after i.v. administration at NT, which could be significantly enhanced (unpaired two-tailed t-
test; p < 0.05) by pre-heating the tumor for 1 h at 41 °C prior to 111In-TSL administration (HT41). The green line shows 
the 4 h time point where a second HT treatment would have taken place in case of a 2-step therapy. Biodistribution of 
111In-TSL was done by γ-counting on excised organs and tumors (E, F) 48h hours after injection. Every group consisted 
of three animals (n = 3).
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histology
After the SPECT-CT study, the tumors were used for H&E, MSB, TUNEL, CD31 and colla-
gen IV staining (Figure 10 & 11). H&E staining indicated that B16 tumors have less strong 
cellular interactions as can be seen by the gaps in the tissue (Figure 10A), whereas BFS-1 
has a much more compact morphology. Furthermore, the H&E (Figure 10A, arrows) 
suggests that the B16 tumors are more apoptotic. Yet after HT41, apoptotic areas could be 
seen in both tumor types. MSB staining showed that B16 tumors have a very low presence 
of extracellular fibers (Figure 10B), whereas BFS-1 showed a more mature extracellular 
matrix (Figure 10C). Quantitative TUNEL staining (Figure 11A) showed high apoptosis of 
14.4 ± 10.0% for B16 when compared to BFS-1 with 0.4 ± 0.1%. HT41 caused an increase of 
apoptosis, showing 24.5 ± 13.2% for B16 and 1.2 ± 0.4% for BFS-1, which was a significant 
increase for the latter. The vessel staining using CD31 indicated a comparable mean ves-
sel density for both tumor models (Figure 11B). The quantitative collagen IV staining 
confirmed the result of the MSB staining with 3.6 ± 0.3% for B16 and 14.8 ± 1.2% mean 
density for BFS-1 (Figure 11C). The B16 vessels were relatively large with collagen almost 
solely associated with the vessels (Figure 11D), whereas BFS-1 vessels were smaller and 
the interstitium consisted of more extracellular collagen matrix (Figure 11E).
A
B
16
B
FS
-1
NT HT41
B C
Figure 10. 5 µm H&E stained sections of B16 and BFS-1 tumors 48 h after NT or HT41 (A). Black arrows indicate apop-
totic areas. MSB stained B16 (B) and BFS-1 (C) collagen in blue. Scale bars represent 200 µm in A and 20 µm in B and C. 
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Discussion
In the field of nanomedicine, substantial research has been performed throughout the 
last decades on HT-triggered drug release from TSLs for treatment of solid tumors. In 
this context, mainly 1-step intravascular drug delivery schemes were employed, where 
tumors are heated to hyperthermic temperatures and drug loaded TSL are injected at the 
start of the HT treatment. In a previous study conducted by Li et al [36], a 2-step treat-
ment scheme was investigated as a possible alternative in a BLM melanoma xenograft, 
where first HT41 is applied to enhance vascular permeability, then a TSLDox formulation 
was injected that subsequently accumulated in the tumor, followed by a second HT42 
step to release the drug from its carrier in order to ensure bioavailability. The aforemen-
tioned study showed in contrast to the 1-step therapy, that the 2-step approach was not 
effective in causing a therapeutic response. In our experimental design we chose for a B16 
melanoma and BFS-1 sarcoma cell line because tumors from these cell lines have been 
previously reported to show high and low EPR-mediated uptake of TSL, respectively [31]. 
We tested how these tumors respond to a 1-step versus 2-step therapy, expanded the 
knowledge on how the tumor models responded to single versus multiple HT treatments 
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Figure 11. Quantification of cryo-section staining with TUNEL (A), CD31 (B) and collagen IV (C) was analyzed by 
unpaired two tailed t-test (* = p < 0.05). B16 (D) and BFS-1 (E) blood vessels colored red for CD31. Collagen IV stained 
in green. Scale bar shows 50 µm. n = 3 for all groups.
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in combination with local chemotherapy and provide extensive information on what 
factors can cause the differences in TSL accumulation between these tumors and which 
of these factors could be influenced by HT to increase TSL accumulation. 
B16 and BFS-1 cells showed a significant increase in Dox sensitivity when the drug 
exposure happened during HT42. The reduced IC50 with HT correlated with the increase 
Dox uptake by the cells discussed hereafter. Previously published data on this correla-
tion showed that the outcome of these experiments depend on cell type and specific ex-
perimental conditions, e.g. exact temperature and duration of HT exposure [27, 41-43]. 
Testing TSLDox on these cells showed that at 37 °C the cytotoxic effect is minimal, whereas 
at 42 °C, the TSLDox released all drug and therefore cytotoxicity was comparable to free 
Dox. The small cytotoxic effect at 37°C could be caused by cellular uptake of TSLDox or by 
Dox leaking from the liposomes into culture medium (Figure 2). Next, we investigated 
the presence of a synergistic effect of Dox and HT for different heating schemes in a 2D 
and 3D cellular model. In a 2D model, it was shown that HT42 induces a faster cellular 
uptake of Dox leading to a 6-9 times higher rate of uptake in B16 and BFS-1 cells than at 
37 °C. Preheating the cells for 1 h with HT41 followed by incubation for 4 h at 37 °C before 
adding Dox did not show any improvement of Dox uptake, indicating that HT-induced 
effects at 41 °C were reversible in nature and could only improve drug uptake during the 
heating and not thereafter. As the Dox uptake is caused by passive diffusion across the 
cell membrane, increase of cellular membrane fluidity and permeability during HT is 
the most likely explanation, since these effects are temporal in nature and fully revers-
ible [27, 28]. Other studies have shown that preheating to slightly higher temperatures 
of 43-45.5 °C lead to a reduced Dox uptake most likely due to a more permanent and 
irreversible temperature of thermal dose induced damage [41, 44]. However, HT41 used 
for preheating in this study did not induce this effect as has also been reported by others 
[45]. Spheroids mimic a solid tumor in terms of cell physiology, presence of extracellular 
matrix and an apoptotic core [46]. For this reason, we employed this model to investigate 
whether Dox penetration depth into a dense structure of cells is influenced by different 
heating conditions [47, 48]. BFS-1 spheroids showed a similar response in Dox uptake as 
the 2D model when different HT protocols were applied. However, it also showed that if 
cells are closely packed, the drug does not penetrate deep into the structure beyond the 
first few layers of cells. Neither the spatial distribution nor the penetration depth could 
be improved by HT in tumor spheroids. A comparative study using B16 cells was not 
possible since B16 cells did not form spheroids. The latter might be caused by the lack of 
a substantial cell-cell adherence, which was also observed in ex vivo examination of B16 
tumors described later in this section.
At this stage we have only shown the potential of local chemotherapy and HT in vitro. 
However, the described features are only a small part of the factors that have to be con-
sidered for drug delivery to solid tumors. Therefore, we performed a therapeutic study 
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as well as in vivo imaging and extensive ex vivo investigation on B16 and BFS-1 tumors 
to better understand the factors that could have played a role in various therapeutic 
responses. For both tumor types, a 1-step approach where TSLDox is i.v. administered 
during HT42 gave a significant therapeutic response, whereas a 2-step approach which 
relied on TSLDox accumulation in a preheated (HT41) tumor followed by a second HT42 
step to induce drug release did not show a therapeutic effect. The SPECT/CT imaging 
in this case was particularly valuable to follow the TSL accumulation in B16 and BFS-1 
tumors. The SPECT data were used for fitting a two compartment model which describes 
tumor uptake of the liposomal carrier as well as the intraliposomal Dox concentration in 
the tumor taking the blood kinetic and pharmacokinetic parameters of TSLDox into ac-
count [39]. For both tumors and regardless of applying HT41 beforehand, the maximum 
concentration of liposomes was reached approx. 4 h p.i., when the second HT42 step was 
applied. The B16 tumors showed a significant higher liposomal uptake compared to the 
BFS-1 tumor with ca. two fold higher kin and kret parameters reflecting a higher intrinsic 
EPR effect for the B16 model. Interestingly, 1 hour of HT41 induced the same effect in 
both tumors leading to a 1.66 times increase in kin and kret and thus maintaining the two 
fold higher uptake of TSLs in B16 compared to BFS1 tumors.
However, calculations suggested that maximum intraliposomal Dox concentrations 
were already reached 2 h p.i., and declining to zero within 20 h due to leakage from the 
TSLs. These data imply that a more favorable time point for the second HT42 step is ca. 
2-3 h p.i. [36]. Based on our calculations, the intraliposomal Dox reached concentrations 
of 1.7 % ID/cc for B16 and 0.6 % ID/cc Dox for BFS-1 at the moment of the second HT42 
step (i.e. after 4 h) at normal temperature conditions, and 3.0 % ID/cc and 1.5 % ID/
cc Dox with a preceding HT41 treatment. These concentrations are lower compared to 
typical values found for a 1-step delivery approach [49], which provides an explanation 
for the lack of a significant therapeutic response in a 2-step drug delivery protocol.
Finally, we performed histological analysis of excised tumors and investigated factors 
that may cause the differences in TSL uptake and the intrinsically higher EPR effect 
found in B16 and BFS-1 tumors. B16 tumors grew more aggressively than BFS-1, reaching 
volumes of 200 mm3 in 7-14 and 14-21 days after inoculation, respectively. Especially 
in preclinical models, fast growing tumors show higher structural and functional ab-
normalities of the vasculature, thereby increasing the odds for a high EPR effect [1, 50, 
51]. The mean vessel density was similar for B16 and BFS-1, however the morphology 
of B16 vessels appeared more tortuous and overall larger in size. Next to the growth 
rate and vascular properties, we also observed noticeable differences in cell packing and 
organization, which is important for the penetration depth of extravasated compounds 
into the tumor interstitium [47, 52, 53]. H&E staining showed less dense cellular pack-
ing with gaps in the B16 tumor tissue, whereas BFS-1 showed a higher density and no 
gaps. Therefore, the finding that BFS-1 cells could form spheroids while B16 cells did 
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not, might be indicative for cell packing and organization in an actual tumor. In vivo, 
cell packing density and organization is, among other reasons, depends on the pres-
ence of a well-defined extracellular matrix. Analysis on the extracellular matrix by MSB 
staining and quantitative collagen IV immunostaining showed that B16 tumors have an 
almost completely absent extracellular matrix, whereas BFS-1 tumors had a more mature 
extracellular matrix. These findings suggest that the immature interstitium of the B16 
tumor could have played a role in facilitating a higher EPR, confirming previously pub-
lished results [54]. Histological analysis and quantitative TUNEL staining also indicated 
a much higher amount of apoptosis in the B16 tumors than in the BFS-1 tumors, which 
is typically associated with a more pronounced EPR effect [55, 56]. The HT41 induced in-
crease of apoptosis was significant for the sectioned BFS-1 tumors. While our study is in 
line with earlier findings showing that HT increases vascular permeability and promotes 
extravasation of nanoparticles [29-31], our histology data also suggest that substantial 
HT41 induced apoptosis can further aid EPR.
In summary, we have shown that HT can aid in drug delivery by making cells more 
susceptible for Dox uptake, increasing the EPR-mediated uptake of liposomal drugs 
and by providing a trigger for drug release from TSLDox. All above factors play a pivotal 
role in the here employed 2-step delivery scheme. However, the actual amount of Dox 
delivered in a 2-step approach is determined by liposomal uptake and stability of the 
formulation and can therefore never exceed the liposomal uptake (in %ID/g). This study 
has shown that preheated B16 and BFS-1 tumors accumulated a maximum of 9.8 %ID/
cc and 5.0 %ID/cc of the injected TSL dose, while the intraliposomal Dox concentration 
only reached 3 and 1.5 %ID/cc at 4 hours p.i. respectively. These Dox concentrations ap-
peared insufficient to induce a noticeable therapeutic response. The 1-step intravascular 
drug release seems to be advantageous, since the injected TSLDox provide a high plasma 
concentration of Dox exposing the tumor to a high area under the curve over the time 
span of HT. Furthermore, the HT induced increase in Dox uptake by tumor cells may 
lead in both delivery schemes to a higher intracellular concentration.
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abstract
Local drug delivery of Doxorubicin (Dox) with thermosensitive liposomes (TSL) and 
hyperthermia (HT) has shown preclinically to achieve high local drug concentrations 
with good therapeutic efficacy. Currently, this is clinically studied for treatment of chest 
wall recurrence of breast cancer, however with various outcomes. This study examines 
the potency of neoadjuvant TSL HT combination therapy in two orthotopic mouse 
models of human breast cancer, MDA-MB-231 and T-47D, which morphologically cor-
relate to mesenchymal and epithelial phenotypes, respectively. Both cell lines showed 
improved in vitro chemosensitivity and Dox uptake at HT. Dox-loaded TSL (TSLDox) was 
stable 0 mm in FBS, BALB/c-nu plasma and human plasma, although release of the 
drug at HT was incomplete for the latter two. Combination treatment with TSLDox and 
HT in vivo was significantly more effective against MDA-MB-231 tumors, whereas T-
47D tumors showed no significant therapeutic response. Ex vivo investigation revealed 
a higher mean vessel density and poorly differentiated extracellular matrix (ECM) in 
MDA-MB-231 tumors relative to T-47D tumors. Although in vitro results of the TSLDox 
and HT treatment were favorable for both cell types, the therapeutic efficacy in vivo was 
remarkably different. The well-differentiated and slowly-growing T-47D tumors may 
provide a microenvironment that limits drug delivery to the target cell and therefore 
renders the therapy ineffective. Mesenchymal and invasive MDA-MB-231 tumors display 
higher vascularization and less mature ECM, significantly enhancing tumor response to 
TSLDox and HT treatment. These results yield insight into the efficacy of TSL treatment 
within different tumor microenvironments, and further advance our understanding of 
factors that contribute to heterogeneous therapeutic outcomes in clinical trials.
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introDuction
According to estimates made by the American Cancer Society, approximately 250,000 
new patients are diagnosed each year in the US with invasive breast cancer and despite 
all medical progress, this disease will be responsible for about 40,000 deaths in the US 
in 2016 [1]. Chemotherapy is the standard of care for invasive breast cancer and can be 
applied as (neo)adjuvant therapy in addition to surgery or mastectomy for stage I-III 
tumors or for metastasized breast cancer (stage IV). Doxorubicin (Dox) is a drug that 
is used in many chemotherapy regimens as a single agent, in combination with other 
chemotherapeutic drugs, or as adjuvant for antibody-based therapies that target the 
estrogen receptor (ER), progesterone receptor (PR) or human epidermal growth factor 
receptor 2 (HER2). When a breast tumor lacks the expression of any of these three recep-
tors, it is diagnosed as a triple negative breast cancer (TNBC). Depending on the stage 
of its diagnosis, TNBC can be particularly aggressive and is more likely to recur after 
local treatments compared to other subtypes of breast cancer. Lacking any response to 
receptor-targeted therapies, chemotherapy remains the only efficacious form of treat-
ment [2]. However, severe side effects have been observed after treatment with Dox, 
including cardiac toxicity, nausea and hair loss, among others [3]. These side effects can 
be largely reduced by incorporation of the drug in long-circulating nanoparticles such as 
liposomes. Due to their size of approximately 100 nm, the liposomes do not extravasate 
into healthy tissue, but passively accumulate in neoplastic tissue where the drug slowly 
diffuses out of its carrier. In fact, the use of liposomal Dox (Doxil®) has resulted in a 
similar therapeutic efficacy as free Dox, yet has greatly reduced the above-mentioned 
side effects [4, 5], therefore becoming a preferred first-line single agent for stage IV 
TNBC [2]. However, further research has indicated that the parental drug Dox is actu-
ally retained too effectively inside the liposomes, which reduces its bioavailability and 
therefore strategies to exploit the full therapeutic potential of these drug delivery sys-
tems are warranted [6]. One solution is the development of thermosensitive liposomes 
(TSLs), which stably encapsulate the drug at body temperature and therefore reduce the 
side effects associated with free Dox, but enable fast Dox release when exposed to mild 
hyperthermia (40-42°C; HT) [7]. This approach requires heating of the tumor area and 
has been shown in numerous preclinical studies to lead to higher accumulation of Dox 
compared to standard treatments, as well as improved tumor control [8-11]. The above-
mentioned temperature–induced drug delivery may be particularly applicable for (neo)
adjuvant treatment of local breast cancer or in case of local recurrence of breast cancer at 
the chest wall. Application to breast cancer has been performed in several subcutaneous 
murine models showing enhanced intratumoral Dox levels and therapeutic response 
[12, 13]. Recently, a first clinical study was performed with a lysolipid-containing TSL 
(LTSL) formulation of Dox (ThermoDox®) in combination with HT for treatment of 
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breast cancer recurrence at the chest wall showing a local response rate of 50% [14-16]. 
Though these results are promising, treatment response remains very heterogeneous 
and requires more investigation to further improve response rates.
Here, we present a study on the therapeutic efficacy of Dox-loaded, lysolipid-lacking 
TSLs for breast cancer. Removal of lysolipid from a thermosensitive formulation estab-
lishes a drug release by membrane defects in the liposome [17] instead of through pores 
established by the lysolipid (LTSL) [18]. Although our lysolipid-lacking TSL (hereafter 
abbreviated as “TSL”) has shown to slightly improve therapeutic outcome over LTSL 
[19], we focused in this study on tumor type comparison and relation to significant 
therapeutic response. For this comparison, ductal breast cancer orthotopic xenografts 
based on cell lines T-47D and MDA-MB-231 were selected. MDA-MB-231 is a TNBC, for 
which chemotherapy would be the standard of care, whereas T-47D expresses estrogen 
and progesterone growth receptors, rendering it susceptible to hormone therapy despite 
resistance remaining a problem in e.g. tamoxifen-based therapies [2, 20]. T-47D cells 
belong to the luminal A class of breast cancer, which are well differentiated, epithelioid 
and relatively poorly invasive, therefore conferring a good prognosis [21]. MDA-MB-231 
belongs to the basal/claudin-low class, is poorly differentiated and mesenchymal in 
nature, making it highly invasive, and resulting in a poor prognosis [22, 23]. Investigat-
ing these extremes in breast cancer differentiation may provide new insights into the 
efficacy of preoperative TSL and HT based therapy among breast cancer subtypes.
materials & methoDs
tsl preparation
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC; Lipoid; Ludwigshafen, Germany) 
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC; Lipoid), and 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-(amino(polyethylene glycol)-2000) (DSPE-PEG2000; 
Lipoid) were dissolved in 9:1 (v:v) chloroform:methanol at a molar ratio of 70:25:5. The 
solvent was gradually evaporated by a rotary evaporator (Büchi; Flawil, Switzerland) 
and the resulting lipid was dried by nitrogen flushing. The lipid film was hydrated in 
(NH4)2SO4 (250 mM, pH 5.3) to form liposomes which were extruded through 5x 200 
nm, 5x 100 nm, 5x 80 nm and 5x 50 nm polycarbonate filters with a thermobarrel 
extruder (Northern Lipids; Burnaby, Canada). The liposomes were run over a PD-10 
column (GE Healthcare Life Sciences; Eindhoven, Netherlands) and eluted with HEPES 
(10 mM) buffered NaCl (135 mM, pH 7.4). The phosphorus concentration of the sample 
was determined by ammonium molybdate spectrophotometry (Bartlett assay [24]) and 
liposomes were loaded with Dox (Actavis; Dublin, Ireland) by a (NH4)2SO4 gradient as 
described before [25] at a 0.15:1 (mol:mol) Dox:lipid ratio, which was incubated for 1 h 
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at 39°C at 300 rpm in a thermoshaker. This (NH4)2SO4 loading gave more stable TSLs at 
body temperature than the commonly used citrate loading [25], which has been used for 
LTSL [26]. Liposomes were concentrated by ultracentrifugation and the final product 
was tested for size, polydispersity and zeta-potential in HEPES buffer (10mM) at a lipid 
concentration of 0.3 mM using a Zetasizer (Malvern Instruments; Worcestershire, UK).
In vitro Doxorubicin cytotoxicity assay
T-47D and MDA-MB-231 breast cancer cell lines were kindly provided by Dr. John Mar-
tens (Medical Oncology, Erasmus MC, Rotterdam, Netherlands). For chemosensitivity 
assays, cells were seeded in a 96-well plate and grown until 50% confluency, followed 
by addition of Dox and incubation at normothermic (37°C; NT) or hyperthermic (42°C; 
HT) temperature for 1 h. After incubation, the Dox-containing medium was removed 
and cells were washed with phosphate-buffered saline (PBS; Sigma-Aldrich; St Louis, 
Missouri). For investigation of the long-term effects of Dox incubation, fresh culture 
medium (RPMI medium + 10% FBS + 1% Penicillin/ Streptomycin; Sigma-Aldrich) 
was added periodically. After a period of incubation (24-72 h), the cells were fixed in 
10% (w:v) trichloroacetic acid (Sigma-Aldrich) for 4 h at 4°C. Following fixation, the 
plates were washed with running tap water and cells were stained with 0.5% (w:v) 
sulforhodamine B (Sigma-Aldrich) for 20 min at room temperature. The plates were 
washed with 1% (v:v) acetic acid (Sigma-Aldrich) and left to dry, after which the stain 
was resuspended and homogenized by adding 10 mM Tris (Sigma-Aldrich). Absorbance 
was measured at 590 nm using a Wallac Victor 2 plate reader (Perkin Elmer; Waltham, 
Massachusetts). In case of a NT experiment, the Dox incubation on the cells took place 
in an incubator set to 37°C, whereas a HT experiment was carried out by vacuum sealing 
the culture plate and submerging it into a water bath set to 42°C. Cellular cytotoxicity 
and the following Dox uptake curves were only generated with free drug as previous 
studies showed that drug fully released from TSLs in culture media within seconds [27] 
and this study focused on an intravascular release approach in a heated tumor and thus 
bioavailable free drug to the tumor cell.
In vitro Doxorubicin uptake studies
Cells were grown until 80% confluency in a T75 culture flask and exposed to 40 µM 
Dox for 1 h, after which the cells were washed with ice-cold PBS. 40 mM was chosen 
as concentration Dox for an adequate fluorescent signal at the time of measurement. 
The cells were scraped from the flask in ice-cold PBS and centrifuged at 200 g at 4°C 
for 10 min. 150 µL lysis buffer (20 mM Tris, 150 mM NaCl, 0.2% NP40, 10% glycerol, 
pH 7.4; Sigma-Aldrich) was used to resuspend the pellet and the resulting suspension 
was incubated on ice for 30 min. The lysates were centrifuged at 14,000 g for 15 min 
and pellets homogenized in 500 µL PBS by vortexing and 1 min probe sonication. Dox 
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concentration was measured at 485 nm excitation and 580 nm emission by a Wallac 
Victor 2 plate reader. One additional T75 culture flask was seeded with cells in parallel 
to the flasks used for Dox uptake experiments in order to determine cell number at the 
time of the experiment. 
tsl stability and release assays by fluorometry
2950 µL freshly isolated BALB/c-nu plasma, human plasma or FBS was put into a quartz 
cuvette and placed into a F-4500 fluorometer (Hitachi; Tokyo, Japan) and heated to 
37°C or 42°C by an externally connected water bath. After 1 min measurement, 50 µL 
of a 5 mM (phosphate) TSL solution was introduced into the heated plasma via a piece 
of surgical tubing and measurement continued for 1 h. The percentage of released Dox 
was calculated by: % Doxrelease= ((Doxn-Doxbase)/ (Doxtotal-Doxbase)) x 100% where Doxn 
= signal at time point n, Doxbase = base signal of sample with no release and Doxtotal = 
maximum Dox release after adding 50 µL 10% Triton X-100 (Sigma-Aldrich).
In vivo orthotopic breast cancer model
The establishment of T-47D and MDA-MB-231 orthotopic tumor models and subsequent 
treatments of tumor-bearing animals has been judged and approved by the Erasmus MC 
animal research committee, Rotterdam, the Netherlands. 10 week old BALB/c nude mice 
were ordered from Janvier Labs (Nijmegen, Netherlands) and were given an ad libitum 
supply of β-estradiol (Sigma Aldrich) enriched drinking water, which was prepared by 
adding 1 mL of a 4 mg/mL β-estradiol solution in ethanol to 1 L of drinking water. 8∙106 
cells were mixed 1:1 (v:v) with Matrigel (BD Biosciences; East Rutherford, New Jersey) 
and injected into the mammary fat pad. Drinking water was refreshed twice a week.
treatment of orthotopic breast cancer with tsl and ht
When tumors reached 200 mm3, mice were treated by a single 5 mg/kg free Dox or TSLDox 
dose which was i.v. administered via the tail vein. The equal dosing of free and liposomal 
drug at 5 mg/kg was chosen in order to show the benefit of TSLDox therapy over free Dox 
without risking severe side effects and adequately compare the results to the outcome 
of our previously published results [25, 27]. For NT experiments, mice were put under 
anaesthesia on a heating pad, and covered with aluminium foil for 1 h after injection. 
For HT experiments, mice were put under anaesthesia and tumors were submerged into 
a water bath to reach an intratumoral temperature of 42°C which was maintained for 1 
h after injection. The intratumoral temperature was expected to be similar to previous 
findings where tumors inoculated on the hind limb were heated by a water bath set at 
42.5°C [25]. Injections took place after 10min of tumor heating. Skin exposed to HT was 
protected by covering a 1 cm radius surrounding the tumor with vaseline as a precaution 
to prevent possible skin damage. After treatment, every other day, mice were weighed 
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and tumors measured by a calliper and volumes calculated (volume = length x width x 
height x 0.4). Statistical comparison between treatment groups was done using tumor 
volume doubling time and Kaplan-Meier plots were generated accordingly. Tumor size 
analysis was normalized to the starting size of 200 mm3 and MDA-MB-231 inoculated 
animals were sacrificed when tumors reached 18 mm in one dimension or 15 mm in 
all dimensions while T-47D inoculated animals were sacrificed when tumor volume 
doubled (100% size increase). For statistical analysis, the tumor doubling time was used 
as a measure for therapeutic efficacy.
Ex vivo staining and analysis of excised tumors
Tumors were excised from sacrificed mice, snap frozen in liquid nitrogen and sliced into 
5 µm sections. The sections were stained by Martius Scarlet Blue (MSB), for TUNEL, 
CD31, collagen IV and fibrillin I. For MSB staining, slides were fixed in Bouin’s fixative 
(4% formalin: saturated picric acid : glacial acetic acid; 25:70:5; Sigma-Aldrich) for 1 h 
at 60°C, followed by staining with Weigert’s hematoxylin (Boom; Meppel, Netherlands), 
Martius yellow, crystal scarlet and methyl blue (Sigma-Aldrich). Stained slides were 
mounted with Entellan (EMD Millipore; Billerica, Massachusetts) and smaller regions 
were imaged using a DM 4000B microscope (Leica; Wetzlar, Germany) and analysed 
by Leica QWin Y2.8 software (Leica Microsystems Imaging Solutions Ltd; Cambridge, 
UK). A cell death detection kit (Roche; Basel, Switzerland) was used for TUNEL stain-
ing on paraformaldehyde fixed slides. Immunologic stains for CD31 and fibrillin I were 
done on acetone fixed slides with primary rat anti-mouse CD31 (BD Pharmingen; San 
Diego, California) and rabbit anti-mouse fibrillin I (Abcam; Cambridge, UK), followed 
by secondary goat anti-rat AlexaFluor594 and goat anti-rabbit AlexaFluor488 (Thermo 
Fisher; Waltham, Massachusetts), respectively. Collagen IV staining was performed with 
a primary rabbit anti-mouse collagen IV antibody (EMD Millipore; Billerica, MA) and 
a secondary goat anti-rabbit AlexaFluor488 antibody. Slides were mounted with DAPI 
(Molecular Probes; Eugene, Oregon) enriched Fluoromount-G (Southern Biotech; Bir-
mingham, Alabama). Confocal and widefield fluorescence microscopy was performed on 
a LSM 510 Meta (Zeiss; Oberkochen, Germany) and Axiovert 100M microscope (Zeiss) 
with Hamamatsu Photonics C4742-98 camera controller, respectively. Tile scans gener-
ated from the confocal microscope yielded whole-tumor images that were subsequently 
processed in ImageJ (version 1.48). Whole-tumor ROIs were drawn, excluding artifacts 
such as tissue folds, and CD31, collagen IV and fibrillin I signal were quantified as % posi-
tive pixels. A fixed, manually set threshold was implemented for each individual stain 
and maintained for all replicates. The mean and standard deviation were determined for 
each tumor type (N = 5), whereby one section was analyzed per tumor.
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statistical analysis
All statistical tests were performed in Graphpad Prism 6.07. For the comparative in vitro 
cytotoxicity (Figure 1A-D), cellular Dox uptake (Figure 1E and F), in vitro Dox release 
(Figure 3 and Additional file 1: Table S1) and in vivo tumor growth analysis (Additional 
file 1: Figure S1) an unpaired two-tailed t-test was applied to determine statistical sig-
nificance between groups. One-way ANOVA Bonferroni tests were done to determine 
statistical significance between different TSL treatment groups of the in vitro cytotoxic-
ity experiment (Figure 2) and of the in vivo therapeutic study (Figure 4A and B), with 
the only exception of the T-47D model which was only composed of PBS NT and a TSLDox 
HT groups (Figure 4C and D) and therefore analyzed by an unpaired two-tailed t-test. 
Statistical analysis of histological sections (Figure 5) was done by Mann-Whitney test.
results
In vitro cytotoxicity and Dox uptake in breast cancer cell lines under nt and ht 
conditions
MDA-MB-231 and T-47D cells were tested for Dox sensitivity and the drug showed a com-
parable growth inhibitory effect in both cell lines. These cell lines exhibited IC50 values of 
9.6∙10-3 ± 0.2∙10-3 and 2.5∙10-2 ± 1.3∙10-2 mM Dox (Figure 1A-D), respectively, 72 h after a 1 
h Dox incubation at NT (37°C). The Dox sensitivity of the cell lines was enhanced by HT, 
where MDA-MB-231 cells showed an IC50 of 1.5∙10
-3 ± 0.6∙10-3 mM Dox (significant versus 
NT) and T-47D showed an IC50 of 6.8∙10
-3 ± 2.1∙10-3 mM (not significant versus NT because 
of large variation in NT group) at HT conditions. Next, the Dox uptake by these cells at 
NT and HT was tested (Figure 1E, F). When the cells were exposed to 40 µM Dox for 1 h, 
MDA-MB-231 and T-47D cells showed 0.06 ± 0.03 and 0.14 ± 0.03 pg Dox/cell uptake, 
respectively. At HT conditions, the Dox uptake significantly increased for both cell lines 
with 0.25 ± 0.03 pg Dox/cell for MDA-MB-231 and 0.44 ± 0.05 pg Dox/cell for T-47D.
Before TSLs were tested on cells, they were analyzed for size, polydispersity, zeta-
potential and Dox loading efficiency. The liposomes had a hydrodynamic diameter of 
77 ± 3 nm, a polydispersity index of 0.036 ± 0.006 and a zeta-potential of -12 ± 1 mV. 
Dox loading was established with 100% efficacy (0.15:1 Dox:lipid ratio was maintained 
after Dox loading). The transition temperature (Tm) of this Dox-loaded formulation was 
44.4 ± 0.3 °C (obtained by differential scanning calorimetry), as described previously 
[25]. The presence of Dox in the formulation seemed to lower the Tm with ± 1 °C when 
compared to similar TSL formulations that did not contain Dox [17]. When cells were 
exposed to 10 µM free Dox or TSLDox for 1 h, a limited cytotoxic effect was observed 24 h 
after the experiment (Figure 2A), which was only significant for MDA-MB-231 with 81 ± 
9% surviving cells.
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A simultaneous HT and Dox incubation caused a significant cytotoxic effect with free 
and TSLDox for both cell lines after 24 h. However, 72 h after incubation, the cytotoxic 
effects of the different treatments became more pronounced (Figure 2B). Dox exposure 
at NT resulted in 67 ± 16% and 38 ± 7% cell survival for MDA-MB-231 and T-47D, re-
spectively. Similarly, 72 h after exposure, the HT TSLDox groups showed a relatively high 
cytotoxic effect with 11 ± 7% cell survival for MD-MB-231 and 23 ± 3% for T-47D. The 
T-47D cell line also showed significant cytotoxic effects in the NT TSLDox (71 ± 6% cell 
survival), and HT (empty) TSL groups (81 ± 5% cell survival). 
C D
E F
BA
Figure 1. In vitro chemosensitivity and Dox uptake at NT (37°C; ●) or HT (42°C; ●). MDA-MB-231 (A, B) and T-47D (C, 
D) cell lines showed increased Dox sensitivity at HT, which was significant for the former. Dox uptake was significantly 
improved under HT conditions for both MDA-MB-231 (E) and T-47D (F). 40 µM Dox was used for the drug uptake 
experiment (E, F). N = 3 for all experimental groups and unpaired two-tailed t-test was used for statistical analysis. 
*** = p < 0.005.
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validation of Dox retention and release in balb/c-nu mouse plasma
Fresh plasma was collected from BALB/c-nu mice to validate the stability and release of 
TSLDox prior to animal experimentation. TSLDox was stable at 37°C, showing 2 ± 1% Dox 
release in 1 h (Figure 3A). A rapid release, which reached a maximum of 69 ± 7%, was 
established after TSLDox was exposed to HT for 1 h. This was considerably lower than Dox 
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Figure 2. Chemosensitivity assay 24 h (A) or 72 h (B) after a 1 h incubation with empty 67 µM TSL (as determined 
by PO4 quantification), 10 µM TSLDox or 10 µM free Dox at NT (37°C) or HT (42°C). N = 3 for all experimental groups. 
Statistical differences were determined by one-way ANOVA Bonferroni test. * = p < 0.05, ** = p < 0.01, *** = p < 0.005.
A B
Figure 3. 1 h Dox release from TSLDox (A) at 37°C in FBS (purple), fresh BALB/c plasma (orange) or human plasma 
(brown); or at 42°C in the same media (green, red and blue, respectively) with a magnification of the first 30 s of release 
(B). N = 3 for all experimental groups. An exponential one-phase association curve was fitted through the 42°C release 
data sets obtained in FBS (solid line), BALB/c plasma (dotted line) and human plasma (dashed line). K-value and pla-
teau value were used as parameters to determine statistical differences between release curves (Table 1).
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release in FBS in terms of speed and completeness of release (Figure 3A, B). However, 
the Dox retention at NT and release at HT in BALB/c-nu plasma did closely resemble 
that of human plasma.
Table 1. Doxorubicin release characteristics from thermosensitive liposomes in serum or plasma from different spe-
cies. Plateau1h and K30s parameters calculated from the exponential fits in Figures 3A and 3B, respectively. The pa-
rameters were statistically compared by one-way ANOVA Bonferroni test. Asterisks indicate statistically significant 
differences compared to FBS (* = p < 0.05, ** = p < 0.01).
K30s
(% Dox release/ sec)
plateau1h
(max % Dox release)
fbs 0.29 ± 0.03 104 ±1
balb/c plasma 0.11 ± 0.05** 79 ± 8**
human plasma 0.17 ± 0.05 85 ± 6*
therapeutic study of tsl in orthotopic breast cancer
After inoculation, MDA-MB-231 and T-47D showed significantly different tumor growth 
rates. MDA-MB-231 tumors reached 200 mm3 at 38 ± 9 d after inoculation, while T-47D 
inoculated mice showed a 200 mm3 tumor after 113 ± 20 d (Figure 4). The MDA-MB-231 
tumors showed a significant therapeutic response to TSLDox and HT, exhibiting 25 ± 4 d 
until tumor doubling was reached versus 15 ± 1 d for the PBS NT group (Figure 5A, B). All 
control treatments did not lead to any significant therapeutic response. T-47D tumors 
responded heterogeneously to TSLDox and HT therapy, which resulted in no significant 
difference in tumor growth delay compared to the NT group. In this tumor model, the 
PBS NT group had an average tumor doubling time of 34 ± 16 d after therapy, while for 
the TSLDox HT group this was 51 ± 25 d (Figure 5C, D). Because of the relatively slow 
tumor growth for T-47D and the lack of a significant response for the TSLDox HT group, 
additional control groups were omitted.
MDA-MB-
231
T-47D
Figure 4. Orthotopic tumor growth MDA-MB-231 and T-47D tumors in BALB/c-nu mice (N = 14 for both groups). T-
47D tumors grew significantly slower than MDA-MB-231 tumors (two-tailed unpaired t-test; *** = p < 0.005). When 
tumors reached 200 mm3, they were treated with one of the treatments described in the therapeutic study.
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Ex vivo investigation
MDA-MB-231 and T-47D tumors were examined for overall tissue morphology, apoptosis, 
vascularization and fibrillin I/collagen IV density. The MSB stained sections show that 
MDA-MB-231 tumors possess a relatively poorly organized extracellular matrix (ECM) 
with fibers randomly distributed, while T-47D tumors show a more organized structure 
of dense ECM with thick fibers (Figure 6A, B). Fluorescence microscopy analysis also 
revealed a random distribution of vessels and extracellular fibers for MDA-MB-231 
tumors, whereas blood vessels of T-47D tumors were often found in close proximity to 
the dense extracellular fibers (Figure 6C, D; Figure 7). Quantitative tile scan analysis of 
fluorescently stained sections revealed that both tumor types did not differ in viability 
(Figure 6E). However, MDA-MB-231 tumors had a higher degree of vascularization with 
5.7 ± 0.8 % mean vessel density versus 2.3 ± 1.4 % for T-47D. Furthermore, the mean 
fibrillin I density was also significantly lower for MDA-MB-231 tumors with 3.7 ± 1.2 
% relative to 6.8 ± 3.0 % for T-47D (Figure 6F, G; Figure 7). MDA-MB-231 and T-47D 
tumors showed similar levels of collagen IV expression (Figure 6H).
A B
C D
*
Figure 5. Therapeutic efficacy using TSLDox on orthotopic MDA-MB-231 and T-47D tumors. MDA-MB-231 average 
growth curves normalized against the start of therapy at a tumor size of 200 mm3 (A) and a Kaplan-Meier plot for 
tumor doubling time (B) show that PBS HT, TSLDox NT and control groups with free Dox did not show a significant 
difference compared to PBS NT (N = 4 for all groups). TSLDox HT (N = 5) did elicit a significant therapeutic effect based 
on one-way ANOVA Bonferroni test (* = p < 0.05). A similar growth curve (C) and Kaplan-Meier plot (D) for T-47D 
tumors indicate no significant tumor growth inhibition for TSLDox HT versus PBS NT (N=6 for both groups). Additional 
control groups similar to the therapeutic efficacy study on MDA-MB-231 were omitted due to the slow growth of the 
T-47D tumors and the lack of statistical significance of the TSLDox HT treatment in this tumor model.
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Discussion
It has been shown in numerous cases that the heterogeneity of breast cancer subtypes 
results in varying chemotherapy response rates [28-31]. This warrants the evaluation of 
therapies across various tumor subtypes towards patient-specific treatment planning. 
In many of the preclinical cancer models employed, a rapidly growing, invasive tumor is 
often chosen. However, a debate continues as to whether these preclinical models suffi-
ciently recapitulate the disease in a clinical setting [32], as they often lack an appropriate 
tumor microenvironment. By using an orthotopic xenograft, the tumor develops within 
a more native microenvironment, resulting in a more clinically translatable model [33, 
34]. T-47D and MDA-MB-231 reflect two distinct breast cancer subtypes varying in 
invasiveness and tumor morphology. Epithelial T-47D is less aggressively growing than 
mesenchymal MDA-MB-231 and possesses a cell morphology much like cells found 
in the healthy ducts of the breast [35]. Relatively high expression of E-cadherin and 
claudins confer good cell-cell adhesion for T-47D cells [36, 37] and the low invasiveness 
Figure 6. Histological analysis of MDA-MB-231 and T-47D tumors. MSB staining indicated differences in overall tis-
sue make up regarding extracellular matrix distribution (blue) for MDA-MB-231 (A) and T-47D (B). MDA-MB-231 (C) 
and T-47D (D) sections were immunostained for CD31 (red), fibrillin 1 (green) and nuclei were stained by DAPI (blue) 
and imaged by widefield fluorescence microscopy. Quantification of tile scans (obtained by confocal fluorescence 
microscopy; Supplemental Fig 2) of both tumor types was done on TUNEL (E), CD31 (F), fibrillin 1 (G) and collagen IV 
(H) stained sections. Scale bars for MSB sections (A, B) represent 20 µm. Scale bars for immunostained sections (C, 
D) represent 100 µm. For quantitative analysis (E-G), 5 sections were used for each group (N = 5), with exception for 
the collagen IV staining (N = 3). Groups were statistically compared by Mann-Whitney test. * = p < 0.05. Contrast and 
brightness were enhanced in A-D for publication purposes only.
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MDA-MB-231 T-47D
Figure 8. Schematic representation of hypothesized Dox delivery by TSL (represented by orange intravascular par-
ticles) and HT in MDA-MB-231 and T-47D tumors. MDA-MB-231 tumors show a relatively high Dox uptake (orange 
cells), due to greater tissue perfusion (vessels in red) and a lower presence of mature extracellular fibers (green), which 
enables an increased Dox extravasation into the tumor interstitium. T-47D tumors are less likely to take up high 
A B
C D
Figure 7. Representative histology images of MDA-MB-231 (A, B) and T-47D (C, D) tumors. CD31 is marked in red and 
fibrillin in green. The original images (A and C) were subjected to a constant threshold (B and D) and the positive pixel 
count of the whole section was used as a measure for CD31 and fibrillin expression. Scale bar indicates 50 µm. The given 
pictures are a magnification of the whole section tile scans used for the quantitative analysis.
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is usually paired with a well-defined ECM, reducing the chance of metastasis [38]. MDA-
MB-231 on the other hand, has lower E-cadherin and claudin expression and a more 
disorganized ECM, resulting in poor cell-cell adhesion and greater metastatic potential. 
Therefore, these cell lines represent two very different types of breast cancer and are 
used herein to investigate their response to local drug delivery of Dox using TSLDox in 
combination with HT.
Hyperthermia-triggered local drug delivery using TSLDox has shown considerable 
success in solid tumor treatment over the last decades [39], with the LTSL formulation 
currently being tested in clinical trials [14, 15]. In earlier work, we have shown that Dox 
can be effectively released from TSLs in physiological media and that HT can increase 
Dox uptake in cells, leading to a higher cytotoxic effect for B16 melanoma and BFS-1 
sarcoma cell lines [27]. In the present study, a similar effect was observed for T-47D 
and MDA-MB-231 breast cancer cells. Nevertheless, for the epithelial T-47D cell line, 
there was higher variability between experiments leading to higher standard deviations 
relative to mesenchymal MDA-MB-231 since the former grows inconsistent, slowly and 
clustered while the latter grows consistent, rapidly and as a robust monolayer [35, 40]. 
Incubation of these cells with TSLDox at HT was equally effective as free Dox in vitro, 
indicative of the complete release of the drug from its temperature-sensitive carrier and 
its bioavailability to the cells. Similar work in this field has shown that drug release 
and stability assays are heavily dependent on the media (buffer, serum, plasma) and 
the dilution in which they are performed, and it is still relatively unknown why drug 
release varies between different plasma/ sera of different sources [41, 42]. Therefore, we 
conducted Dox release assays from TSLDox in freshly isolated BALB/c and human plasma 
to give a better indication of drug release that may occur in the (pre)clinical setting. 
Dox release in these media was slightly slower and incomplete when compared to the 
typically used medium consisting of FBS. BALB/c and human plasma showed identical 
Dox release curves, suggesting comparable release and stability of TSLDox in the systemic 
circulation of both species, though extrapolation from in vitro to in vivo behavior is 
cautioned [25] and may be further subject to differences as a function of the chosen in 
vivo model [42, 43]. 
The growth of the invasive MDA-MB-231 orthotopic tumor model was found to be 
significantly faster than the growth of T-47D tumors in immunodeficient BALB/c mice. 
TSLDox with HT could significantly reduce tumor growth for MDA-MB-231, but the rela-
tive therapeutic response of T-47D tumors was not statistically significant. Differential 
chemosensitivity is a common observation among cancer subtypes. T-47D, being a lumi-
nal breast cancer [44], exhibiting low proliferation [45] and enhanced ER/PR expression 
[46], is likely less chemosensitive than MDA-MB-231. Surprisingly, local drug delivery 
by TSL and HT failed to elicit a statistically significant therapeutic response, despite the 
therapy proving successful in a variety of tumor types [12, 27]. The considerable variation 
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in response in the T-47D model (i.e. high SD) and limited tumor growth rate narrowed 
our study to that of one treatment and one control group (i.e. TSLDox HT and PBS NT). As 
the results of the TSLDox HT therapy did not show statistically significant superiority over 
PBS NT, the remaining control groups in addition to PBS NT were omitted. However, a 
statistically significant difference may have been achieved by adding more animals to the 
experimental groups. This is particularly pertinent given that only two animals remained 
in the study at 50-100 d post-treatment. Alternatively, repeated treatment cycles may 
have proven to be a more effective therapeutic strategy against slowly progressing tumors, 
as performed in the LTSL clinical trial [16]. Nevertheless, the differences in the MDA-
MB-231 and T-47D tumor microenvironments may provide important insights into the 
disparate therapeutic responses between these tumor types. The MSB staining showed a 
highly organized ECM with dense fibers that seemingly divided T-47D tumors into sub-
compartments, whereas MDA-MB-231 tumors showed relatively less dense fibers and 
were more randomly distributed in their composition. Furthermore, T-47D tumors also 
had a higher fibrillin-I density; however, this was not the case for all ECM components 
as there was no difference observed in collagen IV density between both tumor types. 
This compartmentalized tumor morphology, irrespective of overall stromal content, 
has previously been related to lower chemosensitivity [47]. Further investigation of the 
tumor vascular network between models was performed as a measure of the efficacy of 
our drug delivery approach. We observed that blood vessels of T-47D tumors could often 
be found in the vicinity of the extracellular fibers, analogous to a basal membrane that in 
healthy breast separates the blood capillary from the epithelial ducts [48]. Conversely, 
MDA-MB-231 tumors showed no distinct organization of blood vessels within the ECM, 
which corresponds with its mesenchymal and invasive characteristics [49]. We hypoth-
esize that the basal membrane-like features in T-47D tumors may have reduced Dox 
delivery to the tumor cellular compartment (Figure 8), as previous results have shown 
lower vascular permeability and lower degradation of the endothelial ECM by T-47D 
cells when compared to MDA-MB-231 [50-52]. Furthermore, the poorly vascularized 
nature of T-47D tumors relative to MDA-MB-231 tumors limits the overall delivery of 
Dox to the tumor, as tumor perfusion is one of the key factors in temperature-induced 
drug delivery [27]. Our study has limitations. Firstly, the therapeutic study for the T-47D 
tumor type lacks additional control groups next to PBS NT. These groups were omitted 
since tumor progression was slow and there was no significant delay in tumor growth by 
treatment with TSLDox and HT. Adding extra animals or altering treatment regimens in 
the T-47D therapeutic study might have given a more significant tumor growth delay. 
Secondly, a comparative Dox uptake study between MDA-MB-231 and T-47D tumors 
could have provided a relation between therapeutic response and achieved Dox uptake 
in the tumor. Also on a microscopic scale, in tumor sections, this would be interesting 
to investigate, although low Dox levels in sections can be difficult to detect because of 
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the relatively weak fluorescence of Dox when compared to commonly used fluorophores 
used for histology. As suggested above, the organization of the ECM in a tumor can 
provide an important barrier for effective targeting of therapeutic compounds towards 
the tumor cell, which results in more therapy resistance [53, 54]. However, other factors 
like tumor cell density [55, 56], hypoxia [57, 58], high interstitial fluid pressure [59], 
low pH in tumor interstitial space [60] and tumor cell – stroma molecular signaling [61, 
62] can also induce lower therapeutic response. In addition, the amount of therapeutic 
agent accumulating in the tumor cannot always be directly correlated to therapeutic 
response [63]. Because of these reasons, it still not entirely certain if a drug uptake study 
would answer the lack of therapeutic response for the T-47D tumors. The T-47D tumors 
are clearly different in growth rate and microenvironment factors than tumors which 
we have observed previously [27]. Although we hypothesize that the ECM has played 
a dominant role in preventing effective drug accumulation in T-47D tumors, the other 
above-mentioned factors also have to be carefully investigated in future studies in order 
to create an understanding on which cancers are suitable for TSL-based therapy.
Local drug delivery by TSL and HT to solid tumors is a rapidly growing field, likely 
resulting in a rapid increase of clinical trials in the years to come. Therefore, it is impor-
tant to investigate the heterogeneity in therapeutic response that has been observed in 
clinical trials thus far. (L)TSL and HT therapy has been shown to outperform free drug 
and non-TSL based therapies in previous reports [8, 64]. However, as cancer treatment 
adapts towards a more personalized approach, a greater understanding of the possi-
bilities and limitations of TSL and HT based treatments for specific tumor (sub)types is 
important. By comparing the therapeutic potential of TSL and HT in MDA-MB-231 and 
T-47D tumors, we show that this treatment strategy remains promising for breast cancer, 
but that well-differentiated and slowly proliferating tumors may prove more challenging 
for TSL based treatments. Our study shows that a single treatment is insufficient to 
achieve statistically significant tumor growth inhibition in the T-47D tumor model. For 
slow growing, well-differentiated and poorly perfused tumors, a multiple-dose regimen 
for local drug delivery should be further investigated.
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abstract
The combination of combined administration of thermosensitive liposomes (TSLs) and 
hyperthermia (HT) has been increasingly shown to be a powerful tool for the treatment 
of solid tumors. At present, it is hypothesized that the circulation of TSLs through the 
vasculature of a heated tumor results in the rapid release of the entrapped drug, followed 
by its uptake and distribution within the tumor microenvironment. However, simple 
questions on how much of the nanoparticles travel through the heated tumor and how 
much drug is retained in this tumor upon a passage of a TSL has not been investigated 
in an experimental setting to date. The present work describes a novel isolated limb 
infusion (ILI) procedure developed in a rat model of sarcoma. This approach was used 
to assess the efficacy of Doxorubicin (Dox) delivery by TSL in a heated (42°C) tumor 
following a single passage of TSL through the tumor vasculature. Analysis of the effluent 
post-ILI, whole-tumor histological sections, and tissue homogenates revealed that upon 
a single  passage, Dox delivery by TSL at 42°C did not exceed delivery under conventional 
(i.e. free Dox) or physiological (i.e. TSL at 37°C, or normothermia; NT) conditions. In 
fact, mathematical modeling demonstrated that at least thirteen passages are required to 
obtain the intratumoral Dox levels typically achieved using TSL (i.e. ~5 %ID/g). Overall, 
this work investigates TSL-based determinants for achieving efficacious drug delivery 
using a model of ILI in tumor-bearing rats and the results bear important implications 
for TSL disposition in vivo.
111
Isolated limb infusion with TSL
5
introDuction
Liposomes are established delivery vehicles for chemotherapeutic drugs to solid tumors 
[1, 2]. The encapsulation of drugs into these carriers prolongs their circulation time by 
preventing rapid renal excretion and extravasation into healthy tissues. Tumor accumu-
lation is obtained via passive uptake of the liposomal carrier, mediated by the enhanced 
permeability and retention effect [3-6]. The stable encapsulation of the drug inside the 
liposome ensures high plasma concentrations, but also hampers quick release of the drug 
from the carrier once it accumulated in the tumor tissue [7-9]. As a result, there has been 
increasing interest in the development of nanoparticle-based drug delivery systems that 
rely on an external, non-invasive trigger for intratumoral drug release [10-12]. Among 
such external triggers, hyperthermia (HT) constitutes a versatile choice as it can render 
the tumor vasculature more permeable to liposomes [13-15], but can also induce vascular 
damage [16, 17] or apoptosis [18, 19] in the tumor as a single modality, depending on the 
dose and the duration of heating [20, 21]. Furthermore, it can enhance chemo- [22] and 
radiosensitivity [23] of tumors. The first description of thermosensitive liposomes (TSL) 
by Yatvin and Weinstein et al prompted an increased interest in using this platform for 
heat-mediated drug delivery to tumors [24, 25]. This resulted in numerous studies de-
scribing TSL formulations of which doxorubicin (Dox) has been consistently employed 
as the incorporated drug (Dox-TSL) [26, 27]. Despite slight variations in TSL design and 
experimental setup, these studies showed a significant therapeutic response in a variety 
of pre-clinical tumor models [28, 29]. However, there remains considerable uncertainty 
in the mechanism(s) governing HT-mediated drug delivery via TSL in vivo. Recently, a 
theoretical framework was presented by Gasselhuber et al, describing the most impor-
tant parameters for HT-induced drug delivery using TSLs [30, 31]. While some of these 
parameters can be experimentally assessed [15, 32], others are difficult to determine in 
a typical experimental session. For example, the amount of TSLs that pass through the 
heated tumor depends on tumor perfusion and tumor size (vessel quantity and size). 
Drug release from these TSLs has to be fast enough to ensure adequate accumulation 
of the drug in the tumor tissue during this transition time. The theoretical framework 
described above has addressed tumor transition time of TSL versus time to release and 
how this can affect drug accumulation [30, 31]. However, experimental validation of this 
computational model, for example using subcutaneously growing tumors, has not been 
performed to this date. To investigate the efficacy of Dox delivery using TSL, we present a 
novel isolated limb infusion (ILI) model that may allow evaluation of particle delivery at 
the single-passage level through the tumor (Figure 1). Using this model, we can establish 
a controlled inflow of Dox-TSL into the limb bearing a heated tumor. By sampling frac-
tions of the effluent following TSL administration, Dox delivery can be characterized 
upon immediate exposure at the tumor site, represented by a quantitative measurement 
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of systemic Dox levels after a single passage through the tumor-bearing limb. Further 
insight into the heterogeneity of delivery is revealed via microscopy of whole tissue 
sections obtained from the excised tumors. Determination of the Dox concentration in 
the whole tumor provides a quantitative measure of drug deposition, yielding more in-
formation on TSL-mediated drug delivery. By investigating the efficacy of drug delivery 
following a single passage through the tumor, these findings support efforts to optimize 
delivery platforms that rely on triggered release and/or extended circulation strategies 
within the vascular compartment.
materials & methoDs
materials
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
(methoxy (polyethylene glycol)-2000) (DSPE-PEG2000) were purchased from Lipoid 
(Ludwigshafen, Germany). Doxorubicin-hydrochloride solution (2 mg/ml) was obtained 
from Accord Healthcare (Middlesex, UK). PD-10 columns were purchased from GE-
Healthcare Life Sciences (Little Chalfont, UK). Gelofusine was from Braun (Melsungen, 
Germany). Heparin was obtained from Leo Pharma (Ballerup, Denmark). Normal rat 
serum was purchased from MilliPore (Billerica, Massachusetts, USA). Mouse anti-rat 
Figure 1. Schematic representation of the ILI setup. The rat is fixed on a stage and a cannula is placed in the femoral 
artery for the influent and in the femoral vein for the effluent. A groin tourniquet (green) is placed to occlude collateral 
vessels. A temperature probe is placed into the tumor at 0.5 cm depth, followed by bringing the tumor to 42¡C by a 
goose neck light source. Dox (free or in TSL) is infused by a peristaltic pump and effluent fractions are collected. After 
the procedure, the rat is sacrificed and tumors dissected and snap frozen in liquid nitrogen.
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CD31 antibody and goat anti-mouse AlexaFluor 488 antibody was obtained from Abcam 
(Cambridge, UK) and Thermo Fisher (Waltham, Massachusetts, USA), respectively. All 
remaining chemicals were bought from Sigma-Aldrich (St. Louis, Missouri, USA).
liposome preparation
TSL liposomes consisted of a 70:25:5 DPPC, DSPC and DSPE-PEG2000 molar ratio, 
respectively, and were prepared by the film hydration and extrusion method. In brief, 
lipids were dissolved in a 9:1 chloroform:methanol mixture and the solvent was evapo-
rated to create a thin lipid film. The film was hydrated in a 250 mM NH4SO4 solution 
(pH 5.3) to form TSL. The TSL were extruded five times through 200 nm, 100 nm, 80 
nm and 50 nm polycarbonate filters and loaded with Dox by a pH gradient at a Dox:lipid 
molar ratio of 0.15:1. The resulting Dox-TSL were concentrated by ultracentrifugation 
and resuspended in HEPES-buffered saline (10 mM HEPES, 135 mM NaCl). Size and 
Zeta-potential were measured in 10 mM HEPES buffer by dynamic light scattering using 
a Zetasizer (Malvern Instruments, Worcestershire, UK).
In vitro drug release and liposome stability by fluorometry
2950 µL fresh Brown Norway (BN) rat serum or filtered (400 nm pore size) commercial 
rat serum (MilliPore; MP) was added to a quartz cuvette and placed into a fluorimeter 
(Hitachi F-4500; Tokyo, Japan). The sample was heated to 37°C or 42°C by an externally 
connected water bath. A sample of 50 µL Dox-TSL (5 mM PO4) was injected into the 
sample via surgical tubing during measurement. The sample was scanned for a period of 
1 h at 482 nm excitation and 594 nm emission. 10% Triton was added to the sample after 
the 1 h scan to determine the maximum Dox fluorescent signal (Smax) and percentage 
release calculated by: % release = (Sn-Sbase) / (Smax-Sbase) x 100%. Sn = Dox signal at a given 
time point. Sbase = Background signal of Dox-TSL in serum.
In vivo bn175 tumor growth
BN rats were used at 8 weeks old from Charles River Laboratories (Wilmington, Mas-
sachusetts, USA) and were given a subcutaneous injection of 1 ∙ 106 BN175 sarcoma cells 
on the flank to grow tumors. When tumors reached 1 cm3, they were excised and 10 mm3 
pieces were used for subcutaneous implantation on the hind limb of recipient BN rats 
for the subsequent ILI experiment. Tumors were measured using calipers, and tumor 
volumes determined by the standard formula for ellipsoids: V = length * width * depth * 
0.4; with dimensions being diameters.
isolated limb infusion (ili)
The experiment was conducted as illustrated in Figure 1. Rats bearing a 1 cm3 BN175 
tumor on the hind limb were fixed on a heating pad and subjected to isoflurane an-
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esthesia. The tumor was punctured in the center with a 25 gauge 5/8th sterile needle 
at a 5 mm depth, followed by placement of a thermocouple thermometer. The rat was 
left for 5 min before the start of the ILI procedure to allow blood clotting to close the 
wound. 50 UI heparin in physiological saline solution were i.v. administered via the 
penile vein before installing the ILI setup. An incision was made on the inner thigh of 
the tumor-bearing limb, followed by cannulation of the femoral artery and vein using 
silastic tubing, and placement of a groin tourniquet. The arterial tube was connected to a 
peristaltic pump used for inflow of the influent (influent tube: 0.012 inch inner diameter 
& 0.025 inch outer diameter) at a rate of 0.75 ml/min. The tube connected to the femoral 
vein provided the effluent (effluent tube: 0.025 inch inner diameter & 0.047 inch outer 
diameter) of the ILI setup. First, the system was washed two times with 3 mL of 1 UI 
heparin in 37°C Gelofusine (40 g/L succinylated gelatin), followed by a two times 3 mL 
wash in filtered commercial rat serum (MP) at 37°C. During the washing step, a goose 
neck light source was used to bring the tumor to 42°C (HT) or no lamp in case of a body 
temperature infusion (normothermia; NT). Subsequently, the influent tube was placed 
in a 0.25 mM free Dox or Dox-TSL solution in filtered commercial rat serum, while the 
effluent tube was placed in the first of fifteen tubes for collection of 0.5 mL fractions. 1 
mL of the solution was introduced, after which the influent tube was placed back into 
filtered commercial rat serum maintained at 37°C (136 µg Dox total dose, ~0.5 mg/kg 
total body weight; ~13 mg/kg for the infused leg given the average weight of the hind 
limb of 10 g). This Dox dosage was chosen since the hind limb of the used rats makes up 
for approximately 5-10% of the total body weight [33] and we used 5 mg/kg in previously 
published therapeutic studies [15, 32]. The ILI lasted until the fifteen fractions were 
collected and were finally stored at -20°C until further use. A heat lamp was used to 
keep the body temperature on the ventral side of the rat stable during the procedure. 
At the conclusion of the experiment, the tumors were excised and snap-frozen in liquid 
nitrogen. Rats were sacrificed by cardiac puncture.
analysis of Dox concentration in ili fractions and tumors
Each effluent fraction was added to a 0.5% Triton X-100 solution for a series of seven 1:1 
dilutions in a black 96-well plate. Dox concentrations were determined by a fluorimetry 
plate reader (Wallac Victor 2 Counter) at 485 nm excitation and 580 nm emission 
wavelengths. Intratumoral Dox analysis was determined by a method highly similar as 
described by Charrois et al [34]. 200 mg of the excised tumors was ground into small 
fragments in 200 µL lysis buffer (20 mM Tris, 150 mM NaCl, 0,2% NP40, 10% glycerol, 
pH 7.4) using a Bio-Gen PRO200 homogenizer (Pro Scientific, Oxford, UK). 50 µL of 
10% Triton X-100 and 750 µL 9:1 (v:v) isopropanol/HCl was added and slurries were 
homogenized on ice. Following overnight storage at 4°C, samples were centrifuged at 
15000 g for 20 min and supernatants measured for Dox fluorescence as described above.
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imaging of Dox delivery in ili-treated tumors
5 µm sections were cut from frozen tumors and imaged for Dox fluorescence using a 
tile scan on a confocal microscope (Zeiss LSM 510 Meta; Oberkochen, Germany). The 
sections were left to dry and were fixed in acetone after which vessels were stained by 
mouse anti-rat CD31 and goat anti-mouse AlexaFluor 488. The CD31-stained slices were 
also imaged by confocal microscopy in a similar fashion as described above. 
statistics
All statistical tests were performed using Graphpad Prism version 7 software.
results
tsl stability and release in rat serum
Before starting the ILI experiment, we verified the release and stability of Dox-TSL in 
commercial rat serum (source: MilliPore; hereafter labeled ‘MP’) versus serum extracted 
from BN rats. After 1 h at 37°C, Dox-TSL showed good stability in both rat sera, with 7.9 
± 1.5% Dox release in MP serum and 1.5 ± 0.1% in BN serum (Figure 2A; Figure 3A, B). 
However, a significant difference in release was found as a function of serum origin (p < 
0.01), as the maximum Dox release at 42°C was 73 ± 5% in MP serum and 87 ± 4% in BN 
serum (p < 0.05). The difference in release rate between sera was examined and found 
to be most significant during the first 30 sec of incubation at 42°C (Figure 2B; Figure 3C, 
D). Specifically, BN serum revealed 58 ± 8% Dox release, while release in MP serum was 
considerably slower with 14 ± 3% release (p < 0.01).
0 5 10 15 20 25 30
0
20
40
60
80
100
MP
BN
Time (s)
%
 D
ox
 r
el
ea
se
0 10 20 30 40 50 60
0
20
40
60
80
100
37C MP
42C MP
37C BN
42C BN
Time (min)
%
 D
ox
 r
el
ea
se
A B
Figure 2. Time-dependent Dox release at 37°C or 42°C in commercial rat serum (source: MilliPore; MP), or serum 
extracted from BN rats. 1 h time scans show full extent of release (A), while the first 30 sec reveal the rate of release at 
42°C (B). Error bars represent SD, and release rates were compared by unpaired two-tailed t-test (Figure 3). N=3 for 
all groups.
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Dox quantification of effluent fractions and tumors after ili
The individual effluent fractions did not show a significant difference in Dox quantity 
between ILI-treated groups i.e. tumors that were heated (HT) versus tumors that were 
normothermic (NT). This observation was found irrespective of Dox formulation i.e. 
using free Dox (Figure 4A) or Dox-TSL (Figure 4B). When the values of all fractions were 
summed up, it showed that the majority of Dox infused was retrieved in the total effluent. 
For free Dox at NT, 30 ± 8% of the infused dose was retained in the tumor-bearing limb, 
while rats in the HT group yielded a Dox level of 35 ± 4%. For TSL, the amount of Dox 
retained was significantly lower with 10 ± 4% at NT and 16 ± 5% for HT-treated animals. 
The blood collected from the heart at the end of the experiment showed no presence 
of Dox in all groups, indicating no leakage passed the groin tourniquet. Measurement 
of Dox content from excised tumors showed no difference in uptake between free and 
liposomal Dox, or between NT and HT conditions (Figure 5A). Dox-infused tumors at 
NT contained 0.14 ± 0.17 % ID/g tumor versus 0.36 ± 0.37 % ID/g under HT conditions. 
For infusions of TSL at NT and HT, the tumors contained 0.17 ± 0.03 and 0.28 ± 0.19 % 
ID/g tumor, respectively. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
0
5
10
15
20
25
30
35
NT
HT
Fraction No
%
 D
ox
 e
ffl
ue
nt
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
0
5
10
15
20
25
30
35
NT
HT
Fraction No
%
 D
ox
 e
ffl
ue
nt
Dox NT Dox HT
0
10
20
30
40
50
TSL NT TSL HT
0
10
20
30
40
50
A B
Figure 4. Analysis of ILI fractions with free Dox (A) and Dox-TSL (B) under NT and HT conditions. Inserts show the 
percentage that was retained in the rat calculated from the total amount of Dox in the entire effluent. N=5 for each 
group and error bars represent SD. Dox retention between free Dox and Dox-TSL and between NT and HT (inserts) was 
compared by one-way ANOVA Bonferroni test.
A B C D
Figure 3. In vitro Dox release parameters at 37 ºC and 42 ºC in commercial rat serum (MP) or freshly isolated rat 
serum (BN). At 37 ºC, a linear Dox leakage pattern was observed with MP serum showing a higher slope (A) and total 
Dox leakage after 1h of incubation (B). At 42 ºC, an exponential Dox release curve was observed (C), where MP serum 
showed a lower plateau level of Dox release after 1h of incubation (D). For each data set, MP and BN was compared by 
unpaired two tailed t-test (N=3). * = p < 0.05, ** = p < 0.01.
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The Dox amount retained in the leg after ILI (Figure 5B) was significantly higher for legs 
infused with free Dox (4.05 ± 1.26 % ID/g for NT and 4.65 ± 0.65 % ID/g for HT) than 
for TSL infused legs (1.07 ± 0.51 % ID/g for NT and 1.77 ± 0.43 % ID/g for HT). To verify 
the presence of Dox in the tumors, cryo-sections were made and imaged by confocal 
fluorescence microscopy (Figure 6). The tumors were found to be well-vascularized, as 
shown by CD31 staining (Figure 6A), and Dox signal could be observed throughout the 
tumor section (Figure 6B).
correlation to therapy experiment
If these results would to be used as a predictor for future therapeutic efficacy experi-
ments, several parameter corrections have to be considered. Firstly, we require a correc-
tion for the different Dox leakage rates at 37°C between commercial rat serum (MP) used 
for the ILI, and the isolated, endogenous BN rat plasma. Both curves (MPleak & BNleak) 
A B
Figure 5. Dox uptake in tumors (A) and residual Dox uptake in the infused leg (B) after ILI treatment. The amount of 
Dox retained in the leg was obtained by subtracting the Dox quantity in the total effluent and total intratumoral Dox 
level from the infused dose. Two-way ANOVA Bonferroni test was conducted to analyze differences between groups. 
N=5 for all groups and error bars represent SD. Asterisks represent the statistical difference between free Dox and Dox-
TSL groups by one-way ANOVA Bonferroni test (** = p < 0.01).
A B
Figure 6. Tile scan of excised cryo-section after ILI. CD31 immunostaining (green) showed that the BN175 tumor is 
well- and homogenously vascularized (A). Dox (red) could be visualized in other sections of the tumor (B). Both pic-
tures originated from a Dox-TSL and HT treated tumor. Scale bar represents 2 mm.
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showed a linear correlation with a slightly different slope. The leakage correction factor 
(Corrleak) was calculated as follows:
MPleak (%) = 100 – αMP * t
BNleak (%) = 100 – αBN * t
Corrleak(t) = BNleak(t) / MPleak(t)
Where: αMP: Dox leakage kinetics in MP serum = 0.150 % Dox per minute 
αBN: Dox leakage kinetics in BN serum = 0.026 % Dox per minute
t = time in minutes
Next to the different Dox leakage rates at 37ºC, there was also a difference in the Dox 
release from TSL at 42ºC. In both data sets (MPrelease & BNrelease), an exponential curve 
could be plotted from which a release correction factor (Corrrelease) could be determined:
MPrelease (%) = MAXMP * (1 – e
–βMP * t )
BNrelease (%) = MAXBN * (1 – e
–βBN * t )
Corrrelease(t) = BNrelease / MPrelease
Where: MAXMP: Maximal Dox release in MP serum = 77 %
 βMP: Dox release kinetics in MP serum = 0.55 % Dox per minute
 MAXBN: Maximal Dox release in BN serum = 88 %
 βBN: Dox release kinetics in BN serum = 1.79 % Dox per minute
 t = time in minutes
Lastly, a correction was made for the infusion pressure relative to the blood pressure 
inside the femoral artery. The infusion via the femoral artery was performed using 0.8 
m silastic tubing with an inner diameter of 0.0305 cm and a 0.0635 cm outer diameter. 
The inflow rate by the peristaltic pump was fixed at 0.75 mL/min and influent was kept 
at 37 ºC. With these data, we calculated that the inflow pressure was 30.26 kPa according 
to the Hagen-Poiseuille equation [35, 36]:
∆P = 8 η L Φ / π r4
Where ∆P:  Pressure difference between two ends of tube in Pa
 η: Dynamic viscosity in Pa∙s = 6.9 ∙ 10-4 Pa∙s for water at 37 °C
 L: Length of the tube in m
 Φ: Volumetric flow rate in m3/ s
 r: Inner radius of tube in m
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The reported average blood pressure in the rat femoral artery when the animal is under 
anesthesia is ± 90 mm Hg (i.e. 12 kPa) [37], which indicates that the infusion pressure 
of our ILI system is a factor of 2.52 higher. This correlates to a flow rate of 0.28 mL/min, 
which is a factor 2.68 lower than the flow rate used for in the infusion. 
The average amount of Dox accumulated in tumors was 0.28 ± 0.19 % ID/g for TSL 
infusion at HT. With these data, we assumed a simple exponential formula for intratu-
moral Dox accumulation and in vivo passage number (P):
Doxtumor = Doxsat ∙ (1 - e
-K ∙ P)
Where Doxsat: Saturation for Dox accumulation in tumor in % ID/g
 K: HT-induced Dox delivery by TSL-Dox per passage = 0.28 ± 0.19 % ID/g
 P: Number of passages
Discussion
Throughout the last decades, much work has been published on TSL and the delivery of 
Dox to solid tumors. The design of TSL-based therapy constitutes a balance between the 
need for fast release and full availability of the drug, and high particle stability and cir-
culation time, allowing for TSL particles to pass through the heated tumor an adequate 
number of times for optimal drug accumulation [32, 38]. The investigation on delivery 
dynamics using TSLs has currently only been analyzed by mathematical modelling [30, 
31]. Using the here presented ILI model, we assessed the delivery of Dox form TSLs to 
heated solid tumors upon a single passage. In principle, the animal model for the ILI 
system is similar to that of the isolated limb perfusion (ILP) [39], with the exception that 
the drug is not continuously pumped through the limb. Furthermore, the tumor was 
heated to hyperthermic temperatures using a light source, similarly as described recently 
[40]. In our study, the effluent fractions indicated that the majority of the infused free 
Dox and Dox-TSL is not retained in the tumor-bearing limb following a single passage. 
However, free Dox-infused limbs retained significantly more Dox than Dox-TSL infused 
limbs, with 4.05 ± 1.26 % ID/g versus 1.07 ± 0.51 % ID/g, respectively. These findings 
confirm the non-specific accumulation of free drug in healthy tissues [41]. Nevertheless, 
within one passage, HT-induced Dox release from TSLs could not achieve significantly 
higher intratumoral Dox concentrations compared NT and free Dox infusions. 
A recent study by Willerding et al where the same tumor model was used as for our ILI 
study reported an intratumoral Dox concentration of 23.1 ± 0.4 µg Dox/g tumor tissue 
using an i.v. administration of 2 mg/kg and 60 min of heating [40]. This would cor-
respond to 4.6 ± 0.1 % ID/g for an average sized (~ 250 g) rat and is also in concordance 
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with other recently published data using a different tumor model and 90 min of heating 
[42]. If one would consider this value to be Doxsat in the above-mentioned formula given 
the long HT duration, the amount of passages required by our ILI system to achieve 
98% of Doxsat in the tumor would be 13.7. To the best of our knowledge, this is the first 
account of empirical data on drug delivery via TSL upon a single passage at the tumor 
site, and further complements previously reported models [10, 30, 31]. 
In order to translate these results to therapeutically relevant conditions, there are 
considerations that must be made (Table 1). Firstly, our ILI experiment was conducted 
using commercial rat serum, which does not fully mimic the composition of the blood 
compartment in vivo. We have previously reported that the leakage of Dox from TSL in 
vivo is much more profound than when evaluated in vitro. Furthermore, it was shown 
that an immediate burst release can take place when the particles come into contact 
with blood components [32]. As a result, our data reveal that we cannot accurately 
predict the release of drug from TSL in vivo by solely incubating the particles at 42˚C. 
The blood compartment is far more complex in its composition and fluid dynamics [43, 
44] and more research is required to determine actual drug release kinetics and release 
completeness in circulation. 
A possible improvement for the described ILI model would be to infuse the limb with 
pooled rat blood with an anti-coagulant for conditions as close to the (patho)physi-
ological state as possible. In addition, the ILI model does not simulate the traditional 
pharmacokinetics and biodistribution of TSL, i.e. clearance from the systemic circula-
tion and accumulation of the particles in distant organs. It is well-known that particles 
can be taken up by liver and spleen within minutes of i.v. injection in rodent models 
[45, 46]. Therefore, the local and limited manifestation of the ILI model is an important 
factor to take into account for further therapeutic translation. The flow rate of infusion, 
compared to that of systemic blood flow, is also an important factor for particle circula-
tion and clearance. Not only is blood flow rate correlated to particle circulation half-life 
[47], it also influences the retention time of TSLs travelling through the heated tumor 
via the blood stream. Because the inflow pressure of the ILI was higher than the normal 
Table 1. Comparison of variables between the Isolated Limb Infusion model and an intravenous administration for 
therapy.
isolated limb infusion i.v. administration for therapy
Drug leakage Minimal (in commercial serum) Higher [32]
particle clearance Absent Present
Drug release Adequate (in commercial serum) Unknown
blood flow 30.26 kPa (high) 12 kPa (normal)
administration Concentrated bolus Bolus/ distribution in total blood volume
Dosage ~13 mg Dox/ kg leg weight 2-5 mg Dox/ kg total body weight
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femoral arterial blood pressure in rat under anesthesia, it is likely that the observed 
TSL retention and Dox delivery constitute an under-estimation of levels that would be 
achieved upon systemic i.v. administration for therapy. Lastly, we have to correct for 
the administration method and dosage. With the presented ILI model, the TSLs are 
introduced into the tumor bearing limb as a highly concentrated bolus, increasing the 
odds for higher drug delivery. In common i.v. injections or infusions, the TSLs reach the 
target site in a much more diluted fashion, likely giving altered kinetics for Dox delivery. 
Furthermore, with ~13 mg Dox/ kg leg weight, the administered dose is rather high 
compared more commonly known dosages (2-5 mg/kg). This could for example cause a 
2 mg/kg leg weight ILI to require 89 passages to reach intratumoral Dox accumulation 
values close to Doxsat. 
This study has validated the use of an ILI system for the investigation of quantitative 
drug delivery kinetics by TSLs in heated solid tumors. Recognizing the limitations of 
ILI, this model has nonetheless revealed the distinct influence of serum components 
and haemodynamics on drug release from TSL, abrogating sole dependence on in vitro 
release studies. Furthermore, Dox-TSL demonstrates superior tumor-specific accumula-
tion compared to free Dox as less drug accumulates in the healthy tissues for the former. 
The ILI model may prove a useful tool for the evaluation of local drug delivery, and can 
be further extended to alternate forms of delivery. Overall, the evaluation of distinct 
TSL properties (e.g. release versus stability) in controlled, representative experimental 
conditions is something that can be investigated in future studies using this model.
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abstract
In this study, the goal was to produce magnetoliposomes (MLs) with either iron oxide 
nanoparticles entrapped in the lipid bilayer, or encapsulated in the aqueous core of a 
liposome to establish a nanocarrier that is capable to be imaged by MRI and can release 
drug by hyperthermia (HT) upon exposure to an alternating magnetic field (AMF). 
Film hydration, reversed phase evaporation, detergent removal and modified ethanol 
injection were the liposome preparation techniques used to compare loading efficacy of 
oleic acid (C18:1) coated magnetic nanoparticles (MNPs) into liposome bilayers. (Cryo-) 
transmission electron microscopy (TEM) and inductively coupled plasma optical emis-
sion spectrometry (ICP-OES) indicated that the film hydration or reversed phase evapo-
ration methods produced mainly MNP agglomerates next to the DSPC:DSPE-PEG2000 
(95:5) liposome population. ICP-OES analysis showed that the detergent removal and 
modified ethanol injection method showed better retention of iron from C18:1 MNPs, 
but (Cryo-) TEM imaged indicated that these two methods produced detergent-
lipid micelles and disc-shaped micelles, respectively. For incorporation of hydrophilic, 
3-(triethoxysilyl)propyl succinic anhydride (TEPSA) coated MNPs, we were capable to 
produce magnetoliposomes using film hydration and reversed phase evaporation with 
a higher loading efficiency than for C18:1 MNPs. However, the loading efficacy was not 
high enough to conduct consecutive studies on HT and in vivo use.
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introDuction
Mild hyperthermia (HT) in the clinic implies subtle heating of a tissue to 40-43°C. 
This form of treatment has already shown great potency in enhancing the efficacy of 
chemo- and/ or radiotherapy [1, 2]. Typically, heating of the target tissue is established 
using radiofrequency based applicators [3, 4] or emerging alternatives, such as high 
intensity focused ultrasound [5, 6]. As an alternative, iron oxide (magnetic) nanopar-
ticles (MNPs) have been proposed and investigated for local heating using externally 
applied alternating magnetic fields (AMF) [7, 8]. Superparamagnetic particles that are 
sufficiently small to contain only a single magnetic domain heat in an AMF through 
remagnetisation when the magnetization direction coincides with magnetic the easy 
axis (Néel relaxation) [7]. However, the amount of heat produced by MNPs of this size 
is negligible for large volume heating [9]. When superparamagnetic cores are brought 
in close proximity they are considered multi-domain (superferromagnetism) and have 
a higher heating potential because of magnetic hysteresis [8, 10]. Here the material is 
first brought into a saturated state by forcing all the magnetic domains in one direction 
and it retains this magnetization if the magnetic field would be removed. To release 
energy/ heat from the material, multiple magnetic domains have to be forced back to 
the ground state by turning the magnetization direction 180 degrees [7, 11, 12]. Tumors 
occasionally have a chaotically organized vascular system which allow nanoparticles to 
extravasate from the blood stream into the tumor interstitium [13, 14], a system which 
is known as the enhanced permeability and retention (EPR) effect and this has been 
exploited for drug delivery purposes for decades [15]. The EPR effect could also cause 
i.v. administered MNPs to accumulate in the tumor and generate heat when an external 
AMF is applied [16, 17]. However, the accumulation of particles via this mechanism is 
often heterogeneous and inconsistent [18], which often requires MNPs to be intratumor-
ally administered for sufficient heating potential [19, 20].
Thermosensitive liposomes (TSLs) are particles which encapsulate a chemotherapeu-
tic compound and do not rely on the EPR effect for high drug delivery to solid tumors 
as TSLs release their contents intravascularly when passing through the blood vessels of 
a heated tumor [21, 22]. The lipid bilayer of TSLs is composed of lipids that undergo a 
phase transition at hyperthermic temperatures which facilitates drug release [22, 23]. 
Heating of the lipid bilayer can be achieved by encapsulation of hydrophilic MNPs in 
the aqueous lumen [24-26] or by incorporation of hydrophobic MNPs in the lipid bilayer 
of the liposome. However, the latter is restricted to particles below a cut-off diameter of 
~6.5 nm [27-29]. Nevertheless, incorporation of MNPs in a liposomal bilayer might hold 
several advantages over MNPs entrapped in the aqueous lumen of the liposome. Firstly, 
MNPs encapsulated in the lumen of the liposome require heating of the entire bulk fluid 
of the lumen in order to induce a phase transition of the lipid bilayer, whereas the bilayer 
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incorporated MNPs generate heat much more locally and do not require bulk fluid heat-
ing. Furthermore, MNP oscillation while exposed to the AMF might also induce physical 
stress to the lipid bilayer, thereby facilitating drug release [30].
In this study, we have tested the feasibility of incorporating oleic acid (C18:1) coated 
MNPs into the liposome bilayer for direct heating. As a second approach, we investi-
gated the loading of hydrophilic triethoxysilylpropyl succinic anhydride (TEPSA) coated 
MNPs into the aqueous core of the liposome. Samples were characterized with (cryo-) 
transmission electron microscopy (TEM) and inductively coupled plasma optical emis-
sion spectrometry (ICP-OES) to observe the liposome structure, loading of MNPs and 
to quantify iron content. 
materials anD methoDs
materials
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG2000) were 
purchased from Lipoid (Ludwigshafen, Germany). Octyl β-D-glucopyranoside (OG) 
was purchased from Sigma (St Louis, Missouri). Float-A-Lyzer (8-10kDa) was purchased 
from Spectrum Labs (Los Angeles, California). Sepharose CL-4B was obtained from 
GE-healthcare (Freiburg, Germany). C18:1 and triethoxysilylpropyl succinic anhydride 
(TEPSA) coated MNPs were obtained as described before [31, 32]. Crystal diameter (core 
plus amorphous layer) of the C18:1 coated MNPs was on average 5 nm and for TEPSA 
coated particles 10 nm.
preparation of magnetoliposomes using film hydration
200 µmol of lipid (95:5-DSPC:DSPE-PEG2000) was dissolved in chloroform: methanol 
(9:1) and 5 µmol (Fe) of C18:1 MNPs (dispersed in chloroform) were added. The organic 
solvent was evaporated until a lipid/ MNP film was produced. The lipid film was further 
dried in a steady nitrogen stream to remove any remaining solvent. Subsequently, the 
film was hydrated with HEPES buffered saline pH 7.4 (10 mM HEPES, 135 mM NaCl) 
followed by magnetic separation of MNP agglomerates from the liposome fraction by 
an externally placed neodymium magnet. The liposomes were extruded through two 
times 400, three times 200, three times 100 and two times 80 nm polycarbonate filters. 
Liposome hydrodynamic diameter and polydispersity index (PDI) were determined by 
dynamic light scattering (DLS) using a Zetasizer (Malvern Instruments, Malvern, UK). 
When TEPSA-MNPs were used, 8 µmol (Fe) was included into the hydration volume 
and unincorporated MNPs were separated from MLs by an 18 x 1.5 cm sepharose CL-4B 
column. MNP loading efficacy was determined by ICP-OES. 
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preparation of magnetoliposomes using reversed phase evaporation
200 µmol of lipid (95:5-DSPC:DSPE-PEG2000) was dissolved in 24 mL chloroform/di-
isopropylether (1:1) and 5 µmol (Fe) of C18:1-MNPs (dispersed in chloroform) was added. 
8mL HEPES buffered saline pH 7.4 was added and the solution was (probe) sonicated 
briefly to obtain a brown colored emulsion. The organic solvents were gradually removed 
using a rotation evaporator for approximately 1 hour. During the evaporation, first a 
gel state formed which later collapsed into a liposome solution in the remaining aque-
ous phase. The following extrusion and purification procedures were similar as for film 
hydration. MNP loading efficacy was determined by ICP-OES.
preparation of magnetoliposomes using detergent removal
200 µmol of lipid (95:5-DSPC:DSPE-PEG2000) was dissolved in chloroform: methanol 
(9:1) and 5 µmol (Fe) of C18:1-MNPs (dispersed in chloroform) was added. A lipid/ 
MNP film was made similar to the film hydration method, which was hydrated in a 35 
mM OG solution in HEPES buffered saline pH 7.4. This solution was introduced into a 
Float-A-Lyzer (8-10 kDa) and dialysis was performed under gentle stirring against 2L of 
HEPES buffered saline pH 7.4 five times for 1 hour and once overnight at 65°C. Liposome 
size and PDI were determined using DLS and MNP loading efficacy was determined by 
ICP-OES.
preparation of magnetoliposomes by modified ethanol injection
The method is similar as described in previous publications by Maitani and colleagues 
[33, 34]. In short, 200 µmol of lipid (95:5-DSPC:DSPE-PEG2000) was dissolved in 7.5 mL 
60°C ethanol and 5 µmol (Fe) of C18:1-MNPs (dispersed in chloroform) were added. Un-
der rapid stirring, 25 mL of 60°C HEPES buffered saline pH 7.4 was added. The ethanol 
and chloroform was gradually removed, using a rotation evaporator. Liposome size and 
pdi were determined using DLS and MNP loading efficacy was determined by ICP-OES.
electron microscopy
Cryo-TEM was performed similar as described in Lokerse et al [35]. All TEM images 
were obtained using a Microscope Leo960E operating at an accelerating voltage of 60kV 
(Oregon, USA). The sample was prepared by placing a drop of diluted iron oxide 
nanoparticle suspension on a carbon-coated copper grid, followed by drying at room 
temperature.
statistics
All statistical tests were performed using Graphpad Prism version 7 software.
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results
preparation of liposomes loaded with mnps inside bilayers by film hydration
Direct extrusion after hydration of a lipid/ C18:1 MNP film caused membrane obstruction 
and therefore large MNP agglomerates had to be removed from the sample by magnetic 
separation prior to extrusion. Extrusion two times through a 400 nm filter and three 
times through a 200 nm filter resulted in a liposome batch with a 0.57 ± 0.14 ∙ 10-4 Fe/
PO4 ratio (Table 1; encapsulation efficiency 0.23 ± 0.06 %). Cryo-TEM analysis of these 
samples indicated that there were very few C18:1 MNPs that interacted with a liposome 
membrane (Figure 1A) and that the majority of these particles agglomerated (Figure 2A 
and 2C).
A B C
D E F
Figure 1. Cryo-TEM imaging or differently prepared magnetoliposomes. Oleic acid coated MNPs (white arrows) in-
corporated minimally into liposomal bilayers when film hydration (A) or reversed phase evaporation (B) was used. 
Detergent removal samples (C) did not show any nanoparticle structures in the sample, only seemingly filament-like 
membrane-detergent intermediates. The modified ethanol injection method (D) produced disc-shaped micelles and 
MNPs could not be observed in the sample. TEPSA coated MNPs were incorporated more effectively in the aqueous 
core of the liposomes (white arrows) when film hydration or reversed phase evaporation was used. Scale bar indicates 
100 nm for A and B and 200 nm for C-F.
preparation of liposomes loaded with mnps inside bilayers by reversed phase 
evaporation
For reversed phase evaporation, the same extrusion and purification strategy was ap-
plied as for the film hydration method described above. After magnetic separation and 
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extrusion through 400 and 200 nm filters, the Fe/PO4 ratio was with 1.07 ± 0.46 ∙ 10
-4 
(Table 1; encapsulation efficiency 0.43 ± 0.18 %) only slightly higher than for batches 
prepared by film hydration. However, similar MNP agglomeration and low liposome 
bilayer encapsulation was observed after additional extrusion through 100 and 80 nm 
filters (Figure 1B, 2B and 2D).
Table 1. Size and loading characteristics of different liposome preparation techniques determined by DLS and ICP-
OES. For TEPSA-MNPs, only the film hydration and reversed phase evaporation technique were performed (T). For 
film hydration and reversed phase evaporation using C18:1 MNPs, samples were subjected to magnetic separation to 
remove large MNP agglomerates and extruded through 400 and 200 nm filters. The TEPSA magnetoliposome samples 
were extruded through the same filters and unencapsulated MNPs were removed by size exclusion chromatography. 
N=3 samples for each preparation method.
Reversed Phase 
Evaporation
Fe/ PO
4
(mol/ mol)
Film Hydration
Detergent Removal
Modified Ethanol 
Injection
Polydispersity index
Film Hydration (T)
Reversed Phase 
Evaporation (T)
185 ± 9 0.09 ± 0.03
173 ± 20 0.13 ± 0.07
100 ± 20 0.24 ± 0.01
65 ± 3 0.06 ± 0.01
183 ± 7 0.08 ± 0.02
175 ± 6 0.12 ± 0.03
0.57 ± 0.14 ∙ 10-4
1.07 ± 0.46 ∙ 10-4
1.43 ± 0.04 ∙ 10-4
0.77 ± 0.43 ∙ 10-4
0.88 ± 0.29 ∙ 10-4
0.57 ± 0.20 ∙ 10-4
Hydrodynamic
diamater (nm)
A B
C D
Figure 2. Cryo-TEM images of MNP agglomeration using the film hydration method (A, C) or reversed phase evapora-
tion (B, D). Samples were subjected to magnetic separation for large MNP agglomerate removal and extruded. Small 
agglomerates could still be observed after magnetic separation (A, B). At a low incidence, some MNPs appear inside 
liposomes (C; dashed arrow), possibly interact with the liposomal bilayer (C, D; solid arrow) or are found in the lipo-
somal bilayer (D; solid white arrow).
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preparation of liposomes loaded with mnps inside bilayers by detergent removal
Hydration of a lipid/ C18:1 MNP film in a concentrated Triton X-100 solution seemed 
to result in a lowering of MNP agglomeration as could be observed by magnetic separa-
tion and (Figure 3). Because Triton X-100 has a low critical micelle concentration and is 
difficult to dialyze out of a mixed micelle population, OG was selected as the detergent 
of choice for the liposome generation by detergent removal. ICP-OES measurements 
on these OG hydrated lipid/ C18:1 MNP films showed a Fe/PO4 ratio of 1.43 ± 0.04 ∙ 
10-4 after magnetic separation (Table 1; encapsulation efficiency 0.57 ± 0.02 %), which 
was another slight improvement compared to the two previously described methods. 
Removal of the OG by dialysis was not successful and intermediate lipid-OG structures 
were observed by Cryo-TEM (Figure 1C). However, TEM analysis occasionally showed 
small MNP clusters encapsulated in micelle-like structures ( Figure 4A and 4B)
A B C D
Figure 3. Results of lipid/ C18:1 MNP film hydration with Triton X-100. When the concentration of Triton X-100 for 
hydration of the lipid film was increased from 0.1 (A), to 1 (B) and to 10 w/v % (C), a decrease in MNP agglomera-
tion could be observed after magnetic separation (red arrows in A and B). TEM recordings (D) of a 10% Triton X-100 
hydrated lipid/ C18:1 MNP film show a detergent-lipid mesh with individual MNPs (blue arrows) and small MNP ag-
glomerates (red arrows) embedded inside.
DC
BA
Figure 4. TEM images of MNPs in detergent removal (A and B) and modified ethanol injection samples (C and D). Red 
arrows indicate the MNPs. Scale bars in A-C represent 200 nm and 100 nm in D.
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preparation of liposomes loaded with mnps inside bilayers by modified 
ethanol injection
The modified ethanol injection method used in these studies produced particles with 
a hydrodynamic diameter of 65 ± 3 nm, but was considerably smaller than the average 
liposome (± 100 nm). Despite that after magnetic separation the sample had a Fe/PO4 
ratio of 0.77 ± 0.43 ∙ 10-4 (Table 1; encapsulation efficiency 0.31 ± 0.17 %), very few C18:1 
MNPs could be observed in the cryo-TEM images (Figure 1D). Furthermore, the particles 
observed in these images were disc-shaped lipid micelles. TEM analysis showed some 
MNPs which were embedded within these micelles (Figure 4C and 4D; red arrows).
preparation of liposomes loaded with mnps inside the aqueous core
To obtain liposomes with hydrophilic, TEPSA coated MNPs inside the liposome aqueous 
core, we applied film hydration and reversed phase evaporation as preparation methods. 
After extrusion (two times 400, three times 200, three times 100 and two times 80 nm) 
and removal of unencapsulated MNPs by size exclusion chromatography, film hydration 
liposome samples had a Fe/PO4 ratio of 0.88 ± 0.29 ∙ 10
-4 and reversed phase evapora-
tion liposomes a Fe/PO4 ratio of 0.57 ± 0.20 ∙ 10
-4 (Table 1; encapsulation efficiency 0.22 
± 0.07 % and 0.14 ± 0.05 %, respectively). However, the amount of MNPs that were 
loaded into liposomes was not higher than two per liposome (Figure 1E and 1F), which 
makes the loading efficacy too low for conducting any follow up experiments. 
Discussion
In this study, we assessed the feasibility of producing MLs with MNPs incorporated into 
the liposome bilayer or the aqueous core. Several liposome preparation techniques and 
surface modifications to the MNPs have been applied in order to produce MLs with 
a high MNP loading efficacy. However, the latter could not be achieved in this study. 
Several recently published articles give a possible explanation on the obtained results 
[36-39].
Amstad and coworkers are one of the few research groups that have described the 
successful encapsulation of MNPs in a liposome bilayer [37]. In these studies, palmityl-
nitroDOPA was used as a MNP surface modification, which resulted in a ~30% loading 
efficacy of these particles into liposomes. Palmityl-nitroDOPA was compared to C18:1 
as a MNP surface modification and for the latter, agglomeration was similar as observed 
in this study. Amstad and colleagues emphasized that C18:1 is a reversibly adsorbing 
dispersant, which makes MNPs with this surface modification more likely agglomerate 
[36, 37]. Others have also shown that oleic acid stabilized MNPs are more likely to be 
encapsulated in the hydrophobic core of a lipid micelle, rather than to be embedded 
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in a liposome membrane [38, 39]. We hypothesize that the mono-unsaturation and 
the length of the oleic acid carbon chain might hamper effective loading of MNPs in 
liposome bilayers (Table 2). Another illustrative observation is that in the methods 
mentioned above that generated micelles, slightly higher iron levels could be detected, 
thereby confirming the high affinity for these hydrophobic MNPs with micelles over 
liposomes [39, 40]. Removal of OG by dialysis in the detergent removal protocol was not 
fully established, which was likely the cause of the lipids used in this study (DSPC:DSPE-
PEG2000). In most studies describing liposome preparation by detergent removal, Egg-PC 
is used [41, 42]. Egg-PC is a mixture of lipids with one or more double bonds, which 
might create a micelle which is more prone to release detergent monomers which are 
consecutively removed by dialysis. However, increased MNP aggregation after dialysis 
was observed and indicated that the amount of detergent in the dialysis bag decreased 
to a certain extent over time. The modified ethanol injection method, although used 
with a highly similar lipid concentration and ethanol : aqueous phase ratio produced 
disc-shaped micelles instead of liposomes as described by Maitani et al [33, 34]. We 
suggest that the addition of DSPE-PEG2000 to this reaction mixture might have caused 
lipids to organize into micelles using this liposome preparation technique since DSPE-
PEG2000 has the potential to form micelles [43]. Furthermore, TEM observations showed 
a remarkably low MNP encapsulation into these micelles despite the high encapsulation 
efficacy suggested by ICP-OES. This could be caused by a partial dissociation of iron ole-
ate complexes from the C18:1 MNPs in the 60 °C ethanol, which could still be detected 
by ICP-OES, thereby giving a false positive result on encapsulated MNPs in disc-shaped 
micelles.
Table 2. MNP crystal diameter (core plus amorphous layer) distribution based on TEM observations and estimated 
increase in diameter based on the chemical structures of C10:0, C14:0 or C18:0 surface coatings. The sizes marked in 
green represent the particle sizes below the cut-off for liposome membrane incorporation of 6.5 nm.
Crystal diameter 
(nm)
3
4
5
6
7
8
Crystal diameter 
+ C10:0 (nm)
Crystal diameter 
+ C14:0 (nm)
Crystal diameter 
+ C18:0 (nm)
5.25
6.25
7.25
8.25
9.25
10.25
6.25
7.25
8.25
9.25
10.25
11.25
7.25
8.25
9.25
10.25
11.25
12.25
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Next to MNP surface modification and liposome preparation methods, also the size of 
the MNPs plays an important role in successful embedment into the liposome bilayer. 
From several TEM images of the C18:1 MNPs, we established a crystal diameter distribu-
tion profile (Table 2). Given these data, 96 % of all MNPs would be below the ~6.5 nm 
cut off range for liposome membrane incorporation [27-29]. However, the increase in 
size of the MNP including the surface coating reduces the amount of MNPs that meet 
this criterion. In these conditions, none of the C18:0 coated MNPs would be sufficiently 
small for bilayer embedment. Furthermore, the double bond in the carbon tail of C18:1 
coated MNPs could also create steric hindrance for effective embedment into a C18:0 
lipid membrane.
Our experiments for the incorporation of hydrophilic, TEPSA coated MNPs into the 
aqueous core of the liposome were successful, but with a very low yield of MNPs per 
liposome. We aimed to make 200 µmol batches of MLs, which would be sufficient for 
a substantial amount of consecutive animal studies. However, with the current MNP 
loading efficacy, follow up studies are not realistic. Therefore, we required highly more 
concentrated TEPSA MNP batches for lipid film hydration and realizing MLs with a 
higher MNP loading efficacy, which were not available at this time. MLs with hydro-
philic MNPs in the aqueous core are often produced by hydrating fewer lipids in a more 
concentrated MNP solution [24, 44, 45]. Nevertheless, for intensive (large) animal 
studies or clinical trials, more effective methodologies need to be investigated to obtain 
adequate ML batch sizes.
We were not successful in realizing an ML with a high quantity of MNPs in the bilayer. 
The hydrophobic MNPs used in this study can interact with lipids and detergents but are 
rather incorporated into micelles instead of embedded into liposomal bilayers. TEPSA-
MNPs were successfully loaded into the aqueous core of the liposome, but the loading 
efficacy was too low to conduct further studies. Nevertheless, the presented results give 
insight into the pitfalls of effective ML production with high MNP loading efficacy and 
the feasibility of clinical transfer of this technology.
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current status of thermosensitive liposomes for soliD tumor 
therapy
The research to improve current systemic chemotherapy with respect to target-speci-
ficity and side effects, led to clinical approval of several nanoparticles for drug delivery 
[1, 2]. For example, Doxil®, DaunoXomeTM and OnivydeTM are liposomal formulations 
that have shown improved safety profiles but demonstrated only in few applications 
improved efficacy [3, 4]. The latter is hampered by the slow diffusion driven release 
of the parental drug from its liposomal carrier, limiting the bioavailability [5-7]. The 
concept of temperature-induced drug release from thermosensitive liposomes (TSLs) 
has been introduced to counter this problem. Although drug encapsulation in TSLs may 
not be as stable as in non-TSL formulations such as Doxil® [8-11], the intravascular drug 
release in the heated tumor ensures a greater efficiency in drug delivery to the tumor 
cell [12]. Ever since the first description by Yatvin and Weinstein [13, 14], TSLs have been 
under continuous development and optimization. However, the only TSL formulation 
to have reached clinical trials remains the Doxorubicin (Dox)-loaded, lysolipid-based 
TSL (LTSL) developed by Needham & Dewhirst [15, 16]. This LTSL formulation has been 
evaluated in clinical trials conducted by Celsion Corporation under the commercial 
name of ThermoDox (Table 1). Their first clinical studies focused on locally recurrent 
breast cancer (phase I/ II) and liver cancer (phase I/ III). For the breast cancer study, a 
microwave heating device was used, which is practical for heating of superficial tumors 
to mild hyperthermia (HT, 40-43 °C). Conversely, the liver cancer study made use of 
a radiofrequency (RF) applicator that is invasively placed into the center of the tumor 
for ablation at higher temperatures ( > 60 °C; RFA). In this case, the periphery of the 
tumor is expected to be heated to temperatures closer to the mild HT range. The TSLs 
consequently deliver Dox to the tumor periphery and rim, which often constitutes the 
part of the lesion with occult cancer cells that escape thermal ablation. The clinical trial 
for breast cancer showed that ThermoDox can be administered multiple times at a maxi-
mum tolerated dose of 50 mg/ m2, generating a local overall response rate of 48% [17]. 
Furthermore, toxicity levels were considerably lower than what is commonly observed 
in free Dox infused patients. The completed phase III trial for the treatment of hepato-
cellular carcinoma with RFA and LTSLs showed no increase in overall survival compared 
to RFA treatment alone. Here, LTSLs are infused at least 15 min prior to RFA treatment 
which lasted for 12-60 min, depending on the size of the heated lesion [18]. The problem 
that caused these disappointing findings was found in the duration of the RFA treatment 
since consecutive RFA treatments that lasted > 45 min in combination with infused 
LTSLs did result in increased survival for more than two years for a subgroup of patients 
[19-21]. Nevertheless, not for all cancers a superficial or invasive HT treatment is an 
option and therefore more sophisticated heating techniques should be investigated. 
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Heating by focused ultrasound is one technique which is non-invasive, can be used for 
deeper seated tumors and is currently being used in ThermoDox clinical trials for liver 
and pediatric cancers [22, 23]. This heating method, in combination with TSL-based 
drug delivery, has shown increased intratumoral drug levels versus free Dox treatment, 
as well as improved tumor growth delay in various preclinical tumor models [24-26].
The above mentioned results summarize the potential of LTSL-based therapies; how-
ever this particular formulation of TSL using lysolipids has also some shortcomings. 
LTSLs are relatively unstable compared to other TSL formulations in biological media 
[27] and have demonstrated lower therapeutic efficacy compared to formulations that 
lack lysolipid [28]. Furthermore, it has been suggested that the lysolipids dissociate 
from LTSLs in the blood stream, thereby lowering the systemic circulation time of the 
particles and encapsulated drug [10]. These findings may have contributed to the lack 
of therapeutic benefit in adding LTSLs to standard RFA treatment for hepatocellular 
Table 1: Overview of clinical trials performed with ThermoDox
study 
no
start/ end 
year
status cancer type heating method goals/ results
1 2006/ 2016 Terminated Breast cancer Microwave Phase I: Side effects and optimal 
dosing for therapy (Nolen Breast 
Cancer Res 2008; Zagar IJH 2014)
2 2007/ 2016 Completed Primary and 
metastatic 
liver cancer
Radiofrequency 
ablation (RFA)
Phase I: Dose escalation study 
3 2008/ 2014 Unknown Hepatocellular 
carcinoma
RFA Phase III: Therapeutic efficacy and 
safety
4 2009/ 2016 Completed Breast cancer Microwave Phase I/II: Determine maximum 
tolerated dose, safety, 
pharmacokinetics, therapeutic 
efficacy (Zagar IJH 2014)
5 2011/ 2016 Terminated Colon 
cancer liver 
metastasis
RFA Phase II: Therapeutic efficacy and 
safety
6 2012/ 2016 Withdrawn Painful bone 
metastases
MRI-guided high 
intensity focused 
ultrasound (MR-HIFU)
Phase II: Therapeutic efficacy and 
safety
7 2014/ - Recruiting Hepatocellular 
carcinoma
RFA Phase III: Therapeutic efficacy and 
safety
8 2014/ - Recruiting Liver cancer Focused ultrasound 
(FUS)
Phase I: Proof of concept; 
enhanced accumulation in tumors
9 2015/ - Recruiting Pediatric 
cancer
MR-HIFU Phase I: Determine maximum 
tolerated dose and recommended 
Phase II dose
10 2016/ - Not yet 
recruiting
Breast cancer Microwave Phase II: Therapeutic efficacy and 
safety
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carcinoma [29]. Optimizing heating protocols may lead to higher therapeutic response 
[30]; however, a class of alternative TSL formulations warrants further investigation in 
the clinical setting, given the above mentioned disadvantages of the LTSL formulation.
optimization of thermosensitive liposomal formulations
Optimization of TSL formulations has been performed by many groups and continues to 
take place for novel TSLs and compounds. The basis for this can be found in the choice 
and ratio of lipids that determine the bulk transition temperature (Tm) of the particle [11, 
31]. However, similar to the LTSL, most groups have added unique lipids to the formula-
tion in order to achieve the optimal balance between TSL stability and circulation time 
at 37 °C, and fast release at 41-42 °C. For example, the inclusion of a select amount of 
DSPE-PEG2000 to a DPPC/ DSPC formulation can yield a TSL with reasonable stability 
and drug release characteristics, as has been shown by Hossann et al [32] and Li et al 
[33]. These formulations mainly exhibit lower drug leakage at temperatures below 41 °C, 
thereby improving drug circulation time [10, 11]. Another approach which is quite simi-
lar to the LTSL is the addition of Brij78 instead of lysolipid to the main lipid composition 
[34, 35]. Brij78 is a surfactant with a PEG800 structure connected to a single acyl chain, 
which is also capable to form pores within the lipid bilayer for enhanced drug release. 
The PEG chain would stabilize the pore similarly as described for LTSL [36, 37], but is in 
this case linked to the same structure which facilitates the pore. In a comparison with 
LTSL, it was shown that Dox pharmacokinetic profiles were similar, while Dox release 
rates and intratumoral accumulation was slightly higher for Brij78-containing TSLs 
[34]. However, similar findings between lysolipid and Brij78 were found on dissocia-
tion from TSLs in biological media [10, 34]. Another example of a TSL bearing optimal 
circulation and release properties owing to a single component of the formulation is 
the 1,2-dipalmitoyl-sn-glycero-3-phosphodiglycerol (DPPG2)-TSL described by Lindner 
et al [38]. The reported circulation half-life of 5.0 ± 0.9 h (carboxyfluorescein readout) 
in rats is remarkably longer than that of LTSLs which exhibit a half-life of approximately 
1.3 h (radiolabeled lipid readout) [10]. This has likely been attributed to a higher sys-
temic stability at 37 °C, while maintaining fast drug release properties [32]. However, a 
direct comparison between LTSL and DPPG2-TSL has not been performed so far. Other 
examples of strategies that establish fast drug release from TSLs are the incorporation 
of thermosensitive polymers [39, 40] or polypeptides [31, 41] which undergo confor-
mational changes at HT and destabilize the TSL membrane, thereby facilitating drug 
release. The polypeptide-TSL showed an almost threefold greater circulation time and 
significantly higher therapeutic response versus LTSL in a murine model of squamous 
cell carcinoma.
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These above-mentioned examples indicate next to LTSL, other TSL formulations are 
also worthwhile to investigate pre-clinically and clinically. Other formulations have 
shown mainly higher stability and improved circulation time, which frequently resulted 
in higher intratumoral drug accumulation and therapeutic effect. We have shown in 
Chapter 2 that with a variety of relatively stable Dox-loaded TSLs, a significant therapeu-
tic response can be achieved. Needham and Dewhirst based the potential success of the 
LTSL on a model where a particle would need 50-100 s to travel in a perfect horizontal 
line from one side to the other of a 1 cm diameter tumor with normal blood circulation 
and that the drug release has to take place within this timeframe [12]. In practice, the 
vascularization of the tumor is more complex and the TSL transition time is probably 
longer than what is expected according to the above mentioned model. However, there 
are several other parameters which were not considered. The first aspect is that in vitro 
release profiles were used as a predictor of how drug release would take place in vivo. We 
have shown in Chapter 2 that for TSL stability, in vitro plasma incubations only provide 
preliminary information on Dox retention and release characteristics. Upon systemic 
administration, many other factors have an impact on the particle, further compromis-
ing its integrity. Although this has not been investigated so far, this is likely also the case 
for Dox release at HT. Furthermore, the suggested dissociation of lysolipids from LTSL 
in circulation by Banno et al. [10] will certainly alter the Dox release profile in vivo. In 
Chapter 5 we have indicated that an infused bolus of TSLs likely passes through the tu-
mor vasculature in low quantities per passage, and that the bulk amount of the injected 
dose stays in the main circulation. We have not evaluated LTSLs in this study; however, 
our findings imply that a considerable amount of passages are required to obtain typical 
intratumoral Dox levels that are found for TSL and HT based treatments [42]. These 
findings also suggest that longer circulating TSLs might be more effective for solid tumor 
therapy than LTSLs.
factors which leaD to enhanceD therapeutic effect
Next to the composition of the particle, the biology of the tumor must also be considered 
in order to optimize TSL therapy. At this point, the tumor has largely been considered 
as a mass of cancer cells supplied by a network of blood vessels for the delivery of 
nutrients and oxygen. However, there are some aspects of tumor physiology that need 
to be well-understood in order to properly interpret preclinical and clinical results of 
nanomedicine therapy [43]. For in vitro cancer cell cultures, factors such as growth 
kinetics, protein expression and sensitivity to cytotoxic agents are well-defined and 
reproducible characteristics that can be maintained through multiple passages. These 
cultures provide an adequate means to obtain preliminary assessment on the feasibility 
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of a given therapy in order to proceed to more complex, in vivo studies. For instance, 
cells that are located in the tumor core may not receive sufficient oxygen and nutrients 
since the area is often poorly vascularized. These cells are therefore termed hypoxic and 
can alter their proteome, which often negatively affects drug efficacy [44]. Conversely, 
tumor cells located in the periphery are in close proximity to functional blood vessels, 
and therefore are more viable and more likely to possess similar characteristics to those 
observed in culture [45, 46]. The vasculature of a tumor is often chaotically organized, 
tortuous and lacks structural integrity such as pericyte coverage, basement membrane 
and perivascular smooth muscle [47, 48]. Furthermore, the endothelial lining of tumor 
blood vessels can contain gaps up to several micrometers in size, which can be exploited 
for nanoparticle accumulation in tumors [49]. The so-called enhanced permeability and 
retention (EPR) effect is more effective for smaller-sized compounds [50], but can be 
increased by HT, especially for nanoparticles in the liposome size range (i.e., ~100 nm) 
[51, 52]. Despite these pathophysiological features which may enable drug delivery to 
solid tumors, there are some aspects of the tumor microenvironment that also hinder 
drug delivery. The lack of lymphatic drainage contributes to increased interstitial fluid 
pressure (IFP), which reduces the influx of nanoparticles into the tumor interstitium 
[53]. Moreover, tumors frequently contain a considerable amount of stroma, which 
can greatly influence metastatic potential [24, 54]. Tumor stroma is associated with 
increased levels of fibroblasts and extracellular matrix which can significantly hamper 
the transport of cytotoxic compounds towards the tumor cell [55, 56].
The above-mentioned tumor microenvironmental factors differ between tumor types 
and within the same tumor; heterogeneity is ubiquitous. The clinical impact of this ob-
servation on nanoparticle delivery to solid tumors has been thoroughly described in the 
studies of Harrington and coworkers [57]. Their findings have indicated that patients 
with head and neck cancers accumulate more radiolabeled liposomes (33.0 ± 15.8% ID/
kg), with a similar lipid composition to Doxil®, than patients with lung (18.3 ± 5.7% 
ID/kg) or breast (5.3 ± 2.6% ID/kg) tumors. In the preclinical setting, differences in 
nanoparticle accumulation between tumor types [58] and heterogeneous uptake within 
tumors has been observed [59]. However, it is important to consider that when using 
animal tumors, the growth rate is relatively higher than in humans, and tumors therefore 
have a higher potential of accumulating particles through the EPR effect. The B16 tumor 
model described in Chapter 3 constitutes a representative example of this phenomenon. 
EPR-mediated drug accumulation in this family of murine tumors was found to be highly 
pronounced, leading to the superior performance of a Doxil®-like liposome over that of 
an LTSL [60]. In xenograft models, this result has only been shown when tumors were 
subjected to 3 min RFA treatment prior to Doxil® injection versus LTSL injection per-
formed 15 min prior to the same RFA treatment [61]. The therapeutic efficacy of LTSL in 
different subcutaneous tumor models has been extensively investigated by Yarmolenko 
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et al [62]. They found that slower growing cancer cells in vitro have a larger likelihood to 
therapeutically respond to TSL and HT therapy in vivo. We (Chapter 3) and others [58] 
have claimed that more invasive tumors accumulate more liposomes by the EPR effect. 
In Chapter 4, we observed a lower therapeutic response for slowly growing T-47D tumors 
relatively to fast growing MDA-MB-231, which contradicts the findings of Yarmolenko 
et al. In this case, we hypothesize that the high differentiation and relatively mature 
extracellular matrix of the orthotopic T-47D tumor model may limit effective drug ac-
cumulation. Conversely, the rapid development of MDA-MB-231 tumors may yield more 
permeable conduits for drug delivery. Overall, these findings suggest that the efficacy 
of cancer nanomedicines may require a prior identification of tumors that meet select 
criteria for therapeutically significant drug delivery, a concept also known as personal-
ized medicine [63, 64]. Nevertheless, the above-mentioned observations indicate that it 
is likely that the scope of tumors that respond to therapy may prove broader for TSL- and 
HT-based drug delivery than for therapies that rely on stable systemic circulation and 
tumor accumulation. 
the next level of thermosensitive liposomes anD aspects to be 
investigateD
Nanoparticle-based drug delivery is a field wherein intensive research has been con-
ducted for the past decades. A significant number of strategies, nanoparticles and 
targeting principles have been described throughout the literature over these years [65]. 
This raises the question as to whether a saturation level has been reached in optimizing 
nanoparticles and in developing correspondingly novel and clinically relevant treat-
ments. 
In Chapter 6, we investigated the development of liposomes incorporating magnetic 
nanoparticles for heat-triggered drug release when exposed to an alternating magnetic 
field. While the concept provided an attractive platform for in vivo MR-guided interven-
tions, the poor scalability in the formulation process limited further development and 
translation of this research. Nanoparticle research should therefore be performed with 
both specific and realistic aims; the goal of clinical translation can be achieved through 
the development of scalable formulations that prove superior to standard of care. 
Conversely, basic research is critical to the fundamental understanding of nanoparticle 
performance and interactions in vivo. For TSLs, much research has been performed on 
optimal formulation development and rendering particles more target-specific [66, 67]. 
Optimizing formulations has been described above and is absolutely relevant concern-
ing the limitations of LTSLs. For instance, the feasibility of molecularly targeting TSLs 
to specific cell populations is a question that has yet to be addressed. In vitro, targeting 
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of TSLs to major histocompatibility complex (MHC) class I [68], folate receptors [69], 
human epidermal growth factor receptor 2 (HER2) [70] or hydroxyapatite [71] on cancer 
cells resulted in enhanced intracellular drug levels and cytotoxic effect. However, in vivo 
studies showing enhanced drug accumulation via TSL targeting have only been described 
by Al-Ahmady et al [72] and Yang et al [73]. The results of the former study indicated 
that intratumoral Dox accumulation could be enhanced by targeting TSLs to tumor cells 
by an α-MUC1 antibody using specific HT regimes. The latter study did not perform drug 
accumulation studies, but therapeutic efficacy could be enhanced when TSLs contained 
a NGR-peptide residue. However, the doses between targeted, non-targeted and free 
drug groups were inconsistent and hence this result should be interpreted with cau-
tion. The lack of therapeutic benefit of targeted TSLs is likely caused by the significant 
amount of time required for the particles to accumulate in the tumor by the EPR effect. 
We have shown in Chapter 3 that TSLs are too unstable for particle accumulation-based 
studies as the drug leakage is too substantial within the time needed for the TSLs to 
reach their target in sufficient quantities. Furthermore, in vitro binding studies are often 
performed in serum-free conditions while it has been shown that serum component 
interactions can greatly inhibit targeted nanoparticle binding potential [74, 75]. Target-
ing TSLs to the tumor neovasculature has also been investigated by the incorporation 
of cationic lipids [76] or targeting peptides to the formulation [77, 78]. The results for 
these two targeting ligands were remarkably similar, with increased in vitro and in vivo 
affinity to the endothelium. Yet, the therapeutic benefit of vascular targeting for TSLs 
remains to be demonstrated [79]. Recently, one study showed a significant increase in 
therapeutic response when clotted plasma proteins in solid tumors were targeted by a 
peptide-conjugated TSL [80]. Overall, these results indicate that introducing targeting 
ligands to TSLs provides little benefit and that intravascular drug release remains the 
best option for effective solid tumor treatment [81].
These findings on optimization of TSLs and efforts to make the particles more target-
specific might suggest that a saturation level in TSL research has been reached. However, 
key aspects of this delivery methodology still require further investigation in order to 
generate positive and sustained treatment outcomes in patient populations that are 
most likely to respond. We have previously addressed the importance of focusing on TSL 
formulations with higher systemic stability than LTSL; however, a more comprehensive 
understanding of how the drug delivery mechanism functions in vivo is required. This is 
particularly important when considering disparate tumor microenvironments and how 
these might influence drug potency. Few studies have been aimed at further characteriz-
ing the delivery method. For example, murine dorsal skinfold window chamber studies 
have been used to study drug release kinetics from TSLs in circulation, extravasation of 
the drug into the tumor interstitium and how effectively it is taken up by the tumor cell 
[28, 82]. However, for these models, aggressively growing murine or xenograft tumors 
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are used which grow only in two dimensions and therefore key microenvironmental 
factors such as hypoxic areas and extracellular matrix might not be representative 
compared to 3D developing tumors. Furthermore, quantitative drug accumulation in 
the tumor cannot be determined by this method. Accordingly, Dewhirst and coworkers 
have conducted pioneering research in “dose painting”- a method where a MRI contrast 
agent is co-encapsulated with Dox to image, in real-time, the deposition of a released 
compound from a TSL in a heated tumor [83, 84]. Their methods focused on the use 
of manganese as a MRI contrast agent, which was found to correlate remarkably well 
with Dox accumulation in solid tumors. Owing to these studies, the optimal HT regi-
men of heating during the LTSL administration was described using this dose painting 
approach. More recently, the accuracy of dose painting could be reproduced in other 
animal models, heating methodologies, and using gadolinium as a MRI contrast agent 
[24, 54, 81, 85, 86]. In conjunction with the determination of drug uptake rates by cells, 
Dox release rates by LTSLs, and tumor perfusion data, computational models have been 
constructed that better explain heat-triggered drug delivery to solid tumors by RFA and 
high intensity focused ultrasound (HIFU) treatments [87, 88]. 
These data have proven useful in interpreting the results of the therapy as a whole; 
however, what really transpires at the micro-scale in the solid tumor is not yet fully 
understood, leaving several questions that remain unanswered: How much of the drug 
is effectively released upon passage through the tumor vasculature? How much of the 
liposomes actually travel through the heated tumor and how much circulation time is 
required in order to obtain maximal drug accumulation? How much of the released 
drug is retained in the tumor and how much is washed out by blood flow-mediated 
convection? With the isolated limb infusion model described in Chapter 5, we describe 
a model which may address these questions. Although our PEG2000-TSL formulation 
was not directly compared to LTSL, the model indicated that a single passage of the 
particles through the heated tumor was not sufficient to deliver more Dox than infused 
free drug. These findings indicate that longer circulating TSLs might be more effective 
in delivering high drug doses to solid tumors than LTSLs. Taken together, it is plausible 
that the efficacy of drug delivery by TSLs yields is still suboptimal compared to standard 
of care. Nevertheless, with continued optimization of therapy regimens and formulation 
properties (e.g. LTSL), as well as the identification of likely responders and correspond-
ing prognostic factors, significant advances are imminent. 
clinical translation of thermosensitive liposome therapy
So far we have mostly focused on future investigation of TSLs in a pre-clinical setting. 
However, research that focuses on aspects directly linked to clinical application are es-
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sential for successful clinical introduction of the therapy. The earlier-mentioned clinical 
trials show that optimal heating protocols have to be designed to establish maximal 
efficacy for TSL treatments [18-21]. Today, the focus of clinical HT is highly on HIFU and 
trials with this heating methodology in combination with LTSL therapy have recently 
been initiated [23]. One good example on investigation of optimal heating protocols 
with TSLs and HIFU has been recently described by Hijnen and Kneepkens et al [54]. 
Here, rhabdomyosarcoma-inoculated rats were i.v. injected with TSLs followed by a 
treatment regimen of two times 15 min mild HT and tumor ablation versus ablation 
alone. Their results show that Dox accumulation in tumors can be increased when giving 
additional mild HT treatments prior to ablation, which resulted in improved therapeutic 
efficacy. The potential cause for this finding was that first the local mild hyperthermia 
causes increased intratumoral particle and drug accumulation and that vascular shut-
down induced by ablation afterwards results in a reduced efflux of these from the tumor 
interstitial space. This example indicates that studies that focus on optimal treatment 
protocols are important for successful translation of the treatment to the clinic [30, 
54, 89]. Furthermore, more investigation has to be performed on repetitive treatments 
using this methodology, as this more closely represents clinical practice and as a set of 
previous studies have shown total tumor regression doing so [90, 91].
Given the above-mentioned results, it appears that with the right pre-clinical studies, 
treatments of tumors with TSL and HT is steadily approaching clinical introduction in 
an optimized fashion. However, there are some aspects that have to be carefully con-
sidered before this can be realized. The TSL as a carrier is biodegradable and therefore, 
does not induce long-term toxicity. But on short-term, adverse effects can occur such as 
complement activation-related pseudoallergy (CARPA), which is potentially lethal. This 
phenomenon has been extensively described for Doxil® in pig and human studies [92, 
93] and only in pigs so far for LTSLs [30]. Furthermore, some Doxil® treated patients 
showed palmar-plantar erythrodysesthesia, which manifests itself as a skin rash, mainly 
on the hands and feet which has been suggested to be caused by Dox secreted in sweat 
[94-97]. Therefore, a careful assessment has to be made for each patient whether these 
side effects are manageable during treatment. Heating of tumors by HIFU is currently 
restricted to volumes of approximately 15 mm in diameter and larger volumes have 
to be heated by consecutively heating subareas [98, 99]. Therefore, research is being 
conducted on making the HIFU technology capable of heating more clinically relevant 
tissue volumes [100]. Because of the optimization required for the TSL formulation, 
heating protocol and heating equipment, successful clinical introduction of TSL and 
HT therapy is dependent on translational research at a drug-device combination level.
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Summary
summary
The treatment of cancer has been a topic for scientific research for many decades. Espe-
cially in recent years, many new findings are described on the tumor biology and therapy 
methods. However, in the clinic the “classical” chemotherapy and radiotherapy are still 
most frequently applied. These treatments often go together with severe side effects 
because these are not fully tumor directed. In this thesis, cancer therapy using drug 
containing nanoparticles has been described to make the treatment more targeted and 
reduce side effects. Liposomes are nanoparticles which are already clinically applied and 
Doxil®, a liposome that contains the chemotherapeutic Doxorubicin, is the best example 
for this. Doxil® can be very effective in reducing the side effects of Doxorubicin and these 
nanoparticles of approximately 100 nm in diameter can accumulate in the tumor by gaps 
in the endothelial lining of associated blood vessels. Nevertheless, this accumulation 
does not always induce a significant therapeutic response because the encapsulated 
Doxorubicin cannot leave the liposome effectively to be taken up by cancer cell nuclei in 
the tumor. Because of these reasons, thermosensitive liposomes were designed that can 
release their chemotherapeutic payload when exposed to mild hyperthermia (40-43 °C). 
These thermosensitive liposomes have shown to cause a higher Doxorubicin accumula-
tion in tumors relatively to the free drug and Doxil®. These findings have resulted in the 
initiation of several clinical trials for cancer treatment using thermosensitive liposomes, 
which are currently on going. However, these liposomes can improved, especially the 
stability in the blood stream. Moreover, the therapeutic response has proven to be vari-
able.
In this thesis the optimization of themosensitive liposomes is described, which 
treatments in combination with hyperthermia give the best therapeutic effect, which 
tumor types are most likely to give a positive therapeutic response to the treatment and 
a new model is analyzed for a better understanding of the drug delivery mechanism by 
thermosensitive liposomes. Moreover, a feasibility study is presented for the develop-
ment of liposomes that are loaded with magnetic nanoparticles for drug delivery by 
MRI-guidance. A general introduction concerning all these topics is given in Chapter 1.
In Chapter 2, the analysis of thermosensitive liposomes with different lipid composi-
tions and Doxorubicin loading techniques is described. After the determination of the in 
vitro stability and drug release characteristics at mild hyperthermia, in vivo experiments 
concerning pharmacokinetics, intravital microscopy and therapeutic efficacy were con-
ducted and an attempt to correlate the results between all experiments was made. The 
results show that in vitro analyses are a good measure to compare liposomal formula-
tions, but that these cannot be correlated to in vivo outcome.
In Chapter 3, two different tumor treatment strategies are compared in two different 
tumor types. The first strategy is a “1-step” therapy where thermosensitive liposomes are 
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intravenously administered while the tumor is heated. The second strategy is a ”2-step” 
therapy where the tumor is pre-heated to induce a higher accumulation of thermosensi-
tive liposomes into the tumor, followed by a second heating treatment to cause a drug 
release in the tumor interstitial space. SPECT/CT analysis shows that preheating induces 
a higher nanoparticle accumulation, however highly dependent on the tumor type. The 
results of the therapeutic study implicate that a 1-step therapy is more potent in eliciting 
a therapeutic response than a 2-step therapy for both tumor types. This was most likely 
caused by the insufficient accumulation of liposomes in the tumor and the leakage of 
the drug from the liposomes during the accumulation time.
Chapter 4 describes a comparative study on the therapeutic efficacy of thermosensi-
tive liposomes for two subtypes of breast cancer. It concerns a study in an orthotopic 
xenograft model that shows that aggressive and less differentiated breast cancers are 
more prone to respond to treatment with thermosensitive liposomes and hyperthermia 
than slowly progressing and well differentiated breast cancers. We give a hypothesis 
that extracellular matrix in the tumor stroma forms an important barrier for effective 
Doxorubicin delivery to the cancer cell.
In order to better understand the delivery of Doxorubicin in vivo, a novel isolated limb 
infusion model in rats was investigated, which is described in Chapter 5. The amount 
of Doxorubicin that can be delivered after a single passage through a heated tumor can 
be analyzed in this way. The model shows that a considerable amount of passages are re-
quired to obtain similar intratumoral Doxorubicin levels as described in most preclinical 
studies. This implicates that thermosensitive liposomes with a longer circulation time 
might be favourable for optimal drug delivery to solid tumors. However, future studies 
have to investigate this hypothesis.
Chapter 6 describes the production of liposomes that are loaded with magnetic 
nanoparticles for drug release when exposed to alternating magnetic fields and can be 
traced in vivo by MRI. We have attempted to incorporate the magnetic nanoparticles in 
the liposomal bilayer or inside the aqueous core of the liposome. Despite using various 
liposomal preparation techniques, we were not successful in obtaining liposomes with 
a high loading efficacy.
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Thermosensitive liposomes are currently investigated by many groups and with LTSL, 
there is a formulation which currently tested in clinical trials. The therapeutic results 
that were found with LTSL can be considered variable and many studies describe the 
short circulation time and low stability of this formulation in circulation as problematic. 
With the described results in this thesis, we intend to establish a better image on the 
aspects of thermosensitive liposomes that are effective and non-effective for optimal 
tumor therapy. Moreover, we have attempted to also obtain more understanding on the 
drug delivery mechanics in vivo and what could be improved in order to treat a broader 
group of patients effectively.
In the coming years, thermosensitive liposomes could be a realistic option for clinical 
cancer treatment. However, more research on these nanoparticles is required in order to 
improve therapy and make it more patient specific.

169
Samenvatting
samenvatting
De behandeling van kanker is een onderwerp waar al vele decennia onderzoek naar wordt 
gedaan. Zeker in de recente jaren volgen nieuwe bevindingen over de biologie van kanker 
en nieuwe therapie methoden elkaar in rap tempo op. Desondanks worden in de kliniek 
nog met de grootste regelmaat de “klassieke” chemotherapie en radiotherapie toegepast. 
Dit gaat vaak gepaard met grootschalige bijwerkingen omdat de therapie niet volledig 
tumor-gericht is. In dit proefschrift is de behandeling van tumoren met behulp van 
nanodeeltjes die chemotherapeutica bevatten beschreven, om chemotherapie doelge-
richter te maken en bijwerkingen tegen te gaan. Liposomen zijn nanodeeltjes die al in de 
kliniek worden toegepast en Doxil®, een liposoom dat het chemotherapeuticum Doxoru-
bicine bevat is hier het beste voorbeeld van. Doxil® kan zeer effectief de bijwerkingen 
van Doxorubicine tegengaan en deze nanodeeltjes van ca 100 nm in diameter kunnen in 
de tumor ophopen door openingen in het endotheel van de geassocieerde bloedvaten. 
Deze ophoping zorgt alleen niet altijd voor een hoger therapeutisch effect omdat het 
geïncorporeerde Doxorubicine het liposoom niet effectief kan verlaten, om vervolgens 
opgenomen te worden door de kernen van de kanker cellen in de tumor. Om deze reden 
zijn thermosensitieve liposomen ontwikkeld, die chemotherapeutica vrij kunnen geven 
bij blootstelling aan milde hyperthermie (40-43 °C). Deze thermosensitieve liposomen 
hebben laten zien dat ze voor een hogere accumulatie van Doxorubicine in tumoren 
en therapeutisch effect zorgen dan het vrije chemotherapeuticum of Doxil®. Dit heeft 
ervoor gezorgd dat op dit moment, diverse klinische studies lopen met thermosensitieve 
liposomen voor kanker behandeling. Desondanks kunnen deze liposomen verbeterd 
worden, met name de stabiliteit in de bloedbaan. Daarnaast is de therapeutische respons 
is variabel gebleken.
In dit proefschrift wordt de optimalisatie van thermosensitive liposomen beschreven, 
welke behandelingen in combinatie met hyperthermie het beste therapeutische resul-
taat geven, in welke tumoren de beste therapeutische effecten verwacht kunnen worden 
en word een nieuwe methode geanalyseerd om het chemo afgifte systeem met thermo-
sensitive liposomen beter te kunnen begrijpen. Daarnaast wordt een haalbaarheidstudie 
beschreven voor de ontwikkeling van liposomen die beladen zijn met magnetische 
nanodeeltjes voor visualisatie met behulp van MRI. Een overkoepelende introductie 
betreffende deze onderwerpen is beschreven in Hoofdstuk 1.
In Hoofdstuk 2 is de analyse van thermosensitieve liposomen met verschillende li-
pide samenstellingen en Doxorubicine ladingstechnieken beschreven. Nadat in vitro de 
stabiliteit en vrijgave van Doxorubicine bij milde hyperthermie is bepaalt, worden in vivo 
farmacokinetiek, intravitale microscopie en therapie resultaten hiermee vergeleken. De 
resultaten laten zien dat in vitro analyses een goede graadmeter zijn voor vergelijkingen 
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van liposomale formulaties, maar dat deze niet gekoppeld kunnen worden aan in vivo 
resultaten. 
In Hoofdstuk 3 zijn twee verschillende tumor behandelingsstrategieën in twee ver-
schillende tumor types vergeleken. De eerste strategie is een zogenaamde “1-staps” the-
rapie waarbij thermosensitieve liposomen in de bloedbaan geinjecteerd worden terwijl 
de tumor verwarmd word. De tweede strategie is een “2-staps” therapie waarbij de tumor 
voorverwarmd wordt waardoor thermosensitieve liposomen beter kunnen ophopen in 
de tumor, gevolgd door een tweede verwarmings stap om het chemotherapeuticum 
vrij te geven in het interstitium. SPECT/CT analyse laat zien dat de voorverwarming 
van tumoren zorgt voor een hogere ophoping van de liposomen, al is de hoeveelheid 
hiervan zeer afhankelijk van het tumor type. De resultaten van therapeutische studies 
impliceren dat de 1-staps therapie een hogere therapeutische respons induceert dan de 
2-staps variant in beide tumor types. Dit resultaat is hoogstwaarschijnlijk veroorzaakt 
door onvoldoende ophoping van de liposomen en lekkage van het chemotherapeuticum 
uit de liposomen gedurende de periode die nodig is voor ophoping.
Hoofdstuk 4 beschrijft een vergelijkend onderzoek naar de therapeutische effectivi-
teit van thermosensitieve liposomen in twee verschillende borstkanker types. Het betreft 
een studie in een orthotoop muizen model die laat zien dat agressieve en minder gedif-
ferentieerde borsttumoren beter reageren op therapie met thermosensitieve liposomen 
en hyperthermie dan langzaam ontwikkelende en beter gedifferentieerde tumoren. We 
beschrijven een hypothese dat de extracellulaire matrix in het stroma van de tumor een 
belangrijke barrière vormt voor effectieve afgifte van Doxorubicine aan de tumor cel.
Om de afgifte van Doxorubicine door thermosensitieve liposomen in vivo beter te 
kunnen begrijpen is in Hoofdstuk 5 een geïsoleerde poot perfusie model in ratten 
beschreven. De hoeveelheid Doxorubicine die in een tumor ophoopt na één passage van 
de liposomen in een verwarmde tumor is hier geanalyseerd. De resultaten laten zien dat 
in dit model, vele passages nodig zijn om een gelijkwaardige hoeveelheid Doxorubicine 
aan een tumor af te geven dan wat regelmatig gevonden wordt in diverse preklinische 
studies. Dit impliceert dat thermosensitieve liposomen met een langere circulatietijd 
wellicht effectiviever kunnen zijn in optimale chemo afgifte aan een tumor. Desalniet-
temin moeten toekomstige studies deze hypothese onderzoeken. 
Hoofdstuk 6 beschrijft de productie en potentieel van liposomen die beladen zijn met 
magnetische nanodeeltjes voor chemo vrijgave door alternerende magnetische velden 
en die in het lichaam gevolgd kunnen worden met behulp van MRI. We hebben getracht 
de magnetische nanodeeltjes in de liposomale bilaag of in de kern van het liposoom in 
te kapselen. Ondanks dat veel liposomale bereidingstechnieken zijn getest, zijn we niet 
succesvol gebleken om deze liposomen met een hoge beladingsgraad te realiseren.
171
Samenvatting
toeKomstperspectief
Thermosensitieve liposomen worden tegenwoordig door vele groepen onderzocht en 
met de LTSL is er een formulatie die op dit moment in klinische studies word getest. 
De therapeutische resultaten van de LTSL zijn variabel te noemen en diverse studies 
beschrijven de korte circulatietijd en lage stabiliteit van deze formulatie in de bloedbaan 
als problematisch. Met de beschreven resultaten in dit proefschrift willen we een beter 
beeld schetsen in de succesvolle en minder succesvolle aspecten van het gebruik van 
thermosensitieve liposomen voor kanker therapie. Daarnaast hebben we getracht om 
mechanismen achter chemo afgifte met behup van thermosensitieve liposomen aan 
tumoren beter te kunnen begrijpen en wat er verbeterd zou kunnen worden om een 
bredere groep patiënten effectief te kunnen behandelen.
In de komende jaren kunnen thermosensitieve liposomen een reële optie worden 
voor kanker behandeling in de kliniek. Desalniettemin is meer onderzoek naar deze 
nanodeeltjes nodig om de therapie te verbeteren en meer patiënt specifiek te maken.
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